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Chapter 110
InTrOduCTIOn
Kidney transplantation is the only effective treatment for patients with end-stage renal disease. 
Transplantation of a donor organ, however, leads to recognition of the foreign donor antigens by the 
recipient’s immune system, resulting in rejection of the graft. In addition, ischemia-reperfusion injury 
leads to the initiation of immune responses. To prevent graft rejection, transplant recipients need to 
use life-long immunosuppressive medication. These drugs, however, can lead to serious acute and 
chronic side effects, such as infections, nephrotoxicity, cardiovascular disease and malignancies 1. 
As an alternative, cellular therapies may be considered. One of the candidates is the mesenchymal 
stem cell (MSC). Mesenchymal stem cells have tissue regenerative and immunosuppressive 
properties 2-4. These properties make them promising as cellular therapy for tissue regeneration and 
treatment of immunological disease. In solid organ transplantation, MSC may repair graft injury 
and may reduce anti-donor reactivity, thereby improving graft function and alleviating the need for 
immunosuppressive drugs after transplantation. Despite recent clinical trials investigating the use 
of MSC in treating immune-mediated disease, such as therapy resistant graft-versus-host disease 
(GVHD) and inflammatory bowel disease, the applicability of MSC in solid organ transplantation 
is still unknown. The present thesis discusses the immunomodulatory properties of MSC and their 
potential to improve the outcome of solid organ transplantation.
Definition and characteristics of MSC
The definition of mesenchymal stem cells is not precisely defined and still under discussion. In brief, 
MSC are undifferentiated adult stem cells with self-renewal capacity. The term mesenchymal stem 
cell is often used interchangeably with the term mesenchymal stromal cells as ‘stromal’ refers to the 
supportive function of these cells to other cells, such as haematopoietic stem cells or specialized cells. 
It has been shown that MSC are virtually present in all adult tissues, including bone marrow, adipose 
tissue, skin, placenta and heart 2, 5-10, from which they can be isolated and expanded in vitro. Although 
bone marrow is the classical source of MSC for research and therapeutic purposes, currently other 
sources of MSC are investigated. In particular, adipose tissue is of interest as the collection of fat 
tissue is less invasive for the MSC donor, fat tissue is more easily accessible for the clinician and yields 
higher cell numbers than bone marrow 11-12. Cultured MSC are usually identified by a combination of 
characteristics including their (1) morphology in culture; (2) immunophenotype; (3) differentiation 
capacity; and (4) immunosuppressive capacity. 
MSC in culture are plastic-adherent cells, grow in a monolayer and have a spindle-shaped morphology 
(Figure 1). Until now, no specific cell surface marker for MSC has been found and MSC are, therefore, 
identified by a panel of cell-surface markers, including CD29, CD44, CD73 (SH3/4), CD90 (Thy-1), 
CD105 (SH2), CD106 (VCAM-1), CD166 (ALCAM) and HLA class I 2, 13-14. In contrast, MSC do not 
express haematopoietic or endothelial lineage markers such as CD14, CD31 or CD45. In addition, it 
has been suggested that MSC have a low immunogenic phenotype, i.e. low expression of HLA class 
I, and absence of HLA class II and co-stimulatory molecules such as CD80 and CD86 15-17. This 
immunophenotype makes MSC potentially immune privileged.
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Multilineage differentiation capacity of MSC
The first important functional property of MSC is their multilineage 
differentiation capacity. MSC are progenitor cells for various 
specialized cell types, such as adipocytes, osteoblasts, chondrocytes 
and myocytes (Figure 2) 2, 5. This capacity makes them promising 
candidates for use in regenerative medicine, for example for the repair 
of bone 18-19, cartilage 20-21, skin 22-23, and neuronal tissue 24. In addition, 
MSC can improve the function of cardiac muscle 25-27 or kidney 28-29. 
Currently, clinical trials are investigating the use of MSC in treating heart disease, liver cirrhosis and 
bone fractures. In addition, clinical application of bioengineered tissues using in vitro-differentiated 
stem cells cultured on scaffolds is promising, as shown for the production of a trachea 30. Besides 
the hypothesis that MSC contribute to repair of damaged tissue via their differentiation into more 
specialized cells themselves, there is now increasing evidence that secretion of trophic factors by 
MSC that stimulate tissue resident cells is at least as important for the contribution of MSC to tissue 
regeneration 31-32.
Figure 1. MSC in culture
Figure 2. Multilineage differentiation capacity of MSC. MSC were cultured for 21 days under control, adipogenic, 
osteogenic and myogenic conditions. The figure shows undifferentiated MSC, MSC stained with oil-red-O to 
detected lipid vesicles after adipogenic differentiation, MSC stained by von Kossa staining to detect calcified 
minerals after osteogenic differentiation and MSC after induction of myogenic differentiation.
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Immunosuppressive capacity of MSC in vitro
The second important functional property of MSC is their immunosuppressive capacity (Figure 
3). MSC can inhibit the proliferation and production of pro-inflammatory cytokines by activated 
lymphocytes and maturation of dendritic cells in vitro 3-4. Their effects are dose-dependent, appear 
to be independent of major histocompatibility complex (MHC) and do not require mediation by 
antigen-presenting cells (APC) or regulatory T-cells (Tregs) 33. A variety of mechanisms for the 
immunosuppressive effects of MSC have been proposed. Inhibition of lymphocyte proliferation by 
MSC has not been associated with the induction of apoptosis, but is rather dependent on the inhibition 
of cell division (Figure 4) 4, 33-34.
 Experiments using transwell systems showed that the inhibitory effect of MSC on PBMC proliferation 
was reduced, but not abolished, by the physical separation of MSC and PBMC 33, 35. This indicates that 
the immunosuppressive effects are partly mediated by soluble factors. Several soluble factors have 
been suggested to be involved in the immunosuppressive effect of MSC, such as transforming growth 
factor-b1 (TGF-β1), hepatocyte growth factor (HGF), prostaglandin E2 (PGE2), IL-10, HLA-G and 
nitric oxide 36-37. Blocking each of these factors alone does not completely restore the proliferation 
of activated immune cells, indicating that multiple factors are involved. MSC also inhibit T-cell 
proliferation by up-regulating the expression of indoleamine 2,3-dioxygenase (IDO) 3-4, 38-40. IDO is 
not constitutively expressed by MSC, but can be induced by exogenous factors such as IFN-γ, and 
catalyses the conversion of the amino acid tryptophan to kynurenine. Depletion of tryptophan, which 
is an essential amino acid for T-cells, and formation of the immunosuppressive factor kynurenine, 
results in inhibition of lymphocyte proliferation.
In addition to the secretion of soluble immunosuppressive factors, MSC establish cell-membrane 
interactions with immune cells, suggesting that non-soluble communication between MSC and 
immune cells exists 41-42. MSC express a number of adhesion molecules, including ICAM-1, ICAM-2, 
VCAM-1, CD72, and LFA-3 that enable physical interaction with T-cells 42-44. Under inflammatory 
conditions MSC up-regulate these adhesion molecules, which may increase the capacity of MSC to 
bind activated T-cells. By keeping activated T-cells in close proximity, the inhibitory effect of soluble 
mediators generated by MSC may be potentiated 36-37, 41.
Effect of MSC on immune cells
Many studies have demonstrated that MSC inhibit immune responses by affecting various leukocyte 
subsets. Below, we discuss their specific effects on T-cells, B cells, natural killer (NK) cells, and on 
other immune cells such as dendritic cells.
Interaction between MSC and T-cells
The effect of MSC on T-cells has been investigated in various experimental settings, showing that 
MSC modulate the activation, proliferation and function of effector and regulatory T-cell subsets. 
MSC have a dose-dependent effect on the proliferation and cytokine production (e.g. IL-2, IFN-γ) of 
alloactivated and mitogen-activated CD4+ T-cells in vitro 4, 33, 45-46. Although MSC strongly suppress 
the formation of cytotoxic CD8+ T lymphocytes (CTL) in mixed lymphocyte cultures, MSC are not 
capable of inhibiting the cytolytic activity of activated CTL 47-49. Conversely, it has been suggested 
that MSC might be relatively resistant to CTL-mediated lysis 48, 50, which may be explained by the 
low expression of HLA and co-stimulatory molecules on MSC. In addition to their effects on naive 
T-cell populations, MSC also inhibit the proliferation of memory T-cells activated by their cognate 
peptide 4, 33, 48, 51.
Introduction
C
ha
pt
er
 1
13
IF
N
-γ
TN
F-
α
IL
-6
ID
O
IL
-1
0
PG
E-
2
H
LA
-G
M
SC
M
od
ul
at
io
n 
of
 A
PC
di
ff
er
en
tia
tio
n 
an
d 
fu
nc
tio
n
G
en
er
at
io
n 
an
d 
ex
pa
ns
io
n
 o
f r
eg
ul
at
or
y 
T-
ce
lls
af
fe
ct
in
g 
ac
tiv
at
ed
 im
m
un
e 
ce
lls
, 
e.
g.
 b
y 
do
w
nr
eg
ul
at
io
n
im
m
un
e 
re
sp
on
se I
II
III
bF
G
F
IL
-6
In
hi
bi
tio
n 
of
 a
ct
iv
at
ed
 im
m
un
e 
ce
lls
:
C
D
4+
 T
-c
el
ls
 (e
.g
. e
ffe
ct
or
s,
 m
em
or
y 
ce
lls
) 
B
-c
el
ls
N
K
 c
el
ls
ac
tiv
at
ed
 T
-c
el
ls
 b
in
d 
to
 M
S
C
vi
a 
e.
g.
 IC
A
M
-1
 a
nd
 V
C
A
M
-1
IV
In
hi
bi
tio
n 
of
 th
e 
fo
rm
at
io
n
of
 c
yt
ot
ox
ic
 c
el
ls
:
C
D
8+
 T
-c
el
ls
N
K
 c
el
ls
H
G
F
N
O
C
he
m
oa
tt
ra
ct
iv
e 
an
d 
im
m
un
om
od
ul
at
or
y 
ef
fe
ct
s 
on
 o
th
er
 c
el
ls
:
gr
an
ul
oc
yt
es
 (e
os
in
op
hi
ls
, n
eu
tro
ph
ils
, b
as
op
hi
ls)
m
ac
ro
ph
ag
es
he
m
at
op
oi
et
ic
 s
te
m
 c
el
ls
 (e
.g
. f
or
m
at
io
n 
of
 a
nt
ig
en
-s
pe
ci
fic
 T
-c
el
ls)
V
ef
fe
ct
or
 c
el
ls
Fo
xP
3
Fo
xP
3
Fo
xP
3
I +
 II
Le
ge
nd
: I
m
m
un
om
od
ul
at
or
y 
ef
fe
ct
s 
of
 M
SC
. 
Th
e 
im
m
un
om
od
ul
at
or
y 
ef
fe
ct
s 
of
 M
SC
 a
ct
 o
n 
di
ffe
re
nt
 c
om
po
ne
nt
s 
of
 th
e 
im
m
un
e 
sy
st
em
:
I  
 
M
SC
 c
an
 in
hi
bi
t a
ct
iv
at
ed
 ly
m
ph
oc
yt
es
. T
he
se
 im
m
un
os
up
pr
es
si
ve
 e
ffe
ct
s 
ar
e 
m
ed
ia
te
d 
by
 s
ol
ub
le
 fa
ct
or
s 
an
d 
fu
rth
er
 e
nh
an
ce
d 
by
 d
ire
ct
 
 
ce
ll-
ce
ll 
m
em
br
an
e 
co
nt
ac
t (
e.
g.
 v
ia
 IC
A
M
-I)
. T
he
 im
m
un
os
up
pr
es
si
ve
 c
ap
ac
ity
 o
f M
SC
 is
 e
nh
an
ce
d 
un
de
r i
nf
la
m
m
at
or
y 
co
nd
iti
on
s 
(e
.g
. b
y 
IF
N
γ)
II 
 
M
SC
 c
an
 in
du
ce
 re
gu
la
to
ry
 T
-c
el
ls
 (T
re
gs
), 
th
er
eb
y 
M
SC
 in
di
re
ct
ly
 a
ffe
ct
 a
ct
iv
at
ed
 im
m
un
e 
ce
lls
III
 
M
SC
 c
an
 a
ffe
ct
 a
nt
ig
en
 p
re
se
nt
in
g 
ce
ll 
(A
PC
) d
iff
er
en
tia
tio
n,
 m
at
ur
at
io
n,
 m
ig
ra
tio
n 
an
d 
fu
nc
tio
n
IV
 
M
SC
 c
an
 a
ct
 a
s 
an
tig
en
  p
re
se
nt
in
g 
ce
lls
 (A
PC
) t
ha
t a
re
 re
co
gn
iz
ed
 b
y 
ef
fe
ct
or
 c
el
ls
V
 
M
SC
 c
an
 s
ec
re
te
 c
he
m
ok
in
es
 fo
r a
ttr
ac
tio
n 
an
d 
m
od
ul
at
io
n 
of
 o
th
er
 (i
m
m
un
e)
 c
el
ls
.
VI
 
(s
til
l) 
un
kn
ow
n 
m
ec
ha
ni
sm
s
VI ?
Figuur 3. Immunosuppressive effects of MSC
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In addition to the non-antigen-specific modulation of effector T-cells by MSC through the secretion 
of soluble factors and cell-membrane interactions, there is evidence that MSC indirectly modulate 
immune responses through the induction of Tregs. Some studies have reported that MSC increase 
the proportion of Tregs with strong suppressive capacities in the PBMC population 3, 52-55. However, 
the mechanism whereby MSC induce Treg expansion is unclear, as is the specificity of the induced 
cells. If protocols could be developed whereby MSC were used to induce Tregs in an antigen-specific 
manner, this would provide MSC with the capacity to inhibit immune responses in an antigen-specific 
manner.
Interaction between MSC and B cells
The effects of MSC on B-cells have been clarified to a lesser extent than their effects on T-cells. 
Some studies have shown that MSC effectively inhibit B-cell proliferation, differentiation to plasma 
cells, and antibody production 56-58. B-cell proliferation is inhibited by MSC through an arrest in the 
G0/G1 phase of the cell cycle, and not through apoptosis 56, 59. On the other hand, some studies found 
that MSC stimulated polyclonal expansion and antibody production by B-cells 60-61. Interestingly, it 
has been suggested that MSC may resemble follicular dendritic cell-like cells, which prevent B-cells 
from apoptosis and induce their differentiation 62. This may explain the stimulatory effect of MSC 
on B cells. The concentration of MSC may be a decisive factor explaining such results: high doses of 
MSC have an inhibitory effect on B cells, whereas low doses stimulate B-cell activity. Furthermore, 
the absence or presence of T-cells in the MSC-B cell cultures is of importance as well. Activated 
T-cells produce IFN-γ that activate the immunosuppressive mechanisms of MSC, which subsequently 
resulting in an immunosuppressive effect of MSC on B-cells through mechanisms that resemble those 
used to modulate T-cell activity.
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Figure 4. One of the mechanisms of immunosuppression by MSC is the induction of a cell division arrest of 
activated T-cells.This figure demonstrates that MSC inhibit the proliferation and number of cell divisions of 
PKH67-labeled responder T-cells after 7 days in mixed lymphocyte reactions (MLR). Analysis was performed by 
ModFit® software (Verity Software House, USA). Alloactivated T-cells proliferated up to 7-8 cell divisions in the 
absence of MSC, while alloactivated T-cells were kept in a cell division arrest in the presence of MSC.
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Interaction between MSC and natural killer cells
While MSC suppress IL-2- and IL-15-driven NK-cell proliferation and IFN-γ production 3, 48-49, 63, they 
do not inhibit the cytotoxic activity of activated NK-cells 48, 64. The inhibition seems to be independent 
of cell-membrane contact, and PGE2 and TGF-β appear to play a role the regulation of NK-cell 
activity 65. While MSC are not lysed by freshly isolated allogeneic NK-cells, they are susceptible for 
lysis by IL-15-activated NK-cells 48, 63, 66.
Interaction between MSC and antigen-presenting cells 
In addition to directly affecting lymphocytes, MSC modulate immune responses via dendritic 
cells. MSC can reduce the formation and maturation of both monocyte-derived and CD34+-derived 
dendritic cells 67-69. MSC also reduce the expression of co-stimulatory molecules such as CD40, 
CD83 and CD86 on mature dendritic cells 70 and alter cytokine secretion by stimulating IL-10 68, 
IL-12 70 and TGF-β1 4 production, while decreasing TNF-α secretion. It has been reported that MSC 
require activation through IL-1b production by CD14+ monocytes to suppress alloreactive T-cells 35. 
Thus, MSC modulate the activation, proliferation and function of dendritic cells, thereby indirectly 
regulating T- and B-cell activity. 
Interaction between MSC and other immune cells
There is little data on the effects of MSC on other immune cells. MSC secrete soluble factors such 
as monocyte-chemo-attractant protein, macrophage-inflammatory protein, IFN-inducible protein-10 
and IL-8, all of which may attract immune cells such as monocytes, macrophages
and neutrophils. An inflammatory environment may affect the secretion of these factors by MSC, 
thereby changing the attraction of different immune cells. The relevance of the production of these 
factors by MSC for the attraction and function of monocytes, macrophages and neutrophils is 
unknown.
Interaction between MSC and haematopoietic stem cells
It has previously been shown in animal and clinical studies that MSC promote haematopoietic 
engraftment 17, 71-73. This is likely to relate to the important role of MSC in the haematopoietic niche, 
where they support haematopoietic stem cell survival and self-renewal 74-75. It can thus be speculated 
that MSC have indirect effects on the formation of antigen-specific T-cells by their interference with 
haematopoietic development.
The differences found by various studies in the immunosuppressive mechanisms of MSC may reflect 
differences in experimental setups. The type of MSC response to an immune challenge is likely to be 
dictated by the type, magnitude and timing of this challenge. This should be taken into consideration 
when MSC are used for treatment of immunologic disease.
Chapter 116
Immunosuppressive effects of MSC in vivo
Application of MSC for inflammatory disease
In line with the promising results on the immunosuppressive effects of MSC in vitro, animal studies 
demonstrated that MSC treatment can reduce inflammation in various models, such as rheumatoid 
arthritis, colitis, myocarditis and autoimmune encephalomyelitis 76-80. In a clinical setting, the 
application of MSC is currently under investigation in patients with multiple sclerosis, inflammatory 
bowel disease and rheumatoid arthritis. 
Application of MSC in bone marrow and solid organ transplantation
Both regenerative and immunosuppressive properties of MSC may also be beneficial in clinical bone 
marrow and solid organ transplantation. Furthermore, it has been demonstrated that the administration 
of MSC not only increased bone marrow engraftment after haematopoietic stem cell transplantation, 
but also that it reduced conventional therapy-resistant GVHD 71, 81-82. Recently, clinical trials started to 
investigate the effect of MSC on GVHD on a larger and more controlled scale.
It can be hypothesized that the application of MSC in solid organ transplantation has the potential 
to reduces renal ischemia-reperfusion injury, prevent rejection and improve graft function. In a few 
attempts, the use of MSC in solid organ transplantation has been examined in animal transplant 
models. Under particular conditions, MSC were shown to prolong the survival of skin, cardiac and 
liver grafts in primate and rat models 83-86. Other studies failed to confirm the beneficial effect of 
MSC on graft survival or showed that, when infused before transplantation, MSC of donor origin 
may actually accelerate heart and skin graft loss, possibly through HLA recognition and induction 
of a memory immune response 87-90. Although it has been claimed that MSC are immune privileged 
due to their low immunogenic phenotype 91-92, these results indicate allogeneic MSC are recognized 
and cleared by the recipient’s immune system. Clearance by cytotoxic immune cells may also explain 
why intravenously administered MSC can not be traced within a few days after transplantation 90, 
93. For application of MSC in solid organ transplantation, it is important to further investigate the 
immunogenicity and survival of administered MSC.
In conclusion, the immunosuppressive and regenerative capacities of MSC make them attractive 
candidates for numerous clinical applications. Until now, however, little is known of their effects in 
an end-stage renal disease or kidney transplantation setting. Therefore, the present thesis investigates 
the potential of MSC in organ transplantation, with special focus on their immunosuppressive effects.
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AIM And OuTLInE OF ThE PrESEnT ThESIS
The aim of this thesis is to investigate the potential of MSC as an immunomodulatory agent to improve 
the outcome of clinical solid organ transplantation. While bone marrow is the classical source of MSC, 
the collection bone marrow is invasive. Therefore, alternative sources of MSC are investigated, such 
as placenta, umbilical cord blood and adipose tissue. In chapter two we demonstrate the isolation of 
MSC from perirenal adipose tissue of living kidney donors, which is a waste product during the kidney 
donation procedure. The general characteristics of these adipose tissue-derived MSC were compared 
to those of MSC isolated from bone marrow, spleen and heart tissue. Although the immunosuppressive 
properties of MSC have been investigated in various experimental settings, it is unknown whether 
MSC also exert these immunosuppressive effects in a clinical kidney transplantation setting. Thus, in 
chapter three the immunosuppressive effects of kidney donor-derived MSC on recipient anti-donor 
reactivity before and after transplantation were investigated in vitro. Furthermore, we compared the 
efficacy of autologous and allogeneic MSC to inhibit alloreactivity. 
When MSC are applied as cellular therapy in clinical organ transplantation, it is likely that they will 
be used in combination of immunosuppressive drugs. In chapter four we therefore examined the 
effect of the immunosuppressive drugs tacrolimus, rapamycin and mycophenolic acid (MPA) on MSC 
functions. 
Most studies investigated the effect of MSC on activated immune cells. The effects of inflammatory 
conditions on MSC are less known and are investigated in chapter five. MSC were exposed to two 
inflammatory conditions, i.e. (1) alloactivated immune cells (MLR) in transwell culture systems or 
(2) pro-inflammatory cytokines. We performed full gene expression analysis of the treated MSC and 
examined their immunophenotype and function. 
We subsequently investigated how MSC affect non-activated/resting immune cells in chapter six. 
Although it has been claimed that MSC are not immunogenic, there is evidence from animal models 
that MSC can induce memory responses and that systemically infused MSC can not be traced after 
administration, which could be the result of recognition of MSC by the recipient’s immune system. 
In chapter seven the susceptibility of MSC for lysis by cytotoxic CD8+ T-cells and NK-cells was 
studied. In chapter eight the results presented in this thesis are summarized and discussed.
Finally, in chapter nine the properties of MSC in respect to several issues that could be important for 
clinical application of MSC in kidney transplantation are evaluated.
Chapter 118
rEFErEnCES
1. Marcen R. Immunosuppressive drugs in kidney transplantation: impact on patient survival, and incidence of cardiovascular 
disease, malignancy and infection. Drugs. 2009 Nov 12;69(16):2227-43.
2. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, et al. Multilineage potential of adult human 
mesenchymal stem cells. Science. 1999 Apr 2;284(5411):143-7.
3. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood. 2005 Feb 
15;105(4):1815-22.
4. Di Nicola M, Carlo-Stella C, Magni M, Milanesi M, Longoni PD, Matteucci P, et al. Human bone marrow stromal cells 
suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood. 2002 May 15;99(10):3838-43.
5. Hoogduijn MJ, Crop MJ, Peeters AM, Van Osch GJ, Balk AH, Ijzermans JN, et al. Human heart, spleen, and perirenal fat-
derived mesenchymal stem cells have immunomodulatory capacities. Stem Cells Dev. 2007 Aug;16(4):597-604.
6. Toma JG, Akhavan M, Fernandes KJ, Barnabe-Heider F, Sadikot A, Kaplan DR, et al. Isolation of multipotent adult stem 
cells from the dermis of mammalian skin. Nat Cell Biol. 2001 Sep;3(9):778-84.
7. da Silva Meirelles L, Chagastelles PC, Nardi NB. Mesenchymal stem cells reside in virtually all post-natal organs and 
tissues. J Cell Sci. 2006 Jun 1;119(Pt 11):2204-13.
8. In ‘t Anker PS, Scherjon SA, Kleijburg-van der Keur C, de Groot-Swings GM, Claas FH, Fibbe WE, et al. Isolation of 
mesenchymal stem cells of fetal or maternal origin from human placenta. Stem Cells. 2004;22(7):1338-45.
9. Hoogduijn MJ, Crop MJ, Peeters AM, Korevaar SS, Eijken M, Drabbels JJ, et al. Donor-derived mesenchymal stem cells 
remain present and functional in the transplanted human heart. Am J Transplant. 2009 Jan;9(1):222-30.
10. Zuk PA, Zhu M, Ashjian P, De Ugarte DA, Huang JI, Mizuno H, et al. Human adipose tissue is a source of multipotent stem 
cells. Mol Biol Cell. 2002 Dec;13(12):4279-95.
11. Kern S, Eichler H, Stoeve J, Kluter H, Bieback K. Comparative analysis of mesenchymal stem cells from bone marrow, 
umbilical cord blood, or adipose tissue. Stem Cells. 2006 May;24(5):1294-301.
12. Mizuno H. Adipose-derived stem cells for tissue repair and regeneration: ten years of research and a literature review. J 
Nippon Med Sch. 2009 Apr;76(2):56-66.
13. Mitchell JB, McIntosh K, Zvonic S, Garrett S, Floyd ZE, Kloster A, et al. Immunophenotype of human adipose-derived 
cells: temporal changes in stromal-associated and stem cell-associated markers. Stem Cells. 2006 Feb;24(2):376-85.
14. Conget PA, Minguell JJ. Phenotypical and functional properties of human bone marrow mesenchymal progenitor cells. J 
Cell Physiol. 1999 Oct;181(1):67-73.
15. Crop MJ, Baan CC, Korevaar SS, Ijzermans JN, Alwayn IP, Weimar W, et al. Donor-derived mesenchymal stem cells 
suppress alloreactivity of kidney transplant patients. Transplantation. 2009 Mar 27;87(6):896-906.
16. Krampera M, Cosmi L, Angeli R, Pasini A, Liotta F, Andreini A, et al. Role for interferon-gamma in the immunomodulatory 
activity of human bone marrow mesenchymal stem cells. Stem Cells. 2006 Feb;24(2):386-98.
17. Le Blanc K, Ringden O. Immunobiology of human mesenchymal stem cells and future use in hematopoietic stem cell 
transplantation. Biol Blood Marrow Transplant. 2005 May;11(5):321-34.
18. Horwitz EM, Prockop DJ, Fitzpatrick LA, Koo WW, Gordon PL, Neel M, et al. Transplantability and therapeutic effects of 
bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta. Nat Med. 1999 Mar;5(3):309-13.
19. Quarto R, Mastrogiacomo M, Cancedda R, Kutepov SM, Mukhachev V, Lavroukov A, et al. Repair of large bone defects 
with the use of autologous bone marrow stromal cells. N Engl J Med. 2001 Feb 1;344(5):385-6.
20. Ando W, Tateishi K, Hart DA, Katakai D, Tanaka Y, Nakata K, et al. Cartilage repair using an in vitro generated scaffold-free 
tissue-engineered construct derived from porcine synovial mesenchymal stem cells. Biomaterials. 2007 Dec;28(36):5462-70.
Introduction
C
ha
pt
er
 1
19
21. Wakitani S, Mitsuoka T, Nakamura N, Toritsuka Y, Nakamura Y, Horibe S. Autologous bone marrow stromal cell 
transplantation for repair of full-thickness articular cartilage defects in human patellae: two case reports. Cell Transplant. 
2004;13(5):595-600.
22. Rasulov MF, Vasilchenkov AV, Onishchenko NA, Krasheninnikov ME, Kravchenko VI, Gorshenin TL, et al. First 
experience of the use bone marrow mesenchymal stem cells for the treatment of a patient with deep skin burns. Bull Exp Biol 
Med. 2005 Jan;139(1):141-4.
23. Rasulov MF, Vasilenko VT, Zaidenov VA, Onishchenko NA. Cell transplantation inhibits inflammatory reaction and 
stimulates repair processes in burn wound. Bull Exp Biol Med. 2006 Jul;142(1):112-5.
24. Phinney DG, Isakova I. Plasticity and therapeutic potential of mesenchymal stem cells in the nervous system. Curr Pharm 
Des. 2005;11(10):1255-65.
25. Jiang W, Ma A, Wang T, Han K, Liu Y, Zhang Y, et al. Intravenous transplantation of mesenchymal stem cells improves 
cardiac performance after acute myocardial ischemia in female rats. Transpl Int. 2006 Jul;19(7):570-80.
26. Kocher AA, Schlechta B, Gasparovicova A, Wolner E, Bonaros N, Laufer G. Stem cells and cardiac regeneration. Transpl 
Int. 2007 Sep;20(9):731-46.
27. Chen SL, Fang WW, Ye F, Liu YH, Qian J, Shan SJ, et al. Effect on left ventricular function of intracoronary transplantation 
of autologous bone marrow mesenchymal stem cell in patients with acute myocardial infarction. Am J Cardiol. 2004 Jul 
1;94(1):92-5.
28. Kunter U, Rong S, Djuric Z, Boor P, Muller-Newen G, Yu D, et al. Transplanted mesenchymal stem cells accelerate 
glomerular healing in experimental glomerulonephritis. J Am Soc Nephrol. 2006 Aug;17(8):2202-12.
29. Morigi M, Imberti B, Zoja C, Corna D, Tomasoni S, Abbate M, et al. Mesenchymal stem cells are renotropic, helping to 
repair the kidney and improve function in acute renal failure. J Am Soc Nephrol. 2004 Jul;15(7):1794-804.
30. Macchiarini P, Jungebluth P, Go T, Asnaghi MA, Rees LE, Cogan TA, et al. Clinical transplantation of a tissue-engineered 
airway. Lancet. 2008 Dec 13;372(9655):2023-30.
31. Bi B, Schmitt R, Israilova M, Nishio H, Cantley LG. Stromal cells protect against acute tubular injury via an endocrine 
effect. J Am Soc Nephrol. 2007 Sep;18(9):2486-96.
32. Caplan AI, Dennis JE. Mesenchymal stem cells as trophic mediators. J Cell Biochem. 2006 Aug 1;98(5):1076-84.
33. Krampera M, Glennie S, Dyson J, Scott D, Laylor R, Simpson E, et al. Bone marrow mesenchymal stem cells inhibit the 
response of naive and memory antigen-specific T cells to their cognate peptide. Blood. 2003 May 1;101(9):3722-9.
34. Glennie S, Soeiro I, Dyson PJ, Lam EW, Dazzi F. Bone marrow mesenchymal stem cells induce division arrest anergy of 
activated T cells. Blood. 2005 Apr 1;105(7):2821-7.
35. Groh ME, Maitra B, Szekely E, Koc ON. Human mesenchymal stem cells require monocyte-mediated activation to suppress 
alloreactive T cells. Exp Hematol. 2005 Aug;33(8):928-34.
36. Sato K, Ozaki K, Oh I, Meguro A, Hatanaka K, Nagai T, et al. Nitric oxide plays a critical role in suppression of T-cell 
proliferation by mesenchymal stem cells. Blood. 2007 Jan 1;109(1):228-34.
37. Ren G, Zhang L, Zhao X, Xu G, Zhang Y, Roberts AI, et al. Mesenchymal stem cell-mediated immunosuppression occurs 
via concerted action of chemokines and nitric oxide. Cell Stem Cell. 2008 Feb 7;2(2):141-50.
38. Batten P, Sarathchandra P, Antoniw JW, Tay SS, Lowdell MW, Taylor PM, et al. Human mesenchymal stem cells induce T 
cell anergy and downregulate T cell allo-responses via the TH2 pathway: relevance to tissue engineering human heart valves. 
Tissue Eng. 2006 Aug;12(8):2263-73.
39. Meisel R, Zibert A, Laryea M, Gobel U, Daubener W, Dilloo D. Human bone marrow stromal cells inhibit allogeneic T-cell 
responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood. 2004 Jun 15;103(12):4619-21.
40. Selmani Z, Naji A, Gaiffe E, Obert L, Tiberghien P, Rouas-Freiss N, et al. HLA-G is a crucial immunosuppressive molecule 
secreted by adult human mesenchymal stem cells. Transplantation. 2009 May 15;87(9 Suppl):S62-6.
Chapter 120
41. Suva D, Passweg J, Arnaudeau S, Hoffmeyer P, Kindler V. In vitro activated human T lymphocytes very efficiently attach to 
allogenic multipotent mesenchymal stromal cells and transmigrate under them. J Cell Physiol. 2008 March;214(3):588-94.
42. Quaedackers ME, Baan CC, Weimar W, Hoogduijn MJ. Cell contact interaction between adipose-derived stromal cells and 
allo-activated T lymphocytes. Eur J Immunol. 2009 Dec;39(12):3436-46.
43. Ren G, Zhao X, Zhang L, Zhang J, L’Huillier A, Ling W, et al. Inflammatory cytokine-induced intercellular adhesion 
molecule-1 and vascular cell adhesion molecule-1 in mesenchymal stem cells are critical for immunosuppression. J Immunol. 
2010 Mar 1;184(5):2321-8.
44. Majumdar MK, Keane-Moore M, Buyaner D, Hardy WB, Moorman MA, McIntosh KR, et al. Characterization and 
functionality of cell surface molecules on human mesenchymal stem cells. J Biomed Sci. 2003 Mar-Apr;10(2):228-41.
45. Klyushnenkova E, Mosca JD, Zernetkina V, Majumdar MK, Beggs KJ, Simonetti DW, et al. T cell responses to allogeneic 
human mesenchymal stem cells: immunogenicity, tolerance, and suppression. J Biomed Sci. 2005;12(1):47-57.
46. Tse WT, Pendleton JD, Beyer WM, Egalka MC, Guinan EC. Suppression of allogeneic T-cell proliferation by human marrow 
stromal cells: implications in transplantation. Transplantation. 2003 Feb 15;75(3):389-97.
47. Angoulvant D, Clerc A, Benchalal S, Galambrun C, Farre A, Bertrand Y, et al. Human mesenchymal stem cells suppress 
induction of cytotoxic response to alloantigens. Biorheology. 2004;41(3-4):469-76.
48. Rasmusson I, Ringden O, Sundberg B, Le Blanc K. Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, 
but not activated cytotoxic T lymphocytes or natural killer cells. Transplantation. 2003 Oct 27;76(8):1208-13.
49. Spaggiari GM, Capobianco A, Abdelrazik H, Becchetti F, Mingari MC, Moretta L. Mesenchymal stem cells inhibit natural 
killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2,3-dioxygenase and prostaglandin E2. 
Blood. 2008 Feb 1;111(3):1327-33.
50. Morandi F, Raffaghello L, Bianchi G, Meloni F, Salis A, Millo E, et al. Immunogenicity of human mesenchymal stem cells 
in HLA-class I-restricted T-cell responses against viral or tumor-associated antigens. Stem Cells. 2008 May;26(5):1275-87.
51. Potian JA, Aviv H, Ponzio NM, Harrison JS, Rameshwar P. Veto-like activity of mesenchymal stem cells: functional 
discrimination between cellular responses to alloantigens and recall antigens. J Immunol. 2003 Oct 1;171(7):3426-34.
52. Di Ianni M, Del Papa B, De Ioanni M, Moretti L, Bonifacio E, Cecchini D, et al. Mesenchymal cells recruit and regulate T 
regulatory cells. Exp Hematol. 2008 Mar;36(3):309-18.
53. Maccario R, Podesta M, Moretta A, Cometa A, Comoli P, Montagna D, et al. Interaction of human mesenchymal stem 
cells with cells involved in alloantigen-specific immune response favors the differentiation of CD4+ T-cell subsets expressing a 
regulatory/suppressive phenotype. Haematologica. 2005 Apr;90(4):516-25.
54. Prevosto C, Zancolli M, Canevali P, Zocchi MR, Poggi A. Generation of CD4+ or CD8+ regulatory T cells upon mesenchymal 
stem cell-lymphocyte interaction. Haematologica. 2007 Jul;92(7):881-8.
55. Casiraghi F, Azzollini N, Cassis P, Imberti B, Morigi M, Cugini D, et al. Pretransplant infusion of mesenchymal stem cells 
prolongs the survival of a semiallogeneic heart transplant through the generation of regulatory T cells. J Immunol. 2008 Sep 
15;181(6):3933-46.
56. Corcione A, Benvenuto F, Ferretti E, Giunti D, Cappiello V, Cazzanti F, et al. Human mesenchymal stem cells modulate 
B-cell functions. Blood. 2006 Jan 1;107(1):367-72.
57. Comoli P, Ginevri F, Maccario R, Avanzini MA, Marconi M, Groff A, et al. Human mesenchymal stem cells inhibit antibody 
production induced in vitro by allostimulation. Nephrol Dial Transplant. 2008 Apr;23(4):1196-202.
58. Asari S, Itakura S, Ferreri K, Liu CP, Kuroda Y, Kandeel F, et al. Mesenchymal stem cells suppress B-cell terminal 
differentiation. Exp Hematol. 2009 May;37(5):604-15.
59. Tabera S, Perez-Simon JA, Diez-Campelo M, Sanchez-Abarca LI, Blanco B, Lopez A, et al. The effect of mesenchymal stem 
cells on the viability, proliferation and differentiation of B-lymphocytes. Haematologica. 2008 Jul 18;93(9):1301-9.
60. Rasmusson I, Le Blanc K, Sundberg B, Ringden O. Mesenchymal stem cells stimulate antibody secretion in human B cells. 
Scand J Immunol. 2007 Apr;65(4):336-43.
Introduction
C
ha
pt
er
 1
21
61. Traggiai E, Volpi S, Schena F, Gattorno M, Ferlito F, Moretta L, et al. Bone marrow-derived mesenchymal stem cells induce 
both polyclonal expansion and differentiation of B cells isolated from healthy donors and systemic lupus erythematosus patients. 
Stem Cells. 2008 Feb;26(2):562-9.
62. Munoz-Fernandez R, Blanco FJ, Frecha C, Martin F, Kimatrai M, Abadia-Molina AC, et al. Follicular dendritic cells are 
related to bone marrow stromal cell progenitors and to myofibroblasts. J Immunol. 2006 Jul 1;177(1):280-9.
63. Sotiropoulou PA, Perez SA, Gritzapis AD, Baxevanis CN, Papamichail M. Interactions between human mesenchymal stem 
cells and natural killer cells. Stem Cells. 2006 Jan;24(1):74-85.
64. Maccario R, Moretta A, Cometa A, Montagna D, Comoli P, Locatelli F, et al. Human mesenchymal stem cells and cyclosporin 
a exert a synergistic suppressive effect on in vitro activation of alloantigen-specific cytotoxic lymphocytes. Biol Blood Marrow 
Transplant. 2005 Dec;11(12):1031-2.
65. Malygin AM, Meri S, Timonen T. Regulation of natural killer cell activity by transforming growth factor-beta and 
prostaglandin E2. Scand J Immunol. 1993 Jan;37(1):71-6.
66. Spaggiari GM, Capobianco A, Becchetti S, Mingari MC, Moretta L. Mesenchymal stem cell-natural killer cell interactions: 
evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. 
Blood. 2006 Feb 15;107(4):1484-90.
67. Nauta AJ, Kruisselbrink AB, Lurvink E, Willemze R, Fibbe WE. Mesenchymal stem cells inhibit generation and function 
of both CD34+-derived and monocyte-derived dendritic cells. J Immunol. 2006 Aug 15;177(4):2080-7.
68. Jiang XX, Zhang Y, Liu B, Zhang SX, Wu Y, Yu XD, et al. Human mesenchymal stem cells inhibit differentiation and 
function of monocyte-derived dendritic cells. Blood. 2005 May 15;105(10):4120-6.
69. Djouad F, Charbonnier LM, Bouffi C, Louis-Plence P, Bony C, Apparailly F, et al. Mesenchymal stem cells inhibit the 
differentiation of dendritic cells through an interleukin-6-dependent mechanism. Stem Cells. 2007 Aug;25(8):2025-32.
70. Zhang W, Ge W, Li C, You S, Liao L, Han Q, et al. Effects of mesenchymal stem cells on differentiation, maturation, and 
function of human monocyte-derived dendritic cells. Stem Cells Dev. 2004 Jun;13(3):263-71.
71. Lazarus HM, Koc ON, Devine SM, Curtin P, Maziarz RT, Holland HK, et al. Cotransplantation of HLA-identical sibling 
culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. Biol Blood Marrow 
Transplant. 2005 May;11(5):389-98.
72. Maitra B, Szekely E, Gjini K, Laughlin MJ, Dennis J, Haynesworth SE, et al. Human mesenchymal stem cells support 
unrelated donor hematopoietic stem cells and suppress T-cell activation. Bone Marrow Transplant. 2004 Mar;33(6):597-604.
73. Almeida-Porada G, Porada CD, Tran N, Zanjani ED. Cotransplantation of human stromal cell progenitors into preimmune 
fetal sheep results in early appearance of human donor cells in circulation and boosts cell levels in bone marrow at later time 
points after transplantation. Blood. 2000 Jun 1;95(11):3620-7.
74. Valtieri M, Sorrentino A. The mesenchymal stromal cell contribution to homeostasis. J Cell Physiol. 2008 Jul 9.
75. Benvenuto F, Ferrari S, Gerdoni E, Gualandi F, Frassoni F, Pistoia V, et al. Human mesenchymal stem cells promote survival 
of T cells in a quiescent state. Stem Cells. 2007 Jul;25(7):1753-60.
76. Gonzalez MA, Gonzalez-Rey E, Rico L, Buscher D, Delgado M. Adipose-derived mesenchymal stem cells alleviate 
experimental colitis by inhibiting inflammatory and autoimmune responses. Gastroenterology. 2009 Mar;136(3):978-89.
77. Gonzalez-Rey E, Gonzalez MA, Rico L, Buscher D, Delgado M. Human adult stem cells derived from adipose tissue protect 
against experimental colitis and sepsis. Gut. 2009 Jan 9.
78. Ohnishi S, Yanagawa B, Tanaka K, Miyahara Y, Obata H, Kataoka M, et al. Transplantation of mesenchymal stem cells 
attenuates myocardial injury and dysfunction in a rat model of acute myocarditis. J Mol Cell Cardiol. 2007 Jan;42(1):88-97.
79. Constantin G, Marconi S, Rossi B, Angiari S, Calderan L, Anghileri E, et al. Adipose-derived mesenchymal stem cells 
ameliorate chronic experimental autoimmune encephalomyelitis. Stem Cells. 2009 Oct;27(10):2624-35.
80. Zappia E, Casazza S, Pedemonte E, Benvenuto F, Bonanni I, Gerdoni E, et al. Mesenchymal stem cells ameliorate 
experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood. 2005 Sep 1;106(5):1755-61.
Chapter 122
81. Le Blanc K, Samuelsson H, Gustafsson B, Remberger M, Sundberg B, Arvidson J, et al. Transplantation of mesenchymal 
stem cells to enhance engraftment of hematopoietic stem cells. Leukemia. 2007 Aug;21(8):1733-8.
82. Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I, et al. Mesenchymal stem cells for treatment of steroid-
resistant, severe, acute graft-versus-host disease: a phase II study. Lancet. 2008 May 10;371(9624):1579-86.
83. Bartholomew A, Sturgeon C, Siatskas M, Ferrer K, McIntosh K, Patil S, et al. Mesenchymal stem cells suppress lymphocyte 
proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol. 2002 Jan;30(1):42-8.
84. Ge W, Jiang J, Baroja ML, Arp J, Zassoko R, Liu W, et al. Infusion of mesenchymal stem cells and rapamycin synergize to 
attenuate alloimmune responses and promote cardiac allograft tolerance. Am J Transplant. 2009 Aug;9(8):1760-72.
85. Popp FC, Eggenhofer E, Renner P, Slowik P, Lang SA, Kaspar H, et al. Mesenchymal stem cells can induce long-term 
acceptance of solid organ allografts in synergy with low-dose mycophenolate. Transpl Immunol. 2008 Nov;20(1-2):55-60.
86. Wan CD, Cheng R, Wang HB, Liu T. Immunomodulatory effects of mesenchymal stem cells derived from adipose tissues in 
a rat orthotopic liver transplantation model. Hepatobiliary Pancreat Dis Int. 2008 Feb;7(1):29-33.
87. Inoue S, Popp FC, Koehl GE, Piso P, Schlitt HJ, Geissler EK, et al. Immunomodulatory effects of mesenchymal stem cells 
in a rat organ transplant model. Transplantation. 2006 Jun 15;81(11):1589-95.
88. Sbano P, Cuccia A, Mazzanti B, Urbani S, Giusti B, Lapini I, et al. Use of donor bone marrow mesenchymal stem cells for 
treatment of skin allograft rejection in a preclinical rat model. Arch Dermatol Res. 2008 Feb 8;300(3):115-24.
89. Nauta AJ, Westerhuis G, Kruisselbrink AB, Lurvink EG, Willemze R, Fibbe WE. Donor-derived mesenchymal stem cells 
are immunogenic in an allogeneic host and stimulate donor graft rejection in a non-myeloablative setting. Blood. 2006 May 
11;108(6):2114-20.
90. Eliopoulos N, Stagg J, Lejeune L, Pommey S, Galipeau J. Allogeneic marrow stromal cells are immune rejected by MHC 
class I- and class II-mismatched recipient mice. Blood. 2005 Dec 15;106(13):4057-65.
91. Rasmusson I, Uhlin M, Le Blanc K, Levitsky V. Mesenchymal stem cells fail to trigger effector functions of cytotoxic T 
lymphocytes. J Leukoc Biol. 2007 Oct;82(4):887-93.
92. Mammolenti M, Gajavelli S, Tsoulfas P, Levy R. Absence of major histocompatibility complex class I on neural stem cells 
does not permit natural killer cell killing and prevents recognition by alloreactive cytotoxic T lymphocytes in vitro. Stem Cells. 
2004;22(6):1101-10.
93. Beggs KJ, Lyubimov A, Borneman JN, Bartholomew A, Moseley A, Dodds R, et al. Immunologic consequences of multiple, 
high-dose administration of allogeneic mesenchymal stem cells to baboons. Cell Transplant. 2006;15(8-9):711-21.


human heart, spleen, and 
perirenal fat-derived
mesenchymal stem cells have 
immunomodulatory capacities
Chapter 2
Martin J. Hoogduijn1, Meindert J. Crop1, Annemiek M.A. Peeters1, Gerjo J.V.M. van 
Osch2, Aggie H.M.M. Balk3, Jan N.M. IJzermans4, Willem Weimar1, Carla C. Baan1
Stem Cells and Development 
2007 Aug;16(4):597-604
1Departments of Internal Medicine, 2Orthopaedics & Otorhinolaryngology, 
3Cardiology, and 4Surgery, 
Erasmus University Medical Center, Rotterdam, the Netherlands
Chapter 226
ABSTrACT
Mesenchymal stem cells (MSC) have important tissue repair functions and show potent 
immunosuppressive capacities in vitro. Although usually isolated from the bone marrow, MSC have 
been identified in other tissues, including the skin and liver. In the present study, we isolated and 
characterized MSC from human heart, spleen, and perirenal adipose tissue. MSC from these different 
tissue sites were similar to those derived from bone marrow in that they expressed comparable levels of 
the cell-surface markers CD90, CD105, CD166 and HLA class I, were negative for CD34, CD45, HLA 
class II, CD80, and CD86 expression, and were capable of osteogenic and adipogenic differentiation. 
Like bone marrow-derived MSC, MSC from these different tissue sources inhibited the proliferation of 
alloactivated peripheral blood mononuclear cells (PBMC), giving 85%, 79%, 79% and 81% inhibition, 
respectively. Also in line with bone marrow-derived MSC they inhibited proliferative responses of 
PBMC to phytohaemagglutinin, a non-specific stimulator of lymphocyte proliferation, and reduced 
memory T lymphocyte responses to tetanus toxoid. The results of this study demonstrate that MSC 
from various tissues have similar immunophenotypes, in vitro immunosuppressive properties, and 
differentiation potential. 
Immunosuppression by tissue-derived MSC
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InTrOduCTIOn
Mesenchymal stem cells (MSC) constitute a low percentage (0.01-0.001%) of low density bone marrow 
cells 1-2. Their descendents create at least some of the bone marrow stroma, which provides a supportive 
environment for haematopoietic stem cell (HSC) proliferation, maturation and homing 3. Also, and 
not different from bone marrow stroma generation, upon exposure to the appropriate stimuli, they 
give rise to a number of mesenchymal lineages, including osteoblasts, adipocytes, chondrocytes, and 
myocytes, thus providing, when needed, a tissue repair function 2, 4. In addition there is evidence for 
an immune regulatory function of MSC. In vitro, MSC have the capacity to inhibit mixed lymphocyte 
reactions 5-7, probably via mechanisms that are independent of MHC 8 but may involve soluble factors 
such as transforming growth factor-β1 (TGF-β1) 9 and cell-membrane contact with T lymphocytes 10. 
The immunosuppressive properties of MSC have been further evidenced by in vivo administration. 
Skin graft survival in mice was prolonged 11 and graft-versus-host disease in humans after bone 
marrow transplantation was reduced 12.
Although generally considered as bone marrow-residing cells, there is accumulating evidence for a 
widespread distribution of MSC. Systemic infusion of MSC leads to homing to a wide range of tissues 
that include kidney, lung, liver, thymus and skin 13. Recently, MSC have been isolated from peripheral 
blood 14, and it was shown that their numbers in peripheral blood increase in response to hypoxic 
stress 15. However, the biological significance of systemic migration of MSC is unclear. MSC have 
been isolated from adipose tissue 16, dermis 17, and hair follicles 18, where they may reside from early 
developmental stages. Recently, a study in mice demonstrated that MSC reside in virtually all organs 
and tissues 19. In the present study, we have isolated and expanded MSC from human heart, spleen, 
and perirenal adipose tissue and compared their immunophenotype, differentiation, and immune 
regulatory capacity with bone marrow-derived MSC. 
MATErIALS And METhOdS
Isolation and culture of human MSC
Heart: 
Atrium tissue that is routinely removed from donor hearts during heart transplantation surgery was 
collected as approved by the medical ethical committee of the Erasmus Medical Center (protocol no. 
MEC-2006-190) and used for the isolation of MSC. Atrium tissue from 3 hearts was stored in RPMI 
medium (Invitrogen, UK), minced within 24 hours with a scalpel knife, and digested with sterile 
filtered 0.5 mg/ml collagenase type IV (Sigma-Aldrich, Germany) in RPMI for 30 min at 37°C under 
continuous stirring. After two washes in RPMI, the dissociated tissue and cells were transferred to a 
culture flask and cultured in minimal essential medium-α (MEM-α) (Invitrogen, UK) supplemented 
with 15% foetal bovine serum (FBS; Biowhittacker, Belgium) and 100 U/ml penicillin and 100 µg/ml 
streptomycin (1% p/s; Invitrogen, UK). After 3-4 days, the culture medium was refreshed and non-
adherent cells removed. Subsequently, medium was refreshed twice weekly and cells trypsinized at 
subconfluency using 0.05% trypsin-EDTA. Cells were reseeded at 1000 cells/cm2 to ensure optimal 
proliferation and used for experiments between passage 2 and 5.
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Spleen:
Spleen tissue was obtained from three post-mortem kidney or heart donors and stored in RPMI 
medium at 4°C. Not more than 48 hours later, the spleen was mashed and splenocytes were washed 
through a sieve. The residual connective tissue, including the spleen capsule, was then minced with 
a scalpel knife, incubated with sterile filtered 0.5 mg/ml collagenase type IV in RPMI for 30 min at 
37°C under continuous stirring, and treated as described above for the heart tissue.
Perirenal fat tissue:
Adipose tissue surrounding the kidney was removed from three kidney transplant donors during the 
kidney donation procedure after written informed consent (protocol no. MEC-2006-190). The tissue 
was mechanically disrupted with a scalpel knife and, after two washes with phosphate-buffered saline 
(PBS), digested with sterile filtered 0.5 mg/ml collagenase type IV in RPMI for 30 min at 37°C. 
Medium with serum was then added and the cells and tissue pelleted by centrifugation at 1200 x g 
for 10 min. The pellet was then resuspended in 160 mM NH
4
Cl and incubated for 10 min at room 
temperature to lyse contaminating red blood cells. Subsequently, the cells were centrifuged for 10 min 
at 1200 x g, resuspended in MEM-α with 15% FBS and 1% p/s, filtered through a 100-µm cell strainer, 
and transferred to culture flasks. The cultures were maintained as described above. 
Bone marrow:
Bone marrow was obtained from the femoral shaft or iliac crest of patients undergoing hip 
replacement treatment after written informed consent (protocol no. MEC-2004-142). MSC were 
isolated from heparinized femoral shaft marrow aspirate by plating out, and non-adherent cells were 
removed after 24 hours. Adherent cells were initially cultured in Dulbecco’s modified Eagle medium 
(DMEM; Invitrogen, The Netherlands), supplemented with 10% FBS, 50 µg/ml gentamycin (Life 
Technologies), 1.5 µg/ml fungizone (Life Technologies), 1 ng/ml fibroblast growth factor-2 (FGF-
2; Instruchemie, the Netherlands), and freshly prepared 25 µg/ml L-ascorbic acid-2-phosphate. At 
the third passage, the cells were switched to MEM-α supplemented with 1% p/s and 15% FBS and 
maintained as described above.
Flow cytometry
MSC were removed from culture flasks by incubation in PBS with 5 mM EDTA and 0.2% bovine 
serum albumin (BSA) at 37ºC. Cell suspensions were incubated in the above buffer with fluorescent-
labelled antibodies against CD90, CD105 (R&D systems, UK), CD14, CD34, CD45, HLA class II 
(BD, USA), CD80, HLA class I (Serotec, UK), CD86 and CD166 (BD Pharmingen, USA) on ice 
protected from light for 30 min. Isotype control antibodies were used to determine non-specific 
staining. After two washes in PBS with 5 mM EDTA and 0.2% BSA, flow cytometric analysis was 
carried out using a four-colour FACSCalibur with Cell Quest Pro software (Becton Dickinson, USA). 
differentiation assays
Osteogenic differentiation
Osteogenic differentiation was induced by culturing confluent MSC cultures in MEM-αsupplemented 
with 1% p/s, 15% heat-inactivated FBS (56°C, 30 min), 5 mM β-glycerophosphate (Sigma-Aldrich, 
Germany), 50µg/ml L-ascorbic acid-phosphate (Sigma-Aldrich, Germany), and 10 nM dexamethasone 
(Sigma-Aldrich, Germany) for 14 days. The presence of calcified nodules, a marker for osteogenic 
differentiation, was detected by von Kossa staining. Cells were washed with PBS, fixed in cold 4% 
paraformaldehyde for 5 min, washed once with PBS and twice with distilled water, and incubated in 
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1% silver nitrate in water on a light box until blackening occurred. The cells were then washed three 
times with water, incubated with 2.5% sodium thiosulfate in water for 5 min, washed two times with 
water, and photographed.
Adipogenic differentiation
Adipogenic differentiation was induced by culturing confluent MSC cultures in MEM-α supplemented 
with 1% p/s, 15% heat-inactivated FBS, 50 µg/ml L-ascorbic acid-phosphate, 500 mM 3-isobutyl-1-
methylxanthine (IBMX; Fluka, Germany), and 60 mM indomethacin (Fluka, Germany) for 14 days. 
The presence of lipid-filled vesicles was detected by oil-red-O staining. Cells were washed with 
PBS, fixed in 60% isopropanol for 1 min and incubated with filtered 0.3% oil-red-O (Sigma-Aldrich, 
Germany) in 60% isopropanol for 30 min. After three washes in PBS, the cells were photographed.
Effect of MSC on proliferation of peripheral blood mononuclear cells
Mixed lymphocyte reaction
Peripheral blood mononuclear cells (PBMC) were obtained from healthy donors from the blood bank 
(Sanquin, Rotterdam). PBMC (5x104) were seeded in round-bottomed, tissue culture-treated 96-
well plates in RPMI medium with 1% p/s and 10% heat-inactivated FBS and stimulated with 5x104 
HLA class 1 and 2 mismatched γ-irradiated (40 Gy) PBMC for 7 days in the presence or absence of 
1x104 third-party MSC isolated from heart, spleen, adipose tissue, or bone marrow. After 7 days, 
proliferation was measured by incorporation of [3H]-thymidine (0.5 µCi/well) during 8 hours of 
incubation. 
Response to phytohaemagglutinin (PHA)
PBMC (5x104) were cultured for 3 days in RPMI with 1% p/s, 10% heat-inactivated FBS, and 1 µg/
ml PHA (Murex Biotech, UK) in the presence or absence of 1x104 MSC, and proliferation measured. 
Response to Tetanus toxoid
PBMC (5x104) were cultured for 3 days in RPMI with 1% p/s, 10% heat-inactivated FBS and 7.5 limits 
of flocculation (lf)/well tetanus toxoid (Tet; RIVM, Netherlands) in the presence or absence of 1x104 
MSC and proliferation measured. 
Statistical analysis
Statistical analysis was performed by analysis of variance (ANOVA) followed by Dunnett’s multiple 
comparison test using GraphPad Prism software (GraphPad software, USA). p-values < 0.05 were 
considered significant.
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rESuLTS
Isolation and growth of fibroblastic cells from different human tissues
Isolated cells and small pieces of tissue from heart, spleen, and perirenal adipose tissue were transferred 
to culture flasks. After 3 to 10 days, cells with fibroblast morphology appeared, originating from small 
pieces of connective tissue (Figure 1A). The number of these cells rapidly increased (Figures 1B and 
C). The cells from heart, spleen, and adipose tissue were similar in morphology and indistinguishable 
from cultured bone marrow-derived MSC (Figure 1D). Figure 2 shows the collection, isolation and 
culture procedure of MSC from perirenal adipose tissue. To investigate whether the isolated cells 
had MSC characteristics, their cell-surface protein expression, differentiation capacity, and immune 
modulating abilities were examined.
Flow cytometric characterization of MSC
The immunophenotype of MSC isolated from heart, spleen, and adipose tissue and cultured for two to 
four passages was characterized by the expression of the cell-surface markers CD90, CD105, CD166, 
and HLA class I, and the absence of the haematopoietic marker CD34, the leucocyte marker CD45, 
HLA class II, and the co-stimulatory molecules CD80 and CD86 (Figure 3). MSC that were isolated 
from the bone marrow showed the same expression profile, and for most markers there were minimal 
quantitative differences in expression levels of the various markers among MSC from different 
sources. There were larger differences in the expression of HLA class I. These differences were, 
however, not significant because there was considerable variation in HLA I expression within the 
groups. HLA I expression in three cultures of heart MSC was 35%, 54%, and 56%, in spleen MSC 
30%, 62%, and 97%, in adipose tissue MSC 81% and 85%, and in bone marrow MSC 98%, 98%, and 
25%. In some early-passage cultures of spleen-derived cells, a subset of CD14+ cells was detected, 
indicative of monocytes, but CD14+ cells disappeared with ongoing passages (result not shown).
Figure 1. Bright-field microscopic images of cells with fibroblast morphology appearing in spleen cultures at day 
4 [A]; day 6 [B] and day 10 [C]. [D] bone marrow-derived MSC.Bar represents 20 μm.
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Figure 2. Collection, isolation and culture procedure of MSC from perirenal adipose tissue. [A] During the 
kidney donation procedure, perirenal adipose tissue was collected in the operation room and transported to the 
transplantation laboratory. [B-D] Under sterile conditions, perirenal fat was mechanically disrupted. [E] The 
tissue was then enzymatically digested with sterile 0.5 mg/mL collagenase type IV for 30 minutes at 37oC. [F] 
Next, the tissue was centrifuged and [G] resuspended in 160mM NH4Cl in phosphate-buffered saline (PBS) for 
10 minutes at room temperature to lyse contaminating red blood cells and filtered. [H] After centrifugation, cells 
were resuspended in MSC-culture medium and transferred to a culture flask and kept at 37oC, 5% CO2 and 95% 
humidity. [I] After several days adherent cells with a spindle-shaped morphology appeared.
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Figure 3. Flow cytometric analysis of the cell surface proteins CD90, CD105, CD166, CD34, CD45, HLA class I 
and II, CD80 and CD86 on the cells isolated from heart, spleen, adipose tissue and bone marrow. Solid histograms 
show non-specific staining, open histograms show specific staining for the indicated marker. Experiment carried 
out three times, median values shown.
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Osteogenic and adipogenic differentiation
Culturing of heart, spleen, and adipose tissue-derived MSC in osteogenic medium for 14 days resulted 
in their differentiation into the osteogenic lineage, which was characterized by the deposition of 
calcified nodules that stained black by von Kossa staining (Figure 4A-C). Bone marrow-derived MSC 
developed similar nodules after induction of osteogenic differentiation (Figure 4D). 
Induction of adipogenic differentiation of MSC derived from adipose tissue and bone marrow resulted 
in the development of lipid-filled vesicles, which were stained by oil-red-O after 14 days of culture 
(Figure 4E-H). Lipid vesicles were smaller in MSC cultures from heart and spleen tissue, which is 
indicative of an earlier differentiation state.  
Figure 4. A-D: von Kossa staining for calcified mineral nodules (black) after 14 days of osteogenic differentiation 
of MSC derived from [A] heart; [B] spleen; [C] adipose tissue; and [D] bone marrow. Figure 4E-H: oil-red-O 
staining for lipid-filled vesicles (red) after 14 days of adipogenic differentiation of MSC derived from [E] heart; 
[F] spleen; [G] adipose tissue; and [H] bone marrow. Bar represents 20 μm. Experiment carried out three times, 
representative images shown.
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Effect of MSC from different tissues on PBMC proliferation
Bone marrow MSC inhibit PBMC proliferation. The effect of MSC from different tissues on PBMC 
proliferation was examined by measurement of [3H]-thymidine incorporation. Stimulation of PBMC 
with γ-irradiated allogeneic PBMC increased proliferation 31-fold from 891 to 27,514 cpm (Figure 
5A). Co-culture with allogeneic MSC from heart, spleen, adipose tissue, or bone marrow in a 1:5 ratio 
for seven days inhibited PBMC proliferation significantly by on average 85%, 79%, 79% and 81%, 
respectively (n=3) (Figure 5A). The proliferation of MSC was neglectable (<500 cpm).
Stimulation of PBMC with PHA for 3 days resulted in a more than 200-fold increase in proliferation 
with [3H]-thymidine incorporation increasing from 392 to 79,869 cpm (n=3). The addition of allogeneic 
MSC derived from heart, spleen, adipose tissue, or bone marrow in a 1:5 ratio reduced PHA-induced 
proliferation of PBMC by 73%, 43%, 77% and 94%, respectively (Figure 5B). Bone marrow-derived 
MSC were significantly more potent in inhibiting PHA responses than MSC derived from the other 
tissues tested. 
Finally, it was tested whether MSC would inhibit a memory T-cell response to Tet. PBMC were 
stimulated with 7.5 lf/well Tet in the absence or presence of MSC in a 1:5 ratio and proliferation 
measured after seven days. Tet increased proliferation of PBMC six-fold and co-culture with MSC 
from heart, spleen, adipose tissue, and bone marrow reduced proliferation by 55%, 50%, and 53%, 
52%, respectively (Figure 5C).
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Figure 5. Effect of MSC of different origin on PBMC proliferation measured by [3H]-thymidine incorporation. 
PBMC were stimulated by [A] γ-irradiated allogeneic PBMC (L2↓); [B] PHA; or [C] Tetanus toxoid (Tet). MSC 
were added to responder PBMC in a 1:5 ratio. Results shown are the mean values of 3 experiments [Figure A, B] 
or 2 experiments [Figure C] in triplicate ± SEM. * indicates p-value < 0.05 compared to column 2.
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dISCuSSIOn
In the present study, we isolated and expanded cells with fibroblast morphology from the human 
heart, spleen, and perirenal adipose tissue. The immunophenotype of these cells was identical to bone 
marrow-derived MSC described in the literature 2, 20, i.e. the cells were positive for CD90, CD105, 
CD166 and HLA class I, and negative for HLA class II, CD34, CD45, CD80 and CD86 expression. 
In addition, as with bone marrow-derived MSC, they differentiated along osteogenic and adipogenic 
lineages when cultured under the appropriate conditions. Also in line with bone marrow-derived 
MSC, these cells inhibited the proliferative response of allogeneic PBMC after alloactivation and after 
stimulation with PHA or the recall antigen Tet. Therefore, we conclude that these cells under test from 
the human heart, spleen and perirenal adipose tissue are MSC. There were differences among these 
MSC. For example, heart and spleen-derived MSC showed delayed adipogenic differentiation when 
compared to bone marrow and adipose tissue-derived MSC. In addition, there were some differences 
in the capacity of MSC from different body sites to inhibit PBMC proliferation. Spleen MSC, for 
instance, had less of an effect on PHA-activated PBMC proliferation in relation to MSC from the 
other tissues. Thus, our results demonstrate that MSC from these tissues have the same functional 
capacities, but there are differences in their potency. 
Earlier studies have shown that MSC are also present in human placenta, umbilical cord blood, and 
skin and that regardless of the tissue, these MSC possess characteristics that are similar to a large 
extent to bone marrow MSC 16, 21-23. The origin of MSC that are present outside the bone marrow is 
unclear. There is evidence that fibroblast-like stem cells migrate from the bone marrow to other body 
sites via the blood stream 24-25. However, other studies have failed to identify MSC from peripheral 
blood 1, 26. It is possible that these MSC are end products from embryonic differentiation 27-30 and that 
they serve to regenerate these mesenchymal tissues when damaged. In any case, their widespread 
distribution and multifunctionality suggests MSC play an important role in virtually every tissue of 
the body. 
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ABSTrACT
Human mesenchymal stem cells (MSC) have immunosuppressive capacities. Although their efficacy 
is currently studied in graft-versus-host disease, their effect on alloreactivity in solid organ transplant 
patients is unknown. In this study, the immunosuppressive effect of MSC on recipient anti-donor 
reactivity was examined before and after clinical kidney transplantation.
Anti-donor reactivity was established in pretransplant and posttransplant mixed lymphocyte reactions 
(MLR) of 14 living-kidney donor-recipient pairs. MSC from donors and third-party controls were 
added to the MLR in a ratio of 1:5.
MSC were isolated from donor perirenal fat and showed multilineage differentiation potential and 
the capacity to inhibit lymphocyte proliferation. The immunosuppressive effect of MSC was dose 
dependent and mediated by cell-membrane contact and soluble factors, including interleukin-10 and 
indoleamine 2,3-dioxygenase. 
Donor-derived MSC significantly inhibited the recipient anti-donor reactivity before and 1 month 
after transplantation. This effect was independent of human leukocyte antigen (HLA) background 
of MSC. Flow cytometric analysis showed that MSC inhibited the proliferation of CD4+ and CD8+ 
T-lymphocyte subsets in pretransplant and posttransplant donor-directed MLR, whereas MSC had no 
effect on B-cell or natural killer-cell proliferation.
In conclusion, donor MSC significantly inhibited the proliferation of alloactivated recipient T-cells 
before and after kidney transplantation. We believe these findings should encourage MSC-based 
intervention in clinical organ transplantation.
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InTrOduCTIOn
In clinical solid organ transplantation, alloreactivity is controlled by immunosuppressive drugs. 
These drugs, however, can lead to serious side effects. As an alternative, cellular therapies may be 
considered. One of the candidates is the mesenchymal stem cell (MSC). MSC are progenitor cells for 
a variety of cell types, such as osteoblasts, adipocytes, chondrocytes, and myocytes 1 and may play a 
role in tissue repair. In addition, it has been demonstrated that MSC have immunosuppressive effects 
in vitro. They inhibit proliferation and production of pro-inflammatory cytokines by lymphocytes and 
maturation of dendritic cells 2-5. The mechanism of immunosuppression by MSC is unclear, but the 
involvement of factors such as indoleamine 2,3-dioxygenase (IDO), interleukin (IL)-10, transforming 
growth factor-β (TGF-β), tumour necrosis factor-α (TNF-α) and hepatocyte growth factor (HGF) has 
been indicated 2, 4, 6. Blocking each of these factors alone does not restore the proliferation of activated 
immune cells, indicating that multiple factors are involved. 
In a clinical setting, it has been suggested that MSC could be useful for the treatment of graft-
versus-host disease 7. Moreover, the application of MSC for immunological disorders, for example, 
autoimmune-induced rheumatoid arthritis or inflammatory bowel disease, such as Crohn’s disease 
and ulcerous colitis, is currently under investigation 8. Furthermore, there are conflicting data from 
animal transplant models that MSC prolong allograft survival 9-10. Whether MSC are effective in the 
prevention and treatment of alloreactivity in a clinical transplantation setting is unknown 11. Both the 
choice of MSC source and timing of treatment may be important. Autologous MSC of the recipient 
may be first choice, as they are not rejected. However, MSC have a low immunophenotype, that 
is they lack human leukocyte antigen (HLA) class-II and have low HLA class-I expression, which 
would reduce the clearance of allogeneic MSC 12. It has also been suggested that allogeneic MSC are 
more potent immunosuppressors than autologous MSC 13, and there is evidence from animal models 
that donor-derived MSC may be preferable to inhibit allograft rejection 10. In addition, the timing of 
MSC administration may affect the efficacy of MSC treatment, as after transplantation alloreactivity 
is affected by immunosuppressive medication and the development of memory responses against 
the donor graft. This study investigated the efficacy and mechanisms of immunosuppression of 
kidney donor perirenal adipose tissue-derived MSC on alloreactivity before and after human kidney 
transplantation.
MATErIALS And METhOdS
Living-kidney donors and their recipients
Fourteen non-HLA-identical living-kidney donor-recipient pairs were included (November 2006-May 
2007). Their characteristics are described in Table 1 (at the end of this chapter). Immunosuppressive 
therapy for kidney transplant recipients consisted of tacrolimus, mycophenolate mofetil (MMF) and 
low-dose steroids. Biopsy-proven acute rejections occurred in 5 of 14 recipients within 1 month after 
transplantation, median 11 (6-30) days. Histological examination showed three mild tubulointerstitial 
rejections without evidence of vascular rejection and two severe tubulointerstitial rejections with 
vascular rejection. Acute rejections were treated with high-dose steroids (solumedrol) or anti-
thymocyte globulin (ATG).
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During the kidney donation procedure, perirenal fat tissue was surgically removed after written 
informed consent as approved by the Medical Ethical Committee of the Erasmus Medical Center 
Rotterdam (protocol no. MEC-2006-190) and collected in a-minimum essential medium (α-MEM) 
(Invitrogen, Paisley, Scotland) with 1% penicillin/streptomycin (100 U/mL penicillin and 100µg/mL 
streptomycin, p/s, Invitrogen).
Isolation of MSC from perirenal fat
MSC were isolated from perirenal fat as described previously 14. In summary, perirenal fat was 
mechanically disrupted, enzymatically digested with sterile 0.5 mg/mL collagenase type IV (Sigma-
Aldrich, St. Louis, MO, USA) in Roswell Park Memorial Institute (RPMI) (culture medium)-Dutch-
modified-1640 (Invitrogen) with 200 mM L-glutamine (Biowithaker, Verviers, Belgium) and 1% p/s 
for 30 minutes at 37oC. Next, the cells were incubated with 160 mM NH
4
Cl in phosphate-buffered 
saline (PBS) for 10 minutes at room temperature. Cells were resuspended in MSC-culture medium, 
consisting of α-MEM with 1% p/s and 15% fetal bovine serum (FBS, Biowithaker) and transferred to 
a 175 cm2 culture flask (Greiner Bio-one, Essen, Germany) kept at 37oC, 5% CO
2
 and 95% humidity. 
MSC were used for experiments between passages 2 to 7. No functional differences were found 
between MSC from these passages.
Flow cytometric characterization of MSC
Adherent cells were removed from culture flasks by incubation in 0.05% trypsin-EDTA at 37oC and 
then washed twice with FACSFlow (BD Biosciences, San Jose, CA, USA). Next, cell suspensions were 
incubated with antibodies against CD14-PerCP, CD34-APC, CD45-PerCP, CD86-FITC, CD166-PE, 
HLA-DR-FITC (all BD Biosciences), CD40-PE, CD80-PE, HLA-ABC-PE (all Serotec, UK), CD90-
APC and CD105-FITC (all R&D systems, Abingdon, UK) at room temperature protected from light 
for 30 minutes. After two washes with FACSFLOW, flow cytometric analysis was performed using 
an 8-colour FACSCANTO-II with FACSDIVA Software (BD Biosciences) and FlowJo Software (Tree 
Star Inc., Palo Alto, CA, USA).
differentiation of MSC 
Perirenal fat-derived MSC were differentiated in osteogenic, adipogenic, and myogenic lineages as 
described previously 14-15. After osteogenic differentiation, the deposition of calcified nodules was 
visualised by von Kossa staining. MSC differentiated in the adipogenic lineage were stained with 
oil-red-O (Sigma-Aldrich) for identification of lipid droplets.
After 7 days of myogenic differentiation, quantitative expression of desmin was determined by real-
time RT-PCR as described previously 16.
Isolation of peripheral blood mononuclear cells
Peripheral blood samples of kidney recipients were collected before transplantation, and 1 month after 
transplantation. Blood of the living donors was collected before transplantation. Moreover, third-
party peripheral blood mononuclear cells (PBMC), not associated with the third-party MSC donors, 
were collected from buffy coats of healthy blood donors. PBMC were isolated from the collected 
heparinized peripheral blood by density gradient centrifugation using Ficoll Isopaque (d=1.077, 
Amersham, Uppsala, Sweden) and frozen –135oC until use.
Immunosuppressive effects of MSC in kidney transplantation
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Mixed lymphocyte reactions
In mixed lymphocyte reactions (MLR), 5x104 recipient PBMC were stimulated by γ-irradiated (40 Gy) 
donor PBMC or HLA–A, –B and –DR mismatched third-party PBMC in RPMI culture medium+10% 
heat-inactivated FBS (HI-FBS) or vice versa. Donor-derived MSC or third-party MSC were added to 
the various MLR at a 1:5 ratio. On day 7, proliferation was measured by incorporation of 3H-thymidine 
(0.5 μCi/well) during an 8-hour incubation using a b-plate reader (LKB, Bromma, Sweden). 
To determine the proliferation capacity of the PBMC, 5x104 cells were stimulated with 1 mg/
ml phytohaemagglutinin (PHA; Murex Biotech LTd, Kent, UK) for 3 days and 3H-thymidine 
incorporation measured. Only results of PBMC with sufficient proliferation capacity (>10,000 cpm) 
were included. MLR were performed (in round-bottom 96-well plates) in triplicate and medians used 
for further analysis. 
real-time rT-PCr
Total RNA was isolated and cDNA synthesized as described previously 15. Quantitative expression of 
IDO, IL-10, TGF-β and TNF-α was determined by real-time RT-PCR using TaqMan gene expression 
MasterMix (Applied Biosystems, CA, USA) and an Assay-on-demand for IDO (Hs00158627.
m1), IL-10 (Hs00174086.m1), TGF-β (Hs00171257.m1) and TNF-α (Hs99999043.m1) (all Applied 
Biosystems) on an ABI PRISM 7700 sequence detector (Applied Biosystems). HGF was determined 
by real-time RT-PCR using primers (F-5’-GGCTGGGGCTACACTGGATTG-3’ and R-5’-
CCACCATAATCCCCCTCACAT-3’) and quantification of sample amplicons by SybrGreen (Sigma-
Aldrich) using Taq-DNA-polymerase as described previously 17. Expression levels were calculated 
as ratio per 18S RNA or as copies mRNA per 500 ng of total RNA. PBMC-MSC-co-cultures were 
separated by transwell-membranes (Greiner Bio-one); MSC were cultured in the bottom well, whereas 
PBMC were kept in the inserts.
Flow cytometric analysis of proliferating lymphocyte subsets
To determine which lymphocyte subsets were inhibited in proliferation by the addition of MSC in 
MLR, responder recipient PBMC were labeled with PKH67 (Sigma-Aldrich) and the γ-irradiated 
stimulator donor cells with PKH26 (Sigma-Aldrich) according to the manufacturer’s instructions 
and MSC added in a 1:5 ratio. After 7 days, cells were stained for CD3-AmCyan, CD4-PacificBlue, 
CD8-APC-Cy7, CD16/56-APC, CD19-PerCP and CD25-PE-Cy7 (all BD Biosciences) and examined 
by flow cytometry as described above.
Statistical analysis
The effect of MSC on MLR was calculated for each experiment as the fold-change in proliferation. 
Data were analyzed using the (two-tailed) Wilcoxon signed-rank test. Statistical significance was 
defined as p less than 0.05.
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Isolation and characteristics of MSC from perirenal fat
MSC were isolated from 10 to 50 g of perirenal fat of 14 living-kidney donors. The success rate 
for the isolation of these cells was 100% (14/14). The cells were adherent and had a spindle-shaped 
morphology. Flow cytometric analysis demonstrated that the cells expressed CD90, CD105, CD166 
and HLA-ABC (MHC-I) and low CD34 and no CD14, CD40, CD45, CD80, CD86 or HLA-DR 
(MHC-II) (Figure 1A). Culturing of undifferentiated cells for 14 days under adipogenic conditions 
induced the formation of lipid-filled vesicles that stained red by oil-red-O staining, characteristic 
for adipocytes (Figure 1B). Induction of osteogenic differentiation of the cells for 14 days resulted 
in the deposition of mineralised nodules that stained black by von Kossa staining, characteristic for 
osteoblasts. Culturing under myogenic conditions induced morphological changes (Figure 1B) and 
increased mRNA expression of desmin by 2.0-fold (Figure 1C).  These results confirmed that the 
isolated cells were MSC.
Immunosuppressive effects of perirenal fat MSC
The MSC showed dose-dependent suppression of proliferation in MLR (Figure 1D). The median 
(range) 3H-thymidine incorporation of MSC monocultures was 124 (26–450) cpm. Gamma-irradiated 
MSC inhibited proliferation with comparable capacity (data not shown). MLR performed in transwell 
systems in which MSC were separated from PBMC by a membrane demonstrated that MSC were still 
immunosuppressive in the absence of cell contact, although the effect on CD4+ and CD8+ lymphocyte 
subsets was greater when direct contact was allowed. MSC strongly inhibited the proliferation of 
CD4+ and CD8+ T-cell subsets and had a smaller effect on NK-cells, while proliferation of B-cells was 
not affected (Figure 1E). Next, we investigated which factors were involved in the immunosuppressive 
effect of donor MSC in our system and performed real-time RT-PCR analysis of MSC monocultures 
or MSC co-cultured with MLR (in transwell system). The expression of IDO and IL-10 by MSC 
co-cultured with MLR was increased 15,000-fold (p=0.008) and 420-fold (p=0.008), whereas the 
expression of TGF-β and HGF decreased by a factor 1.9 (p=0.008) and 7.6 (p=0.008). The expression 
of TNF-α did not change (p=0.17) (Figure 1F). Further experiments showed that PBMC in MLR co-
cultured with MSC still had proliferative capacity when re-stimulated with PHA and IL-2 (Figure 1G) 
and in secondary MLR (Figure 1H). Interestingly, PBMC that had been cultured in direct contact with 
MSC had less proliferative capacity in response to PHA and IL-2.
MSC inhibit pretransplant anti-donor and third-party reactivity
To examine the immunosuppressive effect of donor-derived MSC and third-party-derived MSC on 
anti-donor reactivity before transplantation, 14 MLR of recipients and their donors were assessed. 
Characteristics of these donor-recipient pairs are listed in Table 1. Figure 2A shows the effect of MSC 
on the proliferation of the pretransplant donor-directed MLR. Before transplantation, donor-derived 
MSC inhibited the proliferation of donor-stimulated recipient PBMC six-fold (2–28) (p<0.001), median 
(range), whereas third-party MSC inhibited this proliferation five-fold (2–19) (p<0.001). Third-party-
directed pretransplant MLR was also inhibited five-fold (2–62) by donor-derived MSC and five-fold 
(1–19) by third-party-derived MSC, which were not associated with the third-party PBMC (data not 
shown). There was no correlation between the development of acute rejections within the first month 
after transplantation and the proliferation in MLR.
Immunosuppressive effects of MSC in kidney transplantation
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Figure 1. Immunophenotypical and functional characterization of perirenal fat mesenchymal stem cells 
(MSC). [A] Flow cytometric analysis MSC showed positive expression for CD90, CD105, CD166 and HLA-
ABC, intermediate expression for CD34, and an absence of CD14, CD40, CD45, CD80, CD86 or HLA-DR. 
[B] Microscopic images of undifferentiated MSC, and MSC differentiated into adipogenic, osteogenic and 
myogenic lineages. After adipogenic differentiation for 14 days, lipid-filled vesicles were stained red with oil-
red-O. Osteogenic differentiation for 14 days induced the deposition of mineralised nodules that stained black by 
von Kossa staining. Myogenic differentiation of MSC for 7 days led to the appearance of cells with a myogenic 
morphology. [C] Real-time RT-PCR analysis of myogenic differentiated MSC showed increased mRNA expression 
of desmin (copies/500 ng) compared to undifferentiated MSC (n=2). [D] Dose-dependent immunosuppression 
by perirenal fat MSC. MSC were added to responder PBMC in MLR at a (1:5), (1:10), (1:20), (1:50) ratio (n=5). 
[E] Inhibition of  the proliferation of lymphocyte subsets by perirenal fat MSC cultured in direct contact or in 
transwell systems (n=5). [F] Real-time RT-PCR analysis of the expression of IDO, IL-10, TNF-α, TGF-β and 
HGF by perirenal fat MSC after 7 days in monoculture (MSC) or in transwell-coculture with MLR (MSC+MLR). 
Data expressed as a ratio to 18S RNA or per 500ng RNA. [G] Proliferation capacity of PBMC isolated after 7 days 
in primary MLR co-cultured with MSC (in direct-contact and in transwell systems). Proliferation capacity was 
tested with PHA and IL-2 for 3 days (n=3) and [H] in secondary MLR (7 days) (n=3).
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MSC autologous and allogeneic to responder cells in MLr have comparable capacity to 
inhibit alloreactivity
Next, we investigated whether the origin of MSC (donor or third-party) had effect on their inhibitory 
effect in MLR. Donor PBMC were used as responder cells, and recipient PBMC (Figure 2B) as 
stimulator cells in MLR, and donor-derived MSC (=autologous to responder cells) or third-party-
derived MSC (=allogeneic to responder cells) added. There was no difference in the inhibitory 
effect of donor-derived MSC, 13-fold (2–54), or third-party-derived MSC, 13-fold (1–67) (p=0.39). 
Furthermore, there was no difference between donor-derived and third-party-derived MSC to inhibit 
third-party PBMC-stimulated donor PBMC proliferation (p=0.68) (data not shown).
MSC inhibit posttransplant anti-donor and anti-third-party proliferation
We then questioned whether MSC could also inhibit posttransplant alloreactivity of kidney transplant 
recipients. After transplantation, donor-directed proliferation in MLR was lower compared to 
pretransplantation: 21,026 (9615–56,757) versus 8198 (1216–41,193) cpm (p=0.04). Donor-derived 
MSC inhibited posttransplant donor-directed reactivity two-fold (0–22) (Figure 3A). Third-party MSC 
had a comparable effect and inhibited the posttransplant donor-directed proliferation thee-fold (0–24) 
(Figure 3B). In contrast to donor-directed proliferation in MLR, third-party-directed proliferation 
of recipient PBMC was not different before and after transplantation (p=0.34). Donor-derived MSC 
inhibited the posttransplant third-party-directed proliferation by a factor 3 (0–91) (p=0.04) (Figure 
3C), and third-party MSC by a factor 4 (0–36) (Figure 3D). There was no difference in the inhibitory 
capacity between donor and third-party MSC to inhibit anti-donor reactivity (p=0.54) or anti-third-
party reactivity (p=0.57).
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Figure 2. [A] Effect of mesenchymal stem cells 
(MSC) on donor-directed pretransplant MLR 
of living-kidney donor-recipient pairs. MSC 
were added in a 1:5 ratio to responder PBMC. 
Proliferation was measured by 3H-thymidine 
incorporation on day 7. Donor and third-
party MSC significantly inhibited anti-donor 
proliferation (n=14). [B] Effect of donor and third-
party MSC on donor PBMC proliferation. Donor-
derived MSC (=autologous to the responder cells) 
and third-party-derived MSC (=allogeneic to 
the responder cells) were added in a 1:5 ratio to 
alloactivated responder PBMC. Independent of 
their origin (donor or third-party-derived) MSC 
inhibited anti-recipient proliferation of donor 
PBMC (n=14). The median (range) 3H-thymidine 
incorporation of MSC monocultures was 124 
cpm (26±450) for donor-derived MSC and 133 
cpm (78±785) for third-party-derived MSC 
(n=14). R = recipient PBMC; D = donor PBMC;  
= γ-irradiation (40 Gy); cpm = counts per minute.
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Effect of MSC on proliferation and activation of lymphocyte subsets in posttransplant MLr
To determine which lymphocyte subsets were inhibited in proliferation by MSC, responder recipient 
PBMC were labeled with PKH67 and γ-irradiated donor PBMC with PKH26 and proliferation analyzed 
by flow cytometry. Before transplantation, MSC inhibited the number of proliferating T-cells 3.1-fold, 
subdivided in CD4+ T-cells (2.2-fold) and CD8+ T-cells (2.3-fold), while the proliferation of B-cells 
(0.7-fold) and NK-cells (1.0-fold) was not inhibited by MSC (Figure 4). After transplantation, the 
proliferation in donor-directed MLR was lower than in pretransplant MLR, as demonstrated before. 
MSC inhibited T-cell proliferation 1.5-fold, including a 1.4-fold reduction for CD4+ T-cells and 1.3-
fold for CD8+ T-cells. MSC had no effect on B-cell proliferation in posttransplant MLR. NK-cell 
proliferation was inhibited by a factor 1.2. 
Finally, the activation state of CD4+ and CD8+ lymphocyte subsets was reduced by MSC in 
pretransplant MLR, as measured by CD25 expression (Table 2). In posttransplant MLR, however, the 
inhibition of T-cell proliferation was accompanied by an increase in CD25 expression. This effect was 
strongest for CD4+ T-cells.
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Figure 3. Effect of mesenchymal 
stem cells (MSC) on the proliferation 
of donor-directed and third-
party-directed pretransplant and 
posttransplant MLR of recipient 
PBMC. MSC were added in a 1:5 
ratio to recipient PBMC. Proliferation 
was measured by 3H-thymidine 
incorporation on day 7. [A] Donor 
MSC inhibited anti-donor proliferation 
before (n=14) and after transplantation 
(n=13). [B] Third-party MSC inhibited 
anti-donor proliferation before (n=14) 
and after transplantation (n=13). [C] 
Donor MSC inhibited anti-third-party 
proliferation before (n=13) and after 
transplantation (n=12). [D] Third-party 
MSC on anti-third-party proliferation 
before (n=13) and after transplantation 
(n=12). R = recipient PBMC; D = donor 
PBMC; 3rdP = third-party PBMC 
(HLA A-B-DR mismatched with 
recipient);  = γ-irradiation (40 Gy); 
cpm = counts per minute.
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This study investigated the immunosuppressive capacities of human MSC on alloreactivity in a 
kidney transplantation setting using recipient and donor PBMC. We found that donor-derived MSC 
significantly inhibited anti-donor reactivity before and after transplantation. Third-party-derived 
MSC inhibited alloreactivity at a similar potency. Our results in a human solid organ transplantation 
setting confirm previous studies that suggested that inhibition of lymphocyte proliferation by MSC 
is independent of HLA 18-19.
In our experimental model, we found that immunosuppression by MSC was dependent on cell-
membrane contact and soluble factors. The strong induction of IDO and IL-10 in MSC co-cultured 
with MLR suggests that these factors play a role in immunosuppression by MSC, confirming earlier 
studies indicating that the immunosuppressive capacity of MSC needs to be induced 20. In contrast to 
other studies, HGF, TGF-β or TNF-α expression was not increased in our hands 2-3. 
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Figure 4. Flow cytometric analysis of the proliferation of recipient lymphocyte subsets in pretransplant and 
posttransplant donor-directed MLR. One representative example is shown of eight experiments. Proliferation 
of PKH67-labeled recipient lymphocytes was measured after 7 days. MSC inhibited the proliferation of CD4+ 
and CD8+ T-lymphocytes in pretransplant MLR, whereas there was no effect on B-cells or NK-cells. MSC were 
capable of inhibiting the proliferation of T-lymphocytes after transplantation and had a small effect on NK-
lymphocyte proliferation.
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Analysis of the proliferation of T-, B-, and NK-lymphocyte subsets in pretransplant MLR showed 
that MSC had a strong inhibitory effect on T-lymphocyte proliferation, whereas they had no effect 
on NK- and B-lymphocytes. In posttransplant MLR, MSC predominantly inhibited T-lymphocytes. 
These results indicate that the strong inhibition of PBMC proliferation by MSC that was observed 
by measurement of 3H-thymidine incorporation was predominantly the result of inhibition of 
T-cell proliferation. Reports on the effect of MSC on B and NK-lymphocytes are contradicting. For 
instance, some failed to demonstrate an inhibitory effect of MSC on the proliferation and cytotoxic 
activity of activated NK-cells 21, while others found that MSC suppress IL-2 and IL-15 driven NK-
cell proliferation and IFN-γ production 4, 22-23. Although we and others 20 found no effect of MSC on 
B-lymphocyte proliferation in MLR, it has been shown that the proliferation and immunoglobulin 
production of B-lymphocytes induced by tropic stimuli can be inhibited by MSC 24. Our results on the 
effect of MSC on T-lymphocyte proliferation before and after transplantation demonstrate that MSC 
are effective in targeting the adaptive immune system. This capacity may be important for potential 
posttransplantation therapy with MSC. 
After transplantation, when the recipient’s immune system had been exposed to donor-antigen and 
immunosuppressive drugs, we found lower donor-directed proliferation of recipient PBMC. This was 
not entirely dependent on immunosuppressive drugs, as third-party-directed proliferation in MLR was 
less reduced after transplantation. It is attractive to hypothesize that the recipient’s immune system 
adapts to the donor graft and achieves donor-specific hyporesponsiveness. Hyporesponsiveness 
after transplantation has been reported previously 25-26. While we found that the proliferation in 
posttransplant donor-directed MLR decreased, MSC still inhibited this proliferation. This suggests 
that MSC may be effective after transplantation to control allograft rejection.
Further analysis of the immunosuppressive effect of MSC on PBMC showed that MSC not only 
strongly inhibit proliferation in pretransplant MLR, but also activation of T-cells. In posttransplant 
MLR the proliferation of responder T-cells was also inhibited by MSC, but the expression of CD25+ 
on the responder cells was increased. It was recently reported that induced CD25 in effector T-cells 
is associated with FOXP3 expression but not with regulatory activity 27. We therefore do not expect 
that the induced CD25 expression observed in posttransplant MLR correlates with the induction of 
regulatory cells. The explanation for the increased CD25 expression may lie in an activating effect 
of MSC on lymphocytes. This effect is obscured by the high proliferation rate of the responder 
T-lymphocytes in pretransplant MLR, which is associated with a high activation state, but becomes 
more clearly in posttransplant MLR where the proliferation rate is lower. Interestingly, a recent study, 
which found that MSC support the survival of T-cells in a quiescent state 28. It suggests that MSC 
adapt their immunomodulatory function to the degree of anti-donor reactivity.
Our finding that the immunosuppressive effect of MSC is not antigen-specific suggests that the 
immunosuppressive capacity of MSC may have a much broader effect than the inhibition of donor-
specific T-cells. An additional beneficial effect of MSC may be the reduction of inflammation in the 
graft due to ischemic injury. Furthermore, it has recently been demonstrated that donor-derived MSC 
can induce the generation of T-cells with donor-specific regulatory capacity 29. Therefore, MSC may 
have potential to be used as anti-rejection and tolerance induction therapy.
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Although our results suggest that both autologous and allogeneic MSC can be used for 
immunosuppression purposes before and after transplantation, it remains possible that allogeneic 
MSC induce an immune response. It is reported that MSC are hypoimmunogenic and do not activate 
allogeneic lymphocytes 21, 30-31. Animal models, however, showed that rejection of allogeneic bone 
marrow and skin grafts can be accelerated by co-transplantation of syngeneic MSC, possibly by 
inducing memory T-cell responses 32-33. It is therefore important to investigate whether MSC can also 
initiate anti-donor immune responses in humans.
The present study in a clinical living-kidney transplantation setting demonstrates that MSC inhibit 
alloreactivity before and after transplantation. MSC may be suitable as prevention therapy when 
applied before or during kidney transplantation, or as anti-rejection therapy after transplantation. In 
combination with their tissue repair function, the application of MSC in solid organ transplantation 
may facilitate graft acceptance and function. This needs to be confirmed in a clinical phase-I study.
Immunosuppressive effects of MSC in kidney transplantation
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ABSTrACT
Mesenchymal stem cells (MSC) have multilineage differentiation and immunomodulatory capacities 
and are potentially useful for therapeutic applications, such as tissue regeneration and control of 
alloreactivity. MSC are present in most tissues including the transplantable organs. It is therefore 
unavoidable that MSC will be exposed to immunosuppressive drugs in a clinical transplantation 
setting. The molecular targets of these drugs are expressed in MSC, but the effect of their inhibition 
on MSC functioning is unknown. 
MSC were isolated and expanded from heart tissue and the effects of the calcineurin inhibitor 
tacrolimus, the cell cycle inhibitor mycophenolic acid (MPA), and the mTOR inhibitor rapamycin on 
MSC survival, proliferation, differentiation and immunosuppressive capacity examined.
Short-term exposure to the immunosuppressants did not induce toxicity or apoptosis in MSC, but 
high-dose tacrolimus induced toxicity after 7 days. MPA and rapamycin inhibited MSC proliferation 
at therapeutic doses. The immunosuppressants had differential effects on the differentiation capacity 
of MSC. Tacrolimus reduced the expression of troponin T type 2 and desmin during cardiomyogenic 
differentiation of MSC, whereas MPA decreased the deposition of calcified minerals during 
osteogenic differentiation. Rapamycin stimulated lipid production during adipogenic differentiation. 
Unexpectedly, MSC had adverse effects on the immunosuppressive efficacy of tacrolimus and 
rapamycin. There was no such effect of MSC on the function of MPA. Pre-incubation of MSC with 
tacrolimus increased the immunosuppressive capacity of MSC. 
In conclusion, the present study demonstrates that therapeutic concentrations of immunosuppressive 
drugs affect MSC function. MSC affect the efficacy of immunosuppressive medication. These 
findings are important for potential clinical use of MSC in combination with immunosuppressants. 
Susceptibility of MSC to immunosuppressive drugs
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InTrOduCTIOn
Mesenchymal stem cells (MSC) are multipotent progenitor cells that reside in the bone marrow and in 
many other tissues, including adipose tissue, liver, spleen, lung and heart 1-4. They can be induced to 
undergo rapid proliferation and differentiation into osteogenic, adipogenic, myogenic, chondrogenic, 
and other lineages 1, 5-6. Furthermore, MSC have the ability to inhibit immune responses in vitro 7-8 and 
in vivo 9-10. There are large expectations for the use of MSC for a variety of clinical applications, from 
regeneration of injured or aged tissues to inhibition of autoimmune responses and allograft rejection. It 
is foreseen that MSC may be used for clinical purposes in combination with immunosuppressive drugs, 
because potential MSC transplant recipients are on immunosuppressive medication for containment 
of autoimmune or allograft responses. Although MSC are considered to be low immunogenic 11, 
there is evidence that they are susceptible for allogeneic rejection by a competent immune system 12, 
suggesting a requirement for immunosuppression after allogeneic transplantation of MSC.
After solid organ transplantation, MSC that reside in transplanted kidneys, livers, lungs or hearts, 
but also the recipient’s own MSC, are exposed to a cocktail of immunosuppressive drugs, including 
calcineurin and/or mammalian target of rapamycine (mTOR) inhibitors and cell cycle blockers 13. 
Although intended to inhibit lymphocyte proliferation, the molecular targets for these drugs are 
also expressed in MSC. Calcineurin, inhibited by tacrolimus and cyclosporine, is expressed in 
MSC together with its downstream target nuclear factor of activated T-cells (NFAT) and plays a 
role in osteogenic 14 and chondrogenic differentiation of MSC 15. The active metabolite of the cell 
cycle inhibitor mycophenolate mofetil, mycophenolic acid (MPA), inhibits inosine monophosphate 
dehydrogenase (IMPDH), which is ubiquitously expressed, and the cell proliferation inhibitor 
rapamycin targets mTOR, which is present in MSC and reported to be involved in osteogenic 
differentiation of mouse MSC 16. The presence of the molecular targets of these immunosuppressive 
drugs in MSC indicates that they may interfere with cellular processes of MSC. The purpose of 
the present study was to investigate the effects of the calcineurin inhibitor tacrolimus, the IMPDH 
blocker MPA and the mTOR inhibitor rapamycin on survival, apoptosis, proliferation, differentiation 
and immunosuppressive capacity of human MSC.
MATErIALS And METhOdS
Cell culture
Donor atrium and ventricular tissue that became available as waste product during heart transplantation 
surgery at the Departmment of Thorax Surgery of the Erasmus Medical Center was collected for 
the isolation of MSC (approved by the medical ethical committee of the Erasmus Medical Center, 
protocol no. MEC-2006-190). The tissue was collected in Roswell Park Memorial Institue (RPMI) 
culture medium with 4mM L-glutamine, 100U/mL penicillin and 100µg/mL streptomycin (1% p/s) 
(all Invitrogen, UK) and minced with a scalpel knife within 24 hours. The tissue was then digested 
with sterile filtered 0.5 mg/mL collagenase type IV (Sigma-Aldrich, Germany) in RPMI for 30 min 
at 37°C under continuous stirring. After two washes in RPMI, the dissociated tissue and cells were 
transferred to a culture flask and cultured in minimum essential medium-alpha (MEM-a)(Invitrogen) 
supplemented with 15% foetal bovine serum (FBS; Biowhittacker, Belgium) and 1% p/s at 37°C, 5% 
CO
2
 and 95% humidity. 
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After 3 to 4 days, non-adherent cells were removed by refreshment of the culture medium. 
Subsequently, medium was refreshed twice weekly and cells trypsinized using 0.05% trypsin-EDTA 
(Invitrogen) at subconfluency and reseeded at 1000 cells/cm2 to ensure optimal proliferation. The 
cultures obtained showed immunophenotypical and functional properties characteristic for MSC, as 
described earlier 4. The cells were used for experiments between passage number 2 and 7. 
Immunosuppressants
Tacrolimus (Astellas, Japan) and rapamycin (Wyeth, NJ, USA) were used from soluble sources. To 
examine the effect of mycophenolate mofetil, its active metabolite MPA (Sigma-Aldrich) was used.
Measurement of mesenchymal stem cell viability by MTT assay
MSC were seeded in a 96-well plate at 5000 cells/well and incubated with tacrolimus (1, 10, 100 ng/
mL), MPA (1, 10, 100 mg/mL) or rapamycin (0.1, 1, 10, 50 ng/mL) in standard culture medium for 24 
hours and 7 days. The MTT assay was used to determine viable cell numbers. Briefly, medium was 
replaced with 100mL fresh medium before the assay, and 25mL of 5 mg/mL 3-(4,5-Dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT, Sigma-Aldrich) in PBS was added and incubated for 4 
hours at 37°C. Dimethyl sulfoxide (DMSO) (100mL) was then added and absorbance read at 595 nm 
using a Victor2 1420 multilabel counter (Wallac, MA, USA).
detection of apoptosis
MSC were seeded in six-well plates at 200,000 cells/well and incubated with 10 ng/mL tacrolimus, 
10 mg/mL MPA or 10 ng/mL rapamycin in standard culture medium for 48 hours and 7 days. The 
cells were then trypsinized and stained for Annexin V using an Annexin V apoptosis detection kit 
according to the manufacturer’s protocol (BD Bioscience), and analysed on a FACSCanto II flow 
cytometer (BD Biosciences). 
Measurement of cell proliferation
MSC were seeded in 96-well plates at 1000 cells/well and cultured in the presence or absence of 
tacrolimus (1, 10 ng/mL), MPA (1, 10, 100 mg/mL) or rapamycin (0.1, 1, 10, 50 ng/mL) in standard 
culture medium for 3 or 7 days. The cells were then pulsed with 0.5µCi 3H-thymidine/well (Amersham, 
UK), harvested after 8 hours and radionucleotide incorporation measured using a Betaplate counter 
(LKB, Sweden). 
Microarray analysis
Gene expression was analysed using a Miltenyi Biotec human stem cell PIQOR microarray according 
to the manufacturer’s protocol (Miltenyi Biotech, Germany). Expression profiles were determined of 
four MSC cultures.
differentiation assays
Osteogenic differentiation
Osteogenic differentiation was induced by culturing confluent MSC cultures in α-MEM supplemented 
with 1% p/s, 15% heat-inactivated FBS (56°C, 30 min), 5 mM β-glycerophosphate (Sigma-Aldrich, 
Germany), 50 µg/mL L-ascorbic acid-phosphate (Sigma-Aldrich), and 10 nM dexamethasone (Sigma-
Aldrich) for 18 days. 
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Osteogenic differentiation was quantified by measurement of Ca2+ contents of the deposited minerals 
17. In brief, MSC were removed from the culture dish with a rubber policeman in 0.1% triton in PBS, and 
cell lysates incubated overnight in 0.24 M HCl at 4°C. Ca2+ content was calorimetrically determined 
after addition of 1 M ethanolamine buffer (pH 10.6), 0.35 mM o-cresolphtalein complexone, 19.8 
mM 8-hydroxyquinoline and 0.6 mM hydrochloric acid at 595 nm. Results were adjusted for the 
protein content of the corresponding cell-lysates. Total protein concentration was measured using 
bicinchoninic acid (BCA) protein assay reagent (Pierce, IL, USA) according to the manufacturer’s 
description.
Cardiomyogenic differentiation
MSC were seeded at 20,000 cells/cm2 in a-MEM with 15% FBS and 1% p/s. The following day, culture 
medium was changed to DMEM/F12 (Invitrogen) supplemented with 2% horse serum (Invitrogen). 
After 7 days the cells were trypsinized, pelleted and kept at –80°C. Total RNA was isolated using 
the High-Pure RNA Isolation kit (Roche Applied Science, Germany), following the manufacturer’s 
instructions and cDNA synthesized with random primers (Promega, The Netherlands). Quantitative 
expression of myogenic genes was determined by real-time PCR using universal PCR mix (Invitrogen) 
and Assay-on-demand products for troponin T type 2 (Hs00165960.m1) and desmin (Hs00157258.
m1) (Applied Biosystems, Foster City, CA, USA) on an ABI PRISM 7700 sequence detector (Applied 
Biosystems) as described before 18. Expression levels were expressed as copies mRNA per 500 ng of 
total RNA.
Adipogenic differentiation
Adipogenic differentiation was induced by culturing confluent MSC cultures in a-MEM supplemented 
with 1% p/s, 15% heat-inactivated FBS, 50 µg/mL L-ascorbic acid-phosphate (Sigma-Aldrich), 
500 µM 3-isobutyl-1-methylxanthine (Fluka, Germany), 60 µM indomethacin (Fluka) and 10 nM 
dexamethasone (Sigma-Aldrich) for 14 days. Cells were then fixed in 10% formalin for 5 minutes 
and incubated with fresh 10% formalin for 1 hour. After washing in 60% isopropanol, the cells were 
incubated in 0.3% oil-red-O (Sigma-Aldrich) solution in 60% isopropanol for 10 minutes to stain lipid 
droplets. After several washes with H
2
O, the oil-red-O was eluted with 100% isopropanol for 10 min 
and absorption measured at 490 nm on a Victor2 1420 multilabel counter (Wallac, MA, USA).  
Mixed Lymphocyte reaction
Peripheral blood mononuclear cells (PBMC) (5x104) were stimulated with 5x104 γ-irradiated (40 Gy) 
fully HLA A/B/DR mismatched PBMC in round-bottom tissue culture-treated 96-well plates (Nunc, 
Denmark) in RPMI medium with 1% p/s and 10% heat-inactivated FBS. MSC that were pre-incubated 
with tacrolimus (1, 10 ng/mL), MPA (1, 10, 100 mg/mL) or rapamycin (0.1, 1, 10, 50 ng/mL) for 48 
hours in standard culture medium were trypsinized and washed three times in large volumes of RPMI 
medium and added at a 1:100 up to a 1:2 ratio (0.5x104) to the mixed lymphocyte reactions (MLR). At 
day 7, the cells were pulsed with 0.5 µCi 3H-thymidine (Amersham, UK) per well, harvested after 8 
hours and radionucleotide incorporation measured using a Betaplate counter (LKB, Sweden). 
Statistical analysis
Data were analysed for significance with Student’s t-test by comparing column means with controls 
using Graphpad Prism software (Graphpad software, USA). 
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Cultures of MSC were established from heart tissue and were phenotypically and functionally similar 
to bone marrow-derived MSC, as described earlier 4. In brief, the cells were positive for CD90, 
CD105, CD166 and HLA class I expression and negative for CD34, CD45, CD80, CD86 and HLA 
class II expression. They were capable of osteogenic, cardiomyogenic, and adipogenic differentiation 
and suppressed allo- and mitogen-stimulated PBMC proliferation.
Effect of tacrolimus, MPA and rapamycin on MSC viability
MSC were incubated with 1, 10 and 100 ng/mL tacrolimus; 1, 10 and 100 mg/mL MPA; and 0.1, 1, 10 
and 50 ng/mL rapamycin, concentrations covering the clinical doses of these immunosuppressants. 
Incubation for 24 hours with the immunosuppressants had no effect on numbers of viable MSC 
(Figure 1A). After 7 days, 100 ng/mL tacrolimus reduced viable cell numbers significantly (Figure 
1B). MPA (100 mg/mL) had a similar but milder effect. 
Induction of MSC apoptosis by tacrolimus, MPA and rapamycin
The effect of therapeutic concentrations of the immunosuppressants on MSC apoptosis was tested 
by Annexin V staining. MSC were incubated with tacrolimus (10 ng/mL), MPA (10 mg/mL), or 
rapamycin (10 ng/mL) for 48 hours or 7 days, then trypsinized and stained for Annexin V. Positive 
Annexin V staining was detected in 12.7% (mean) of untreated MSC after 48 hours of culture (Figure 
2A). The percentages of Annexin V positive cells changed to on 10.3%, 10.7% and 13% after 48 hours 
treatment with tacrolimus, MPA and rapamycin, respectively, but were not significantly different 
from untreated cells. After 7 days of culture, Annexin V positive staining increased to 21.5% in 
untreated cells, and 20.4%, 21.7% and 17.1% in cells treated with tacrolimus, MPA and rapamycin, 
respectively (Figure 2B). There were no significant differences between the treatments. Raw data of 
Annexin V staining of five MSC cultures treated for 48 hours and four cultures treated for 7 days are 
shown in Table 1.
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Figure 1. Effect of 24 hours and 7 days exposure to tacrolimus (ng/mL), MPA (μg/mL), and rapamycin (ng/mL) 
on MSC viability measured by MTT assay expressed as percentage of untreated control. Mean values with SD 
shown of 4 MSC cultures of passage 3 or 4 measured in five-fold.
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Figure 2. Annexin V staining in untreated MSC and after exposure to 10 ng/mL tacrolimus, 10 μg/mL MPA or 
10 ng/mL rapamycin for 48 hours [A] and 7 days [B]. Gray histograms show unstained cells, open histograms 
show cells stained for Annexin V. Representative example of 5 and 4 MSC cultures (of passages 2, 3, 3, 4 and 4) 
examined shown. For complete data see Table 1.
Exposure time No treatment
(%) 
Tacrolimus 
10 ng/mL (%) 
MPA 
10 µg/mL (%) 
Rapamycin
10 ng/mL (%) 
48 hours 14.1 11.3 11.4 15.7
48 hours 17.2 5.9 13.4 11.5 
48 hours 18.3 17.9 12.4 15.5 
48 hours 4.5 6.9 5.6 6.9 
48 hours 9.5 9.3 10.5 15.5 
7 days 30.0 26.2 18.1 17 
7 days 9.8 8.7 10.8 9.7 
7 days 20.8 22.2 33.8 19.4 
7 days 25.2 24.6 24.2 22.1 
Table 1. Percentage of apoptotic MSC after 48 hours or 7 days exposure to immunosuppressants measured by 
Annexin V staining.
Chapter 464
Inhibition of MSC proliferation by tacrolimus, MPA and rapamycin
The intended function of tacrolimus, MPA, and rapamycin is to inhibit lymphocyte proliferation. We 
examined whether these drugs had the same effect on MSC proliferation after 3- and 7-day incubations. 
Tacrolimus did not affect MSC proliferation after 3 or 7 days (Figure 3A, B). All concentrations of 
MPA significantly reduced MSC proliferation after 3 and 7 days, reaching over 90% by concentrations 
from 10 mg/mL. Rapamycin had a dose-dependent effect on MSC proliferation and had no effect at 0.1 
and 1 ng/mL concentrations, but reduced proliferation significantly from 10 ng/mL. 
MPA most potently targets IMPDH isoform II. We found strong IMPDH II expression in MSC by 
microarray analysis, comparable to levels of the MSC marker Thy1 (CD90) (Figure 3C).  
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Figure 3. Effect of tacrolimus (ng/mL), MPA (μg/mL), and rapamycin (ng/mL) on MSC proliferation expressed 
as percentage of untreated controls. MSC were exposed for 3 days [A] or 7 days [B] to immunosuppressants 
and proliferation measured by 3H-thymidine incorporation. Mean values with SD shown of 3 MSC cultures of 
passage 3 or 4 measured in five-fold. The expression of IMPDH isoform II was determined in four MSC cultures 
of passage 3 or 4 and related to GAPDH expression [C]. Expression levels of the MSC marker Thy1 (CD90) 
are shown to demonstrate the high levels of expression of IMPDH II in MSC. * indicates p<0.05,  ** p<0.005 
compared with control.
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Effect of tacrolimus, MPA and rapamycin on osteogenic differentiation of MSC
To determine the effect of the immunosuppressants on MSC differentiation, MSC were cultured 
under osteogenic, myogenic, and adipogenic conditions in the presence of different concentrations 
of tacrolimus, MPA, or rapamycin. Osteogenic induction resulted in significant increases in the 
deposition of calcified minerals. Treatment with tacrolimus and MPA tended to decrease Ca2+ 
deposition by MSC, with a significant reduction in calcified mineralization with 10 mg/mL MPA 
(Figure 4A). Results obtained with 100 mg/mL MPA were not further analysed as 18 days of culture 
in the presence of this concentration of MPA resulted in strongly reduced cell numbers, hampering 
the collection of consistent measurements. Rapamycin had no significant effect on Ca2+ deposition.
Effect of tacrolimus, MPA and rapamycin on myogenic differentiation of MSC
MSC showed relatively strong expression of troponin T type 2 and desmin before induction of myogenic 
differentiation. Culturing of MSC under myogenic conditions for 7 days increased the expression of 
troponin T type 2 by 2.2-fold. Troponin T type 2 expression was significantly reduced by 10 ng/mL 
tacrolimus (Figure 4B). MPA and rapamycin had no significant effect. Myogenic induction did not 
increase desmin expression of MSC. Tacrolimus, however, reduced desmin expression, consistent 
with its effects on troponin T type 2 (Figure 4C). 
Figure 4. (continued) >>
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Effect of tacrolimus, MPA and rapamycin on adipogenic differentiation of MSC
Adipogenic differentiation of MSC for 14 days induced the formation of lipid-filled vesicles (Figure 
4D). Quantification of lipid contents demonstrated that tacrolimus and MPA had no effect on lipid 
production, but rapamycin significantly increased lipid production during adipogenic differentiation 
of MSC (Figure 4E). 
Figure 4 (continued). Effect of immunosuppressants on MSC differentiation. MSC were cultured in expansion 
medium (non dif) or under differentiating conditions (control) in the presence of tacrolimus (ng/mL), MPA (μg/
mL), and rapamycin (ng/mL). After 18 days of osteogenic differentiation Ca2+ deposition by MSC was measured 
[A]. Cardiomyogenic differentiation was induced for 7 days and RNA expression of troponin T type 2 [B] and 
desmin analysed [C]. Adipogenic differentiation of MSC was induced for 14 days and lipid-filled vesicles stained 
red by oil-red-O staining [D, non-differentiated left, differentiated right] and quantified [E]. Results are shown 
as percentages of controls of five MSC cultures (A, B, C, passages 3, 3, 4, 4 and 7), or of three MSC cultures (E, 
passage 3) with SD. * indicates p<0.05 compared with controls.
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Effect of MSC on the immunosuppressive efficacy of tacrolimus, MPA and rapamycin 
MSC have the capacity to inhibit the proliferation of alloactivated PBMC in mixed lymphocyte 
reactions (MLR). The immunosuppressive capacity of MSC used in this study was tested by adding 
MSC at 1:100, 1:25, 1:10, 1:5 and 1:2 ratios to MLR and measuring proliferation after 7 days. 
PBMC proliferation was dose-dependently inhibited by MSC, confirming their immunosuppressive 
ability (Figure 5A). We then examined whether MSC had additive or adverse effects on the 
immunosuppressive efficacy of tacrolimus, MPA, and rapamycin. Tacrolimus dose-dependently 
inhibited PBMC proliferation in MLR from a concentration of 0.01 ng/mL. In the presence of MSC, 
however, the effect of tacrolimus was reduced and did not reach full inhibition of proliferation even at 
the highest tacrolimus concentration (Figure 5B). Such an effect of MSC was not seen in combination 
with MPA. MPA was effective at inhibiting PBMC proliferation from a 0.1 mg/mL concentration. At 
this concentration of MPA, the presence of MSC induced a further decrease in PBMC proliferation 
(Figure 5C). Rapamycin dose-dependently inhibited PBMC proliferation from a concentration of 0.01 
ng/mL. Compared with tacrolimus, MSC reduced the immunosuppressive efficacy of rapamycin at 
all concentrations and full inhibition of PBMC proliferation with the highest doses of rapamycin was 
not reached in the presence of MSC (Figure 5D).
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Figure 5. Effect of MSC on the efficacy of immunosuppressants. MSC have immune inhibitory capacity, as dem-
onstrated by the addition of allogeneic MSC of passage 4 at 1:100, 1:25, 1:10, 1:5 and 1:2 ratios to mixed lympho-
cyte reactions (MLR) [A]. Figures B-D demonstrate the immunosuppressive efficacy of different concentrations 
of tacrolimus, MPA and rapamycin on MLR in combination with increasing numbers of MSC (ratio 1:100, 1:25, 1: 
10 and 1:5). MSC of passage 3 or 4 were added at day 0 and proliferation of MLR measured after 7 days. Results 
of two experiments in three-fold are shown.
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Effect of tacrolimus, MPA and rapamycin on immunosuppression by MSC
To test the effect of immunosuppressants on the immune inhibitory effects of MSC, MSC were 
incubated with 1 and 10 ng/mL concentrations of tacrolimus; 0.1, 1 and 10 ng/mL rapamycin; or 
0.1, 1 and 10 mg/mL MPA for 48 hours and after extensive washing added to MLR at a 1:10 ratio. 
After 7 days proliferation was measured. Untreated MSC significantly inhibited the MLR by 43%. 
The inhibition of MLR by MSC was increased after pre-incubation of MSC with tacrolimus (Figure 
6). Pre-incubation with MPA and rapamycin had no effect on the capacity of MSC to inhibit PBMC 
proliferation.
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Figure 6. Effect of pre-culture of MSC with immunosuppressants on the immunosuppressive capacity of MSC 
in MLR. MSC of passage 3 or 4 were pre-incubated for 48 hours with tacrolimus (ng/mL), MPA (μg/mL) and 
rapamycin (ng/mL) and subsequently added at a 1:10 ratio to MLR. Open bars show MLR without MSC, dotted 
bars show effect of untreated MSC, other bars show the effect of pre-exposure of MSC to immunosuppressants. 
Mean values with SD shown of 4 (tacrolimus) and 3 (MPA, rapamycin) experiments measured in three-fold. * 
indicates p<0.05 compared to MLR with untreated MSC.
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dISCuSSIOn
Immunosuppressive drugs inhibit lymphocyte proliferation by targeting a number of intracellular 
signalling cascades that include calcineurin, IMPDH, and mTOR 19. These targets are not specific for 
lymphocytes and their presence in other cell types may explain several of the reported side effects 
of immunosuppressive drugs. The MSC is a relevant cell type to study these effects, because it has 
fundamental importance for tissue repair processes and if MSC will be used for clinical purposes, 
this may be in combination with immunosuppressive drugs. The molecular targets for tacrolimus and 
rapamycin, which bind FK506 binding protein to inhibit calcineurin and mTOR, respectively, and 
for MPA, which inhibits IMPDH, are expressed in MSC, suggesting that these immunosuppressants 
may have effects on MSC. Data from the present study confirms this. Clinical doses of the tested 
drugs did not induce toxicity or apoptosis of MSC, although a 10-fold increased dose of tacrolimus 
(100 ng/mL) induced cell death after 7 days. There were profound effects of MPA and rapamycin 
on MSC proliferation. MPA had the strongest effect and nearly abolished MSC proliferation from 
subclinical dose. The strong inhibition of MSC proliferation by MPA is remarkable, because MPA 
is a more potent inhibitor of the type II isoform of IMPDH, which is mainly expressed by activated 
lymphocytes, than of the type I isoform, which is expressed by most other cell types 20. We found 
strong expression of IMPDH isoform type II by MSC, which explains the potent effect of MPA on 
MSC proliferation. The effect of rapamycin on MSC proliferation was milder but significant at a 
clinical dose. Expansion of MSC is essential for repair processes of injured tissue and the use of mTOR 
and IMPDH inhibitors has been linked to impaired wound healing 21-22. In contrast, tacrolimus had 
no effect on MSC proliferation. In stead, calcineurin inhibition affected differentiation processes in 
MSC. Tacrolimus tended to inhibit, albeit not significantly, the deposition of calcified minerals during 
osteogenic differentiation of MSC. Reduced capacity of MSC to deposit calcium would correlate with 
earlier findings that show an involvement of calcineurin in the regulation of osteoblastic activity 14 
and with clinical observations demonstrating that the use of calcineurin inhibitors can lead to bone 
loss induced by impaired bone formation 23-24. In addition, tacrolimus reduced the expression of 
the cardiomyogenic genes troponin T type 2 and desmin by MSC. It is known for some time that 
calcineurin plays a role in myogenic differentiation 25. It is important to consider that the use of 
MSC in combination with calcineurin inhibitors may not be optimal for cardiac regeneration. MPA 
and rapamycin showed no inhibitory effect on the expression of myogenic genes and in contrast 
tended to stimulate, albeit not significantly, myogenic gene expression of MSC. A possible increase 
in myogenic gene expression by MPA and rapamycin may relate to the anti-proliferative effects of 
the drugs. The myogenic differentiation protocol involves a slowdown of MSC proliferation and this 
effect is enforced by MPA and rapamycin. Rapamycin furthermore induced the production of lipid 
vesicles by MSC during adipogenic differentiation, but MPA did not have this effect, suggesting 
that inhibition of proliferation play no role. mTOR is a known regulator of metabolic pathways 26-27 
and our results suggest that inhibition of mTOR by rapamycin stimulates lipid production during 
adipogenic differentiation of MSC. At this stage, we can only speculate about whether this relates to 
hyperlipidemia commonly observed in transplant recipients treated with mTOR inhibitors 28-29.
Whereas MPA and rapamycin affected the multilineage differentiation ability of MSC, pre-incubation 
of MSC with these immunosuppressants had no effect on PBMC proliferation under the experimental 
conditions used in this study. In contrast, pretreatment of MSC with tacrolimus increased the inhibitory 
effect of MSC on alloactivated PBMC proliferation. This suggests that inhibition of calcineurin has 
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a relatively long-lasting effect on the immunomodulatory machine of MSC, perhaps by affecting the 
secretion of anti-inflammatory cytokines secreted by MSC. 
So far we discussed the effects of immunosuppressants on MSC functioning. There is evidence from 
previous studies that MSC have a synergistic effect with the calcineurin inhibitor cyclosporin on 
the activation of cytotoxic T-cells 30-31. In the present study, we observed a contrasting effect. Low 
as well as high numbers of MSC reduced the efficacy of subclinical as well as clinical doses of 
tacrolimus and rapamycin to inhibit alloactivated PBMC proliferation. MSC had no adverse effect 
on the function of MPA. In stead, the effects of MSC and MPA seemed to be cumulative. We do not 
know why MSC have an adverse effect on the inhibition of PBMC proliferation by tacrolimus and 
rapamycin. It is possible that a dual role of MSC in the regulation of PBMC is causing this effect. 
Whereas MSC inhibit the proliferation of activated lymphocytes, there is evidence that they support 
lymphocytes that are in a quiescent state 32. In the presence of tacrolimus and rapamycin, the activity 
of lymphocytes is strongly reduced, which may as a result lead to the stimulation of lymphocyte 
proliferation by MSC. Because MPA inhibits the process of cell division itself, MSC cannot stimulate 
the proliferation of lymphocytes in the presence of MPA. 
This study demonstrated that immunosuppressants affect MSC that were isolated from heart tissue. 
Although MSC from different tissues have similar properties, there are quantitative differences 
between MSC from different sources 4, 33. It is therefore possible that the results obtained with heart 
MSC could be different in MSC isolated from bone marrow, considered as the classical source for 
MSC. Furthermore, there are of course important differences between clinical and in vitro conditions. 
For instance, in the present study, MSC were exposed to immunosuppressants for a maximum of 18 
days, whereas transplant recipients need life-long immunosuppression. The effects we detected on 
MSC could, however, be a good indication for clinical effects that can be expected after long-term 
exposure to immunosuppressive drugs. Summarizing, this study demonstrates that tacrolimus, MPA, 
and rapamycin interfere with MSC function, and that MSC affect the efficacy of tacrolimus and 
rapamycin. These results suggest that the immunosuppressive medication chosen for a particular 
group of allograft or potential MSC transplant recipients could influence the desired therapeutic 
effects via their actions on MSC. 
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ABSTrACT
There is emerging interest in the application of mesenchymal stem cells (MSC) for the prevention 
and treatment of autoimmune diseases, graft-versus-host disease and allograft rejection. It is, 
however, unknown how inflammatory conditions affect phenotype and function of MSC. Adipose 
tissue-derived mesenchymal stem cells (ASC) were cultured with alloactivated PBMC (MLR), with 
pro-inflammatory cytokines (IFN-γ, TNF-a and IL-6) or under control conditions, and their full 
genome expression and function examined. 
Pro-inflammatory cytokines mostly increased indoleamine-2,3-dioxygenase expression, whereas 
ASC cultured with MLR showed increased expression of COX-2, involved in prostaglandin E2 
production. Both conditions had a stimulatory, but differential, effect on the expression of pro-
inflammatory cytokines and chemokines, while the expression of fibrotic factors was decreased only 
in response to pro-inflammatory cytokines. Functional analysis demonstrated that inflammatory 
conditions affected morphology and proliferation of ASC, while their differentiation capacity 
and production of trophic factors was unaffected. The immunosuppressive capacity of ASC 
was enhanced strongly under inflammatory conditions. In conclusion, ASC showed enhanced 
immunosuppressive capacity under inflammatory conditions, while their differentiation capacity 
was preserved. Therefore, in vitro preconditioning provides ASC with improved properties for 
immediate clinical immune therapy.
Effect of inflammatory conditions on ASC
C
ha
pt
er
 5
77
InTrOduCTIOn
Mesenchymal stem cells (MSC) are found in a variety of tissues, including bone marrow, skin and 
adipose tissue 1-3 and can be easily expanded in vitro. MSC are thought to have tissue regenerative 
properties, in the first place via their multilineage differentiation capacity 2 and, perhaps more 
importantly, via the secretion of trophic factors that may activate local progenitor cells 4. In 
addition, MSC have potent immunomodulatory capacity. They inhibit the proliferation of T-cells 
5-6 and inhibit dendritic cell maturation 7-8. These properties make MSC promising for a diversity of 
clinical applications; for example, for the prevention and treatment of autoimmune diseases and bone 
marrow rejection. Recently, interest has developed in the use of MSC in solid organ transplantation 
9-10. These conditions are associated with an inflammatory milieu. A restraint for therapeutic use 
of MSC may, however, be the limited understanding of their characterization and biology under 
various inflammatory conditions 10-13. It has been reported that the immunosuppressive effects of 
ASC are mediated via soluble factors, and enhanced further if direct cell-cell contact between ASC 
and immune cells was allowed 14. Different studies have attributed the immunosuppressive effect of 
MSC to different immunosuppressive factors. These include indoleamine 2,3-dioxygenase (IDO) 15-
17, prostaglandin E2 18, transforming growth factor-b (TGF-b) and hepatocyte growth factor (HGF) 
5, HLA-G 19, nitric oxide 20, IL-10 21 and heme oxygenase 22. In addition, there is evidence that cell-
membrane interactions between MSC and immune cells via the adhesion molecules ICAM-1 or VCAM-
1 play a crucial role in the immunomodulatory capacity of MSC 14, 23. Thus, the immunomodulatory 
capacity of MSC is a multifactorial process. The activity of these processes may depend on local 
immunological conditions. It has been demonstrated that in the absence of inflammation, MSC can 
stimulate lymphocyte survival and proliferation 24. Under inflammatory conditions a high production 
of cytokines, such as IFN-γ, TNF-a and IL-6, are largely produced and MSC may respond to these 
factors by changing their immunomodulatory function 25-27. Exposure of MSC to IFN-γ has been 
reported to up-regulate the expression of IDO, TGF-b and HGF 25, 28 and recently, it was demonstrated 
that IFN-γ-activated MSC are more effective for the treatment of graft-versus-host disease 29. Effective 
application of MSC in organ transplantation may require potent and immediate immunosuppressive 
effects. In vitro activation of MSC could therefore be beneficial for clinical effectiveness of MSC in 
organ transplantation.
In the present study, we investigated whether different inflammatory conditions affected the gene 
expression, phenotype and function of adipose tissue-derived mesenchymal stem cells (ASC). ASC 
were cultured with alloactivated PBMC (mixed lymphocyte reaction, MLR) or with a cocktail of pro-
inflammatory cytokines containing IFN-γ, TNF-a and IL-6, while their functions and full genome 
expression were examined.
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MATErIALS And METhOdS
Isolation and culture of ASC
ASC were isolated and expanded from perirenal adipose tissue of four living healthy kidney donors, 
as described earlier 30-31. These donors (3 males, 1 female, mean age 46±7 years) were approved to 
donate their kidney after routine screening. They did not use immunosuppressive medication.
In brief, perirenal fat was minced and digested with 0.5mg/ml collagenase type IV (Invitrogen, Paisley, 
UK) in RPMI (Invitrogen) for 30 min at 37°C. The cells were then washed, transferred to culture 
flasks and kept in MEM-a medium (Invitrogen) with 100U/ml penicillin and 100µg/ml streptomycin 
(p/s, Invitrogen) and 15% fetal calf serum (Biowhittaker, Verviers, Belgium) at 37°C, 5% CO
2
 and 
95% humidity. After three days, non-adherent cells were removed and adherent cells continued in 
cultured. Cultures were refreshed with ASC-culture medium twice a week. At 90% confluence, 
adherent cells were removed from culture flasks by incubation in 0.05% trypsin-EDTA at 37oC and 
cells were used for experiments or frozen at –150oC until use.  ASC were used for experiments at 
between passages 2 to 5. 
To confirm whether the perirenal fat-derived cells were indeed ASC, they were characterized by flow 
cytometry, differentiated in osteogenic and adipogenic lineages, and added to mixed lymphocyte 
reactions (MLR) to test their immunosuppressive capacity as previously described 30-31. For 
independent experiments, ASC were used from different ASC donors.
Exposure of ASC to inflammatory conditions
ASC were seeded at 10,000 cells/cm2 and cultured under two inflammatory conditions for seven 
days. The first condition consisted of alloactivated PBMC at a ratio of 10:1, in which the PBMC were 
separated from ASC by a 0.4mm pore size transwell membrane (Greiner Bio-one, Essen, Germany). 
The second condition consisted of a pro-inflammatory cytokine cocktail containing 50ng/ml IFN-γ 
(U-Cytech, Utrecht, Netherlands), 20ng/ml TNF-a (PeproTech, London, UK) and 10ng/ml IL-6 
(PeproTech). 
Measurement of ASC diameter and proliferation
Adherent cells were removed from culture flasks by incubation in 0.05% trypsin-EDTA at 37oC and 
cells put in cell counting chambers (Bürker). Cells were microscopically photographed (Axiovert 
200M; Carl Zeiss, Munich, Germany) at 40x HPF Ph2. Cell diameters were measured using 
AxioVision software (version 4.7.1) (Carl Zeiss).
Proliferation of ASC cultured under the previously described conditions was determined by counting 
the living cells manually using cell counting chambers. To avoid contamination of PBMC in ASC-
MLR co-cultures, transwell-membrane inserts were used (Greiner Bio-one, Alphen a/d Rijn, The 
Netherlands). 
Flow cytometric characterization of ASC
Adherent cells were removed from culture flasks by incubation in 0.05% trypsin-EDTA at 
37oC and then washed twice with FACSFlow (BD Biosciences, San Jose, CA, USA). Next, cell 
suspensions were incubated with antibodies against CD86-FITC, CD166-PE, HLA-DR-APC-Cy7 
(all BD Biosciences), CD40-PE, CD80-PE, HLA-ABC-PE (all Serotec, Oxford, UK), CD90-APC 
and CD105-FITC (all R&D systems, Abingdon, UK) at RT protected from light for 30 minutes. 
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After two washes with FACSFLOW, flow cytometric analysis was performed using an 8-colour 
FACSCANTO-II with FACSDIVA Software (BD Biosciences) and FlowJo Software (Tree Star Inc., 
Palo Alto, CA, USA).
Differentiation capacity of ASC
Osteogenic differentiation was induced by culturing confluent ASC cultures in a-MEM supplemented 
with 1% p/s, 15% heat-inactivated FBS, 5mM b-glycerophosphate (Sigma-Aldrich, Munich, 
Germany), 50µg/ml L-ascorbic acid-phosphate (Sigma-Aldrich), and 10nM dexamethasone (Sigma-
Aldrich) for 21 days. Cells were then washed with PBS and fixed in cold 4% paraformaldehyde for 
5 min at room temperature. After two washes with H
2
O, cells were incubated in 1% silver nitrate in 
H
2
O at room temperature on a light box until blackening occurred. The cells were then washed three 
times with H
2
O, incubated in 2.5% sodium thiosulfate in H
2
O for 5 min at room temperature, washed 
twice with H
2
O and photographed.
Adipogenic differentiation was induced by culturing confluent ASC cultures in a-MEM supplemented 
with 1% p/s, 15% heat-inactivated FBS, 50µg/ml L-ascorbic acid-phosphate (Sigma-Aldrich), 500µM 
3-isobutyl-1-methylxanthine (IBMX, Fluka, Buchs, Switzerland), 60µM indomethacin (Fluka) and 
10nM dexamethasone (Sigma-Aldrich) for 21 days. Cells were then fixed in 60% isopropanol for 
1 min, and incubated in filtered 0.3% oil red O (Sigma-Aldrich) solution in 60% isopropanol for 10 
minutes to stain lipid droplets. After several washes with PBS the cells were photographed.
Isolation of PBMC
PBMC were isolated from buffy coats of healthy volunteers using Ficoll-PaqueTM Plus (GE Healthcare, 
Uppsala, Sweden) separation and stored at -135°C until use. 
Mixed lymphocyte reactions (MLr)
Immunosuppressive capacity of precultured ASC was tested in MLR. In MLR, 5x104 responder 
PBMC were stimulated by 5x104 γ-irradiated (40Gy) allogeneic PBMC in RPMI+10% HI-FBS in 
round-bottom 96-well plates (Nunc, Roskilde, Denmark). ASC were added at the beginning (day 0) or 
at the end (day 6) of the seven-day MLR to responder cells at a 1:5-ratio. On day 7, proliferation was 
measured following incorporation of 3H-thymidine (0.5mCi/well) during a 16-hour incubation using a 
b-plate reader. To determine the proliferation capacity of the PBMC, 5x104 cells were stimulated with 
1 mg/ml PHA for 3 days and 3H-thymidine incorporation was measured. 
To determine the importance of IDO in the immunosuppressive effect of the ASC precultured under 
the different conditions, ASC were added to MLR, as describe above, with addition of the IDO1-
inhibitor 1-methyl-L-tryptophan (1-MT) (Sigma-Aldrich). 1-MT was prepared by dissolving in 1 M 
hydrochloric acid and diluted in RPMI+10% heat-inactivated FBS. Finally, the pH of the solution was 
neutralized by adding 1M sodium hydroxide. The solution was filtered before use.
Isolation of rnA and gene expression analysis
ASC of four healthy donors were seeded at passage four at 10,000 cells/ cm2. The cells were cultured 
for seven days under control conditions or with alloactivated PBMC (separated by a transwell 
membrane), or in the presence of the pro-inflammatory cytokine cocktail. ASC were then harvested 
by trypsinization and RNA isolated using MINI columns (Qiagen, Valencia, CA, USA). The RNA 
quality and quantity was assessed using the RNA 6000 Nano kit on a 2100 Bioanalyzer (Agilent, Palo 
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Alto, CA, USA). Samples with RNA integrity numbers of >8 were selected. 100ng of total RNA was 
used to prepare sense-strand biotinylated DNA according to the manufacturer’s ‘’Whole transcript 
sense target labeling’’ protocol (Affymetrix, Santa Clara, CA, USA). Hybridization to Affymetrix 
Human Gene 1.0 ST Arrays (764,885 probe sets, representing 28,869 annotated genes), staining, 
washing, and scanning (Scanner 3000) procedures were performed as described by Affymetrix 
(Affymetrix) and performed by Erasmus MC Center for Biomics. Probe set summarization, Array 
QC, and annotations of the probesets were performed using Affymetrix “Gene Expression Consolle” 
(Affymetrix, Santa Clara, CA). All of the different QC metrics analyzed met the standards as required 
by Affymetrix and showed an overall comparability of the signal distribution obtained from the 
different arrays. Principal Component Analysis was used to asses the underlying structure of the 
dataset and define correlation relationships among samples. (Partek Inc., St. Louis, USA). Probesets 
differentially expressed among conditions were identified using the class comparison tool implemented 
in BRB ArrayTools (National Cancer Institute, Bethesda, USA). Briefly, we identified genes that were 
differentially expressed among the two classes using a random-variance t-test. The random-variance 
t-test is an improvement over the standard separate t-test as it permits sharing information among 
genes about within-class variation without assuming that all genes have the same variance. Genes 
were considered statistically significant if their p value was less than 0.0001. A stringent significance 
threshold was used to limit the number of false positive findings. A “per gene” estimate of the false 
discovery rates among genes passing the test was also computed. The false discovery rate associated 
with a row of the table is an estimate of the proportion of the genes with univariate p values less than 
or equal to the one in that row that represent false positives. The Benjamini-Hochberg method for 
false discovery rate control was used for this estimation 32-33. Genes passing the test threshold were 
clustered and displayed as heatmap using Spotfire (Spotfire Inc., Somerville, USA). The change in 
gene expression of a number of genes (IDO, IL6, IL8, CXCL10) as measured by microarray was 
confirmed by real-time RT-PCR. In brief, ASC were precultured under control, MLR (in transwell 
culture systems) or cytokine conditions and trypsinized at day 7. Total RNA was isolated and cDNA 
synthesized as previously described 34. Quantitative gene expression was determined using TaqMan 
Universal PCR Master Mix and assays-on-demand for IDO (Hs 00158027.m1), IL6 (Hs 00174131.
m1), IL8 (Hs00174114.m1) and CXCL10 (Hs 00171042.m1) (all Applied Biosystems, CA, USA) on a 
StepOnePlus (Applied Biosystems).
Statistical analysis
Data were analyzed using paired t-test or Wilcoxon signed-rank test depending on the distribution 
of the data as tested with Kolmogorov-Smirnov test for normality. Parametric data are expressed 
as mean±SD, while non-parametric data are expressed as median (interquartile range). Statistical 
significance was defined as p<0.05 (two-tailed).
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Effect of inflammatory conditions on ASC gene expression
To investigate the effect of inflammatory conditions on ASC gene expression, ASC were 
cultured with alloactivated PBMC or pro-inflammatory cytokines and full genome expression 
analysis carried out by microarray. ASC were cultured for seven days under control conditions 
and inflammatory conditions; either with alloactivated PBMC (MLR) separated by a transwell 
membrane or with a pro-inflammatory cytokine cocktail containing IFN-γ, TNF-a and IL-6. The 
gene expression profiles of ASC derived from four different non-pooled donors showed strong 
clustering within the different treatment groups, as evidenced in Figure 1 and Table 1. ASC that 
were cultured in the presence of MLR for seven days showed significant up-regulation of 233 genes 
and down-regulation of 334 genes compared to ASC cultured under control conditions. ASC that 
were cultured in the presence of pro-inflammatory cytokines showed significant up-regulation 
of 635 genes and down-regulation of 296 genes. Hierarchical clustering demonstrated that gene 
expression changes in response to both inflammatory stimuli only partly overlapped (Figure 1A and 
1B), indicating that ASC respond in a significantly different manner to alloactivated PBMC then 
to pro-inflammatory cytokines. This was evidenced further by the comparison of ASC cultured 
with MLR with ASC cultured with cytokines, which resulted in the identification of 1080 genes 
that showed significantly different expression (Figure 1C). The most significant changes in gene 
expression are described below. In addition, real-time RT-PCR analysis on four relevant genes (IDO, 
IL6, IL8 and CXCL10) was performed to confirm the data obtained by microarray (data not shown). 
The pattern of gene expression changes was similar in microarray and RT-PCR analysis. Only the 
increase in IDO expression in ASC with MLR was a lot larger in the RT-PCR analysis than in the 
microarray analysis.
Figure 1. Hierarchical clustering of genes up (red) and down (green) regulated by ASC after culture under 
inflammatory conditions compared to average gene expression level of all samples, measured by microarray. ASC 
were cultured under control conditions, with alloactivated PBMC (MLR) or with pro-inflammatory cytokines 
(n=4). Microarray data is deposited in Gene Expression Omnibus (GEO), number GSE18662 at http://www.ncbi.
nlm.nih.gov/geo/query/acc.cgi?acc=GSE18662. [A] Gene expression profile of ASC cultured with MLR compared 
to control ASC. ASC cultured with MLR showed partial overlap with ASC cultured with pro-inflammatory 
cytokines. [B] Gene expression profile of ASC cultured with pro-inflammatory cytokines compared to control 
ASC. ASC cultured with pro-inflammatory cytokines showed partial overlap with ASC cultured with MLR. [C] 
Gene expression profile of ASC cultured with MLR compared to ASC cultured with pro-inflammatory cytokines. 
ASC cultured with inflammatory conditions showed partial overlap with control ASC.
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Table 1. Gene expression data of ASC cultured under control conditions or with inflammatory conditions.
Genes Intensity
ASC(control)
(mean±SD)
(log2)
Intensity
ASC(MLR)
(mean±SD)
(log2)
Intensity
ASC(cytokines)
(mean±SD)
(log2) 
Fold change
intensity
ASC(MLR)
vs
ASC(control) 
 
Fold change
intensity
ASC(cytokines)
vs
ASC(control) 
 
Difference
ASC(MLR)
vs
ASC(cytokines) 
(p<0.0001)
Immunosuppressive factors 
HLA-G 11.8±0.2 12.7±0.2 13.5±0.1 1.8* 3.3* - 
COX-2 8.0±0.4 11.3±0.4 8.5±0.3 10.2 1.5 + 
IDO 4.1±0.1 5.6±0.7 12.8±0.1 2.9 394.1* + 
HGF 5.2±0.3 4.6±0.3 7.1±0.3 0.7 3.7* + 
Guanylate binding proteins (GBP) 
GBP1 9.1±0.4 10.9±0.3 12.9±0.1 3.6* 14* + 
GBP2 6.5±0.2 8.9±0.5 11.0±0.1 5.3* 22.2* + 
GBP3 8.2±0.3 9.0±0.8 11.0±0.4 1.8 7.3* + 
GBP4 5.1±0.3 7.7±0.9 11.8±0.1 6.1* 102.0* + 
GBP5 4.5±0.1 6.5±1.1 12.7±0.2 3.9 290.5* + 
GBP6 4.1±0.1 4.6±0.3 6.7±0.4 1.5 6.3* + 
GBP7 4.9±0.1 5.4±0.2 5.6±0.2 1.4 1.7 - 
Myxovirus resistance genes 
1 6.2±.0.5 6.8±0.3 10.5±0.2 1.5 19.1* + 
2 6.4±0.5 6.4±0.1 9.7±0.2 1,0 9.7* + 
Pro-inflammatory factors 
IL1-α 5.8±0.6 7.4±0.9 4.0±0.5 3.1 0.3* + 
IL-1β 6.3±0.4 9.1±0.7 5.4±0.2 7.1* 0.5* + 
IL-6 11.9±0.2 13.1±0.1 11.9±0.1 2.2* 1,0 + 
IL-8 6.6±0.4 12.1±0.4 8.5±0.4 45.6* 3.7 + 
TNF-10 4.5±0.4 5.0±0.2 10.3±0.1 1.4 53.4* + 
TNF-13b
 
5.2±0.2 5.8±0.2 8.7±0.3 1.5 11.2* + 
IL-33 6.0±0.4 9.3±0.4 6.8±0.4 10.5* 1.8 + 
Serum amyloid 
1 5.6±0.3 10.6±0.4 6.6±1.1 31.3* 1.9 + 
2 5.9±0.3 10.2±0.3 6.2±0.5 20.0* 1.2 + 
HLA class I 
A 12.1±0.1 12.9±0.1 13.7±0.1 1.7* 3.0* - 
B 12.0±0.2 13.0±0.2 13.9±0.1 2.0* 3.5* - 
C 12.0±0.1 12.7±0.1 13.6±0.1 1.7* 3.2* + 
E 10.7±0.1 11.8±0.2 12.7±0.1 2.1* 3.8* + 
F 6.9±0.1 8.0±0.1 9.4±0.1 2.2* 5.9* + 
G 11.8±0.2 12.7±0.2 13.5±0.1 1.8* 3.3* - 
HLA class II 
DPα1 7.4±0.8 7.8±1.0 12.9±0.3 1.3 44.9* + 
DPβ1 6.8±0.4 7.0±0.3 11.7±0.3 1.1 29.4* + 
DQα1 6.0±0.1 6.3±0.2 12.3±1.7 1.2 78.9* + 
* = p< 0.0001
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Chemokine ligands (CXCL) 
CXCL1 7.3±0.4 11.4±0.3 10.0±0.2 17.7* 6.7* + 
CXCL3 6.4±0.2 7.9±0.4 6.4±0.2 2.8 1,0 - 
CXCL5 8.3±0.4 11.6±0.7 8.8±0.2 10,0 1.4 + 
CXCL6 6.3±0.5 10.7±0.5 9.5±0.3 21.2* 9.4* - 
CXCL9 4.0±0.2 4.1±0.1 11.7±0.1 1.1 209.0* + 
CXCL10 3.7±0.4 6.5±4.8 12.7±0.2 7,0 521.9* + 
CXCL11 4.0±0.3 4.8±0.8 12.0±0.2 1.8 250.7* + 
CXCL12 9.9±0.6 8.9±0.4 11.1±0.3 0.5* 2.3 - 
Chemokine ligands (CCL) 
CCL2 10.2±0.3 12.2±0.2 12.4±0.1 3.9* 4.5* - 
CCL5 6.8±0.6 9.6±0.6 11.6±0.4 7.1* 27.4* + 
CCL7 4.9±0.1 6.3±0.4 9.1±0.7 2.5 17.2* + 
CCL8 4.9±0.2 5.8±0.6 10.2±0.9 1.9 40.7* + 
CCL13 6.2±0.4 8.8±0.9 9.8±0.7 5.9* 12.1* - 
CCL20 5.0±0.1 8.1±0.2 5.1±0.4 8.1* 1,0 + 
CCL28 5.3±0.1 6.7±0.3 5.9±0.2 2.5* 1.4 - 
Collagens 
Iα1 13.9±0.1 13.4±0.1 11.1±0.4 0.7 0.1* + 
Iα2 13.8±0.1 13.5±0.1 12.0±0.3 0.8 0.3* + 
IIα1 7.6±0.1 7.6±0.1 6.7±0.1 1,0 0.5* + 
IIIα1 13.0±0.1 13.4±0.1 10.4±0.4 1.2 0.2* + 
IVα1 11.4±0.2 11.4±0.2 8.9±0.3 1,0 0.2* + 
IVα2 10.3±0.2 10.1±0.3 8.9±0.3 0.9 0.4* + 
Vα1 10.2±0.1 9.4±0.1 7.6±0.1 0.6 0.2* + 
Vα2 11.5±0.1 11.5±0.1 9.4±0.3 1,0 0.2* + 
VIα3 11.2±0.3 10.9±0.2 9.8±0.4 0.8 0.4* + 
XIIα1 12.4±0.1 11.6±0.1 9.6±0.3 0.6 0.1* + 
XIVα1 7.6±0.4 5.8±0.3 5.6±0.2 0.3 0.2* - 
XVα1 10.6±0.6 9.1±0.8 8.0±0.7 0.4* 0.2* - 
XVIα1 8.7±0.1 8.1±0.2 7.6±0.1 0.7 0.5* - 
Genes Intensity
ASC(control)
(mean±SD)
(log2)
Intensity
ASC(MLR)
(mean±SD)
(log2)
Intensity
ASC(cytokines)
(mean±SD)
(log2) 
Fold change
intensity
ASC(MLR)
vs
ASC(control) 
Fold change
intensity
ASC(cytokines)
vs
ASC(control) 
Difference
ASC(MLR)
vs
ASC(cytokines) 
* = p< 0.0001
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Immunosuppressive factors 
It is well recognized that multiple factors are involved in the immunosuppressive function of ASC 5, 
15, 18-19. In our hands, there was no up-regulation of the anti-inflammatory factors IL-10, TGF-b, iNOS 
or heme oxygenase by ASC after culture with MLR or pro-inflammatory cytokines. There was minor 
up-regulation of HGF (4-fold) and HLA-G (3-fold) (Figure 2A). However, IDO expression was 394-
fold increased by ASC cultured with the pro-inflammatory cytokines. The increase in IDO expression 
was significantly smaller in ASC cultured with MLR (3-fold). In contrast, ASC cultured with MLR 
had 10-fold increased levels of COX-2, which may result in increased production of anti-inflammatory 
prostaglandin E2. Increased COX-2 expression was not seen in ASC cultured with pro-inflammatory 
cytokines. 
Exposure of ASC to the inflammatory conditions resulted in strong induction of genes for guanylate 
binding proteins (GBP) and myxovirus resistance genes, which have antiviral and antimicrobial 
function. The largest increases were observed for GBP5 (291-fold), GBP4 (102-fold), GBP2 (22-
fold) and GBP1 (14-fold) in ASC cultured with pro-inflammatory cytokines (Figure 2B). In addition, 
ASC cultured with pro-inflammatory cytokines strongly up-regulated the expression of myxovirus 
resistance genes 1 (19-fold) and 2 (10-fold) (Figure 2C). This increase in expression was not observed 
in ASC cultured with MLR.
Pro-inflammatory factors
Although ASC can exert immunosuppressive activity, they also express genes for pro-inflammatory 
factors (Figure 2D). IL-6 was expressed highly under all culture conditions. After exposure of ASC 
to alloactivated PBMC, we found a 46-fold up-regulation of IL-8, while also the expression of IL-1b 
(7-fold) and IL-33 (11-fold) increased. In contrast, culture of ASC with pro-inflammatory cytokines 
up-regulated the expression of tumor necrosis factor superfamily (TNFSF) member 10 and member 
13B by a factor 53 and 11, respectively. ASC did not express IL-2. Serum amyloid A1 and A2, factors 
produced by the liver in response to inflammatory stimuli, showed strongly increased gene expression 
after culture of ASC with alloactivated PBMC (31-fold and 20-fold, respectively) (Figure 2E), while 
these factors were not up-regulated in ASC cultured with pro-inflammatory cytokines. 
HLA expression
ASC expressed high levels of HLA class I, whereas HLA class II levels were low under control 
conditions (Figure 2F and 2G). In the presence of alloactivated PBMC, HLA class I expression by 
ASC was increased slightly (2-fold) and HLA class II expression did not change significantly. In 
contrast, ASC cultured with pro-inflammatory cytokines up-regulated the expression of HLA class I 
genes up to 6-fold and HLA class II up to 144-fold. 
Chemokines
Next, the effect of inflammatory conditions on the chemo-attractive properties of ASC was examined. 
Culture of ASC with MLR or pro-inflammatory cytokines induced differential expression of several 
chemokines. ASC cultured with MLR increased the expression of the neutrophil, monocyte and 
eosinophil attractants CXCL1 (18-fold) and CXCL6 (21-fold) (Figure 2H). ASC cultured with pro-
inflammatory cytokines showed strong increases in the expression of the T lymphocyte attractants 
CXCL9 (209-fold), CXCL10 (522-fold), CXCL11 (251-fold), whereas the neutrophil, monocyte, 
eosinophil attractants CXCL1 and CXCL6 showed weaker increases (7-fold and 9-fold).
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Chemokines of the CCL-motive were also induced specifically by ASC depending on the inflammatory 
stimulus (Figure 2I). In ASC cultured with MLR the expression of CCL2 (4-fold), CCL5 (7-fold), 
CCL13 (6-fold), CCL20 (8-fold) and CCL28 (3-fold) was increased significantly compared to control 
ASC. Culture of ASC with the pro-inflammatory cytokines strongly increased the expression of 
CCL2 (5-fold), CCL5 (27-fold), CCL7 (17-fold), CCL8 (41-fold) and CCL13 (12-fold), but had no effect 
on the lymphocyte attractants CCL20 and CCL28.
Fibrosis
To investigate whether inflammatory conditions stimulate ASC to induce fibrosis, we examined the 
expression of collagens by ASC. Pro-inflammatory cytokines significantly reduced the expression 
of 13 of a total of 45 types of collagens (Figure 2J). Culture of ASC with MLR reduced expression 
of collagen type 15a1 only (3-fold). ASC may also induce fibrosis via the secretion of factors such 
as connective tissue growth factor, TGF-b and platelet-derived growth factor that act on other cell 
types. The expression of these factors by ASC, however, did not change in response to inflammatory 
conditions. Furthermore, except from small increases in actin a1 (0.2-fold) and actin γ2 (2-fold) after 
culture with MLR, no significant changes in gene expression of cytoskeletal proteins such as actins or 
intermediate filaments were observed in ASC after exposure to pro-inflammatory conditions.
Effect of inflammatory conditions on the phenotype of ASC 
Next, functional analysis of ASC cultured under inflammatory conditions was performed. ASC 
cultured under inflammatory conditions showed morphological changes compared to ASC cultured 
under control conditions (Figure 3A). ASC cultured under control conditions grew in a monolayer and 
were distributed equally on the surface of the culture flask, while ASC cultured with alloactivated 
PBMC clustered in star-shaped formations.
The number of ASC cultured for seven days with MLR increased compared to control ASC cultures 
(Figure 3B). In contrast, the number of ASC treated with pro-inflammatory cytokines was reduced 
significantly. 
Culture of ASC with MLR or pro-inflammatory cytokines increased significantly the diameter of 
ASC (Figure 3C). ASC cultured under control conditions had a diameter of 21 (interquartile range 
19-25) mm. After culture with MLR, ASC had a diameter of 24 (22-28) mm and treatment of ASC with 
inflammatory cytokines led to an increase in cell diameter to 29 (25-32) mm.
To investigate whether the immunophenotype of ASC changed after culture with inflammatory 
factors, flow cytometric analysis was performed (Figure 3D). ASC expressed the characteristic cell 
surface markers CD90, CD105 and CD166 and the expression of these markers was unaffected by 
culture of ASC with MLR or pro-inflammatory cytokines. Levels of HLA class I expression by ASC 
were independent of inflammatory culture conditions. Control ASC were slightly positive for HLA 
class II (6%), while culture of ASC with MLR or pro-inflammatory cytokines resulted in an increase 
in HLA class II positive cells of 62% and 86%, respectively. Independently of culture conditions, ASC 
stained positive for the co-stimulatory molecule CD80 and were weakly positive for CD86. CD40 was 
not expressed on control or MLR-cultured ASC, but culture of ASC with pro-inflammatory cytokines 
induced expression of CD40.
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Figure 3. Effect of inflammatory conditions on the phenotype of ASC. ASC were cultured under control 
conditions, with alloactivated PBMC (MLR) in transwell culture systems, or with pro-inflammatory cytokines. 
For each independent experiment, ASC were used from different ASC donors. [A] Morphology of ASC. ASC 
cultured under control conditions and with pro-inflammatory cytokines formed confluent monolayers, while ASC 
co-cultured with MLR formed star-like clusters of cells. Representative examples shown of four experiments 
with four different ASC cultures. [B] Proliferation of ASC. Absolute number of viable ASC was counted after 
seven days in culture. Data represent the mean±SEM of six experiments with six different ASC cultures. [C] Cell 
size of ASC. ASC cultured with MLR and pro-inflammatory cytokines significantly increased in size compared 
to ASC cultured under control conditions. Approximately 50 individual trypsinized ASC per culture condition 
were measured. [D] Flow cytometric analysis of ASC. One representative example of each condition is shown 
of three independent experiments using three different ASC cultures. * = p<0.05; ** = p<0.01; ***= p<0.001.
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Effect of inflammatory conditions on the differentiation capacity of ASC
ASC cultured previously for seven days under inflammatory conditions, were cultured under 
adipogenic and osteogenic conditions for three weeks (Figure 4). Independent of previous culture 
conditions, ASC were able to differentiate in adipogenic and osteogenic lineages.
Effect of inflammatory conditions on the immunosuppressive capacity of ASC
To examine the effect of inflammatory conditions on the immunosuppressive capacity of ASC, 
pretreated ASC were added to mitogen (PHA)-stimulated or alloactivated PBMC at different 
concentrations. At an ASC-PBMC ratio of 1:5, ASC inhibited PHA-stimulated PBMC proliferation 
significantly after three days (Figure 5A). At this ratio, ASC cultured under control conditions 
inhibited the PHA-stimulated proliferation by 50±26%, ASC precultured with MLR by 59±6% and 
ASC precultured with pro-inflammatory cytokines by 84±9%. At lower concentrations (1:20 and 
1:50), ASC precultured with pro-inflammatory cytokines were still able to inhibit significantly the 
proliferation of PHA-stimulated PBMC by 36±27% and 20±20%, respectively, whereas ASC cultured 
under control conditions or with alloactivated PBMC did not show this capacity.
Comparable effects of pretreatment conditions on the immunosuppressive capacity of ASC were 
observed when precultured ASC were added to MLR for seven days (Figure 5B). At an ASC-PBMC 
ratio of 1:5, ASC cultured under control conditions inhibited the proliferation of alloactivated PBMC 
by 44±25%, but this effect disappeared at a 1:20 ratio, and at a ratio of 1:50 they even stimulated the 
proliferation. ASC cultured previously with MLR inhibited the proliferation by 55±3% (at 1:5-ratio). 
At lower concentrations (1:20 or 1:50), ASC precultured with MLR had no inhibitory effects. ASC 
precultured with MLR, however, did not stimulate the proliferation as observed with control ASC. 
Figure 4. Effect of inflammatory conditions on the differentiation capacity of ASC. ASC cultured under control 
conditions, with MLR or with pro-inflammatory cytokines were continued in culture for three weeks under 
osteogenic or adipogenic conditions. One representative example is shown of four experiments using four different 
ASC donors. [A] Osteogenic differentiation. Deposition of calcified nodules (brown/black) was visualized by von 
Kossa staining. [B] Adipogenic differentiation. Lipid droplets (red) were stained with oil-red-O.
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Pretreatment of ASC with pro-inflammatory cytokines increased further the immunosuppressive 
capacity of ASC. At a ratio of 1:5 to responder cells, these pretreated ASC inhibited the proliferation 
in MLR by 76±18%. Their immunosuppressive effect was still present at lower ratios and the 
proliferation of alloactivated PBMC was inhibited by 42±35% and 32±27% at a ratio of 1:20 and 1:50, 
respectively.
To examine whether the anti-proliferative effect of ASC was instant, ASC were added on day 6 of 
a seven-day MLR at a 1:5 ratio (Figure 5C). Addition of control and MLR-precultured ASC did 
not inhibit, but stimulated, the proliferation of responder cells in MLR by 26±21% and 24±19%, 
respectively. In contrast, ASC pretreated with pro-inflammatory cytokines inhibited PBMC 
proliferation by 25±14% during the final day of the seven-day MLR (p<0.001). Thus, pretreatment 
with MLR increased the capacity of ASC to inhibit the proliferation of mitogen and alloactivated 
PBMC. Pretreatment of ASC with pro-inflammatory cytokines resulted in even stronger and instant 
immunosuppressive function of ASC.
B. Addition pre-treated ASC to MLR at day 0
A. Addition pre-treated ASC to PHA stimulated PBMC
C. Addition pre-treated ASC to MLR at day 6
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Figure 5. Effect of inflammatory conditions on 
the inhibition of PBMC proliferation by ASC. 
ASC were pretreated under control conditions, 
with alloactivated PBMC (MLR) or with pro-
inflammatory cytokines conditions and added to 
mitogen- or alloactivated PBMC. The proliferation 
in the test conditions is normalized to the 
proliferation in the control situation (i.e. MLR 
without addition of ASC, which is set to 100%). 
[A] Effect of pretreated ASC on the proliferation 
of PHA-stimulated PBMC. ASC were added 
to PBMC at various concentrations (1:5, 1:20, 
1:50) (n=8). Proliferation was measured by 
3H-thymidine incorporation on day 3. [B] Effect 
of pretreated ASC added on day 0 to MLR on the 
proliferation of alloactivated PBMC (MLR). ASC 
were added to PBMC at various concentrations 
(1:5, 1:20, 1:50) (n=6). Proliferation was measured 
by 3H-thymidine incorporation on day 7. [C] 
Effect of pretreated ASC added on day 6 to 
MLR. ASC were added to responder PBMC at a 
1:5 ratio (n=11). Proliferation was measured by 
3H-thymidine incorporation on day 7. 
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Because of the striking increase in the expression of IDO by ASC cultured with pro-inflammatory 
cytokines, the importance of IDO as a mediator of the enhanced immunosuppressive capacity of ASC 
was investigated. Pretreated ASC were added to PHA-stimulated PBMC or MLR in the presence or 
absence of the IDO inhibitor 1-MT. 1-MT had no effect on the capacity of control and MLR pretreated 
ASC to inhibit the proliferation of PHA and alloactivated PBMC (Figure 5D and E). However, 1-MT 
decreased significantly the inhibitory effect of ASC pretreated with pro-inflammatory cytokines. The 
percentage inhibition of PHA-stimulated PBMC reduced from 84±8% to 64±17% and the inhibition 
of MLR from 68±20% to 29±45% after addition of 1-MT. The reduction of the immunosuppressive 
capacity of pro-inflammatory cytokines-activated ASC by 1-MT confirms the involvement of IDO in 
the increased immunosuppressive activity of ASC.
no 1-MT + 1-MT
Mitogen-activated responder PBMC (PHA)D
Allo-activated responder PBMC (MLR)
0
20
40
60
80
100
120
%
 p
ro
lif
er
at
io
n 
(m
ea
n+
S
EM
)
0
20
40
60
80
100
120
%
 p
ro
lif
er
at
io
n 
(m
ea
n+
S
EM
) no 1-MT + 1-MT
E
***
***
***
**
*
***
***
***
*
***
*
*
*
ASC (control)
ASC (MLR)
ASC (cytokines)
no ASC
ASC (control)
ASC (MLR)
ASC (cytokines)
no ASC
Figure 5 (continued). Effect of inflammatory conditions on the inhibition of PBMC proliferation by ASC. 
[D] Effect of IDO1-inhibitor 1-methyl-L-tryptophan (1-MT) on the capacity of pretreated ASC to inhibit the 
proliferation of PHA-stimulated PBMC (n=4). ASC were added to responder PBMC at a 1:5 ratio. Proliferation 
was measured by 3H-thymidine incorporation on day 3. [E] Effect of IDO1-inhibitor 1-methyl-L-tryptophan (1-
MT) on the capacity of pretreated ASC to inhibit the proliferation in MLR (n=8). ASC were added to responder 
PBMC at a 1:5 ratio. Proliferation was measured by 3H-thymidine incorporation on day 7. * = p<0.05; ** = 
p<0.01; *** = p<0.001.
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dISCuSSIOn
In the present study we have demonstrated that inflammatory conditions have an important impact 
on the phenotype and function of ASC. Stimulation of ASC with MLR was used to study the effect 
of a range of inflammatory cytokines that are associated with immune responses. Stimulation with 
the pro-inflammatory cytokines IFN-γ, TNF-a and IL-6 represents a controlled and reproducible 
method of immune activation of ASC. Culture of ASC with alloactivated lymphocytes (MLR) or 
pro-inflammatory cytokines did not affect their differentiation capacity and production of trophic 
factors. Both inflammatory conditions, however, affected ASC morphology, proliferation and gene 
expression of cytokines, chemokines and HLA molecules. These gene expression changes led to 
increased immunosuppressive capacity of ASC.
Exposure of ASC to MLR or a cocktail of pro-inflammatory cytokines resulted in a change in 
ASC morphology and distribution in culture. The typical monolayer distribution of ASC changed 
to a star-shaped clustered distribution of ASC after culture in an inflammatory milieu. This effect 
was most striking in cultures of ASC in the presence of MLR. The clustering could be the result 
of differential expression of cell adhesion molecules. Whereas cadherin and selectin expression 
was not affected, the expression of a number of integrins changed modestly in ASC in the presence 
of MLR compared to control ASC and ASC cultured with pro-inflammatory cytokines. We 
also observed that ASC cultured with MLR showed a high proliferation rate, while culture with 
pro-inflammatory cytokines resulted in ASC with enlarged cell size and dramatically reduced 
proliferation. These findings indicate that ASC are affected in a different manner by the two 
inflammatory conditions used.
Inflammatory conditions did not only affect the phenotype of ASC, but also the immunosuppressive 
function of ASC. Culture of ASC with MLR improved the capacity of ASC to inhibit the 
proliferation of mitogen or alloantigen-stimulated lymphocytes. Culture of ASC with pro-
inflammatory cytokines enhanced the immunosuppressive capacity of ASC even further. In contrast 
to ASC precultured under control conditions, ASC precultured with pro-inflammatory cytokines 
were able to inhibit lymphocyte proliferation when added at day 6 of a seven-day MLR. This 
suggests that pro-inflammatory cytokines activate the immunosuppressive machinery of ASC. This 
can lead to immediate immunosuppressive activity when ASC are added to an active MLR.
The increased immunosuppressive effect of these ASC was dependent largely upon increased 
expression of IDO. Blocking IDO reduced the immunosuppressive effect of cytokine-treated ASC 
to levels found in control ASC, but did not abolish the immunosuppressive capacity completely. 
This shows that IDO is important for the induced immunosuppressive capacity of ASC treated with 
cytokines, but less so for the basic immunosuppressive capacity of ASC. As a consequence, other 
factors must play a role in the immunosuppressive function of ASC, of which several have been 
reported in the literature, such as HGF, HLA-G and NO 5, 19-20. We found high expression of HLA-G, 
TGF-b1 and COX-2, which have been reported to be involved in the immunosuppressive effect of 
ASC 5, 18-19. In MLR-cultured ASC we found strong up-regulation of COX-2, which could indicate 
that prostaglandin E2 is responsible for some of the enhanced immunosuppressive capacity of these 
cells. 
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Culture under inflammatory conditions not only changed the expression of anti-inflammatory 
factors by ASC, but also increased the expression of HLA class I. The expression of HLA class II 
was increased predominantly by pro-inflammatory cytokines, whereas culture of ASC with MLR 
had less effect. Up-regulation of HLA makes ASC potentially more immunogenic. This could have 
consequences for clinical application of ASC of allogeneic origin.
Inflammatory conditions also increased the expression of pro-inflammatory factors and 
chemokines. The type of pro-inflammatory factors and chemokines produced by ASC depended on 
the inflammatory condition. Whereas ASC cultured with MLR showed up-regulation of chemokines 
for, in particular, neutrophils, monocytes and macrophages, culture of ASC with pro-inflammatory 
cytokines resulted in the up-regulation of chemokines for T lymphocytes. The relevance of the 
chemoattraction of the different immune cells by ASC is not clear, but could lead to binding of 
activated immune cells to ASC 23. Close contact of activate immune cells and ASC may increase the 
efficacy of the immunomodulatory function of ASC 20, 35. These results indicate that ASC can exhibit 
diverse immunomodulatory effects. The local inflammatory milieu is of crucial importance for the 
balance between the pro- and anti-inflammatory effects of ASC. Furthermore, it determines the 
mechanisms that ASC employ to execute their immunomodulatory function.
Apart from their immunomodulatory properties, ASC have potential to support tissue regeneration. 
While this is partially mediated via their differentiation in other cell types 2, there is now increasing 
evidence that the regenerative effect of ASC is also the result of the production of tropic factors, 
which stimulate resident progenitor cells 4. Under inflammatory conditions, ASC maintained 
the capacity to differentiate in adipogenic and osteogenic lineages. Moreover, inflammatory 
conditions did not affect the expression of growth factors, such as epidermal growth factor, vascular 
endothelial growth factor and fibroblast growth factors by ASC, and even increased the expression 
of stem cell factor. Thus, while ASC gain immunosuppressive capacity under inflammatory 
conditions, their regenerative capacity is preserved.
A suggested undesired property of ASC is their potential transformation into fibrosis 36. We found 
that culture of ASC with MLR had no effect on collagen gene expression, while culture of ASC with 
pro-inflammatory cytokines induced a down-regulation of the expression of multiple collagens. 
The expression of connective tissue growth factor, TGF-b and platelet-derived growth factor, which 
can induce epithelial-mesenchymal transition, was not affected by inflammatory conditions. This 
suggests that inflammatory conditions do not favor the induction of fibrosis by ASC. 
The present study demonstrates that the type of inflammatory stimulus affects the response of ASC. 
In an alloactivated setting, ASC remain functional and even enhance their immunosuppressive 
function. Their immunosuppressive activity can be further enhanced by culturing ASC with 
pro-inflammatory cytokines. This offers the possibility to in vitro generate ASC with strong and 
instant immunosuppressive capacity. The potential regenerative capacity of ASC is not affected 
by inflammatory conditions and there is no evidence for an increased risk of fibrosis. Therefore, 
immune activation of ASC could be of benefit for potential clinical immune therapy with ASC. 
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Chapter 6
ABSTrACT
Mesenchymal stem cells (MSC) inhibit the proliferation of alloactivated lymphocytes. This effect 
is primarily dependent on the secretion of anti-inflammatory factors by MSC and is enhanced 
under inflammatory conditions. MSC, however, also produce factors that can potentially activate 
resting immune cells. Full understanding of the behaviour of MSC under inflammatory and non-
inflammatory conditions is crucial when clinical application of MSC is considered. Human adipose 
tissue-derived MSC were cultured with non-activated peripheral blood mononuclear cells (PBMC) 
and activation, proliferation and function of PBMC examined.
Seven days of co-culture with autologous or allogeneic MSC significantly increased the proliferation 
of PBMC (3-fold). This effect was observed in both direct and transwell co-culture systems. MSC 
co-cultured with PBMC showed increased mRNA expression of the pro-inflammatory mediators IL-
6, IL-8, TNF-a, the growth factors bFGF and VEGFa, and the anti-inflammatory factor IDO. After 
removal of MSC, PBMC showed a spectacular further increase in proliferation with a maximum of 
25-fold after seven days. This increase in proliferation was not seen when PBMC were kept in the 
presence of MSC. The proliferating fraction of PBMC largely consisted of CD4+ T-cells with high 
CD25 expression and the proportion of CD127negFoxP3+ regulatory T-cells significantly increased 
from 5.0% to 8.5% of total CD4+ T-cells. The expanded T-cells demonstrated normal responses to 
mitogen or alloantigen stimulation. The CD25pos fraction of these cells had immunosuppressive 
capacity. In conclusion, MSC can stimulate activation and proliferation of resting T-cells and generate 
regulatory T-cells. These findings are important when MSC are applied in the clinic.
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InTrOduCTIOn
Over the last decade there has been increasing interest in the immunomodulatory properties 
of mesenchymal stem cells (MSC). MSC inhibit the proliferation and function of alloactivated 
lymphocytes and other immune cells 1-2. The mechanisms of immune modulation by MSC are 
not fully understood, but partly depend on the secretion of anti-inflammatory factors, such as 
interleukin-10 (IL-10), indoleamine 2,3-dioxygenase (IDO), nitric-oxide (NO) 3, prostaglandin E2 
1, HLA-G 4, hepatocyte growth factor (HGF) and transforming growth factor-b (TGF-b) 2. It has 
also been suggested that MSC modulate immune responses via the generation of regulatory T-cells 
(T-regs) 1, 5-7.
Animal models have demonstrated that MSC can effectively reduce inflammatory processes, 
for example in autoimmune encephalitis 8, myocarditis 9, inflammatory bowel disease 10 and 
glomerulonephritis 11. In a clinical setting, MSC therapy has been shown to be effective for 
the treatment of patients with severe therapy-resistant graft-versus-host disease (GVHD) 12. 
Furthermore, clinical trials are ongoing to determine whether MSC are also effective for the 
treatment of autoimmune diseases, such as inflammatory bowel diseases, multiple sclerosis and 
rheumatoid arthritis.
The immunosuppressive properties of MSC make them interesting candidates for cell-based therapy 
in organ transplantation 13. Treatment with MSC may provide an immunosuppressive environment 
that controls anti-donor reactivity. A number of studies with animal transplant models have reported 
a beneficial effect of MSC on skin 14, heart 6, 15 and liver 16 graft survival. 
We recently reported that MSC derived from perirenal adipose tissue of living kidney donors have 
the capacity to inhibit anti-donor reactivity of kidney transplant patients in vitro both before and 
after transplantation 17. The immunosuppressive function of MSC is triggered under inflammatory 
conditions where T-cells produce interferon-gamma (IFN-γ) and tumour-necrosis-factor-alpha 
(TNF-a) 18-19. T-cells in a quiescent state, however, are promoted in survival by MSC 20. Despite 
many studies investigating the effect of MSC on alloantigen or mitogen-activated immune cells, 
the effect of MSC on non-activated immune cells remains largely unknown. Understanding the full 
spectrum of immune modulation by MSC is, however, important when the application of MSC in a 
clinical setting is considered. In the present study we investigate the effect of human autologous and 
allogeneic MSC on non-activated immune cells.
MATErIALS And METhOdS
Isolation, culture and differentiation of MSC from perirenal adipose tissue
MSC were isolated from 10-50 grams of perirenal adipose tissue of living kidney donors as previously 
described 21. Briefly, perirenal adipose tissue was collected during the kidney donation procedure after 
written informed consent of the kidney donors as approved by the Medical Ethical Committee of the 
Erasmus Medical Center Rotterdam (protocol no. MEC-2006-190). The tissue was collected in RPMI-
Dutch-modified-1640 (RPMI, Invitrogen, Paisley, Scotland) with 200mM L-glutamine (Biowithaker, 
Verviers, Belgium) and 1% penicillin/streptomycin (100U/ml / 100μg/ml, p/s, Invitrogen). 
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Next, it was mechanically disrupted and enzymatically digested with sterile 0.5mg/ml collagenase 
type IV (Sigma-Aldrich, St. Louis, MO, USA) in RPMI for 30 minutes at 37oC. Subsequently, the cells 
were incubated with 160mM NH
4
Cl (dissolved in PBS) for 10 minutes at room temperature. Cells 
were resuspended in MSC-culture medium, consisting of alpha-MEM medium (a-MEM, Invitrogen) 
with 1% p/s and 15% foetal bovine serum (FBS, Biowithaker), transferred to a 175cm2 culture flask 
(Greiner Bio-one, Essen, Germany) and kept at 37oC, 5% CO
2
 and 95% humidity. Cultures were 
refreshed with MSC-culture medium twice a week. At 90% confluence, adherent cells were removed 
from culture flasks by incubation in 0.05% trypsin-EDTA at 37oC and cells were used for experiments 
or frozen at –150oC until use.  MSC were used for experiments between passages 2 to 5. To confirm 
whether the perirenal adipose tissue-derived cells were indeed MSC, they were characterized by 
flow cytometry, differentiated in osteogenic, adipogenic and myogenic lineages, and added to mixed 
lymphocyte reactions (MLR) to test their immunosuppressive capacity as previously described 17, 21.
Isolation of peripheral blood mononuclear cells (PBMC)
Peripheral blood samples were collected from living kidney donors and from buffy coats of healthy 
blood donors. PBMC were isolated from the collected heparinised peripheral blood by density 
gradient centrifugation using Ficoll Isopaque (d=1.077, Amersham, Uppsala, Sweden) and frozen at 
–150oC until use.
Experimental set-up (day 0-7): co-culturing PBMC with MSC
The experimental set-up is shown in Figure 1. At day 0, PBMC were cultured for 7 days with MSC 
in a (5:1)-ratio in direct or in transwell co-culture systems. In transwell co-culture systems PBMC 
were separated from MSC by a 0.4-μm-pore-size membrane (Greiner Bio-one); MSC were cultured 
in the bottom well, while PBMC were kept in the inserts. In 6-well plates, 1x106 PBMC were added 
to 0.20x106 MSC, while in 96-well plates 50,000 PBMC were added to 10,000 MSC. After 7 days, 
proliferation was determined after 16-hour incorporation of 3H-thymidine (0.5mCi/well, Amersham, 
UK) using a b-plate reader (LKB, Bromma, Sweden). In six out of 56 cases, PBMC in the absence 
of MSC already showed 3H-thymidine incorporation of 5000 cpm or more (day 7) and these samples 
were excluded from further analysis as these cells could not be defined as ‘’non-activated’’.
In addition, proliferation was measured after 7 days by flow cytometry after labelling of PBMC on 
day 0 with PKH67 (Sigma-Aldrich) according to the manufacturer’s instructions. Flow cytometric 
analysis was performed as described below. To investigate whether IL-6 and IL-8 were involved 
in the stimulatory effect of MSC on T-cell activation and proliferation, neutralizing antibodies 
against IL-6 (10 mg/ml) and IL-8 (10 mg/ml) (both R&D systems, Minneapolis, MN, USA) were 
used. Immunoassays (Immulite 1000, Siemens, Deerfield, IL, USA) were performed to determine the 
protein levels of IL-6 and IL-8 in supernatants of cultures with neutralizing antibodies.
Experimental set-up (day 7-17): continued culture of PBMC previously cultured with MSC
After 7 days, PBMC were collected from PBMC-MSC co-cultures, washed, resuspended in fresh 
medium (RPMI with p/s, L-glutamine and 10% HI-FBS). There was no evidence for contamination 
with MSC after removal of PBMC from direct MSC-PBMC co-cultures, as investigated by 
morphology in culture and flow cytometric analysis. Subsequently, PBMC were continued in culture 
for 1, 3, 5, 7 and 10 days in the absence of MSC (Figure 1, day 7 to 14). Proliferation was measured by 
3H-thymidine incorporation (on experimental day 8, 10, 12, 14 or 17) or flow cytometry (experimental 
day 14). 
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Experimental set-up (day 14-21): functional analysis of PBMC previously cultured with MSC
On experimental day 14, PBMC were collected for real-time RT-PCR analysis (as described below). 
To examine whether these cells were still capable of responding to alloantigens, they were used as 
responder cells and stimulated with 1 mg/ml phytohaemagglutinin (PHA; Murex Biotech LTd, Kent, 
UK) for 3 days or with γ-irradiated (40Gy) allogeneic PBMC (added at a 1:1-ratio). 
Furthermore, to determine whether the precultured PBMC had immunosuppressive capacity, they 
were added to MLR at a 1:10-ratio. Finally, the PBMC were sorted for CD25 by auto MACS (as 
described below). The suppressive capacity of both the CD25pos and the CD25neg fraction was examined 
by adding the cells to MLR at a 1:5, 1:10 and 1:20 ratio. 
Mixed-lymphocyte reactions (MLr)
Immunosuppressive capacity of MSC and PBMC previously cultured with MSC was tested in MLR. 
In MLR, 5x104 responder PBMC were stimulated by 5x104 γ-irradiated (40Gy) allogeneic PBMC 
in RPMI+10% HI-FBS in round-bottom 96-well plates (Nunc, Roskilde, Denmark). On day 7, 
proliferation was measured following incorporation of 3H-thymidine (0.5mCi/well) during a 16-hour 
incubation using a b-plate reader. To determine the proliferation capacity of the PBMC, 5x104 cells 
were stimulated with 1 mg/ml PHA for 3 days and 3H-thymidine incorporation was measured. Only 
results of responder PBMC with sufficient proliferation capacity (>10,000 cpm after stimulation with 
PHA) were included.
Flow cytometric analysis
PBMC were washed twice with FACSFlow (BD Biosciences, San Jose, CA, USA) and stained 
with antibodies against CD3-AmCyan, CD4-PacificBlue, CD8-APC-Cy7, CD16/56-APC, CD19-
PerCP, CD25-PE-Cy7, CD62L-APC, CD69-PE, CD127-FITC (all BD Biosciences), CCR7-PE 
(R&D systems, Minneapolis, MN, USA), FASL-APC (Biocarta, San Diego, CA, USA) at room 
temperature and protected from light for 30 minutes. After two washes with FACSFlow, flow 
cytometric analysis was performed using an 8-colour FACSCANTO-II with FACSDIVA Software 
(BD Biosciences). FoxP3-APC staining was carried out as described previously 22.
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Figure 1. Experimental set-up. PBMC were co-cultured with MSC in direct or transwell co-culture systems 
during the first week (= week 1). On day 7, MSC were removed from the co-culture systems and culture of PBMC 
continued in the absence of MSC for another 7 days (= week 2). On experiment day 14, the functionality of the 
cells previously cultured with MSC was investigated (= week 3).
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Isolation of Cd25pos cells by autoMACS
On experimental day 14, the CD25positive (CD25pos) cells were isolated from PBMC previously 
transwell co-cultured with MSC using anti-CD25 microbeads (10 ml /10x106 cells) (Miltenyi 
Biotech, Bergisch Gladbach, Germany), followed by positive selection (POSSELD-program) on the 
autoMACS (Miltenyi Biotech). To check the purity, both fractions were stained with CD3-FITC, 
CD4-PerCP and CD25-PE epitope B (clone M-A251, BD Biosciences) and flow cytometric analysis 
was performed.
real-time rT-PCr
PBMC and MSC for real-time RT-PCR were obtained from transwell co-culture systems. Total 
RNA was isolated and cDNA synthesized as previously described 23. Quantitative gene expression 
was determined using TaqMan Universal PCR Master Mix and assays-on-demand for IDO 
(Hs00158627.m1), IL-10 (Hs00174086.m1), TGF-b (Hs00171257.m1), TNF-a (Hs99999043.m1), 
CD25 (Hs00166229.m1), FoxP3 (Hs00203958), IL-2 (Hs00174114.m1), IL-6 (Hs00174131), IFN-γ 
(Hs00174143) and IL-8 (Hs00174114.m1) (all Applied Biosystems, CA, USA) on a StepOnePlus 
(Applied Biosystems). VEGFa and bFGF were determined by real-time RT-PCR using homemade 
primers (F-5’-GCA-GAC-CAA-AGA-AAG-ATA-GAG-CAA-G-3’ and R-5’-CGC-CTC-GGC-TTG-
TCA-CAT-3’) and (F-5’-GTT-GAC-GGG-GTC-CGG-G-3’ and R-5’-GAT-AGA-CAC-AAC-TCC-
TCT-CTC-TTC-TGC-3’), respectively. Gene expression levels were normalized to the concentration 
of 18S per 500ng RNA.
Statistical analysis
Data were analyzed using paired t-test or Wilcoxon signed-rank test depending on the distribution 
of the data as tested with Kolmogorov-Smirnov test for normality. Parametric data are expressed as 
means, while non-parametric data are expressed as medians. Statistical significance was defined as 
p<0.05 (two-tailed).
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MSC stimulate PBMC proliferation and activation 
In contrast to our previous studies 17, 21, in which MSC were added to alloactivated PBMC, the 
present study investigated the effect of human MSC on non-activated PBMC. The experimental set-
up is shown in figure 1. Seven-day co-culture of PBMC with allogeneic MSC significantly increased 
PBMC proliferation by a factor 4 compared to PBMC cultured without MSC (Figure 2A). This 
increase in PBMC proliferation was independent of HLA, since also autologous MSC induced a 
3-fold increase in PBMC proliferation. There was no significant difference in the proliferative effect 
of autologous and allogeneic MSC. When PBMC were co-cultured with γ-irradiated MSC, a similar 
increase in proliferation of the PBMC was observed.
To identify which PBMC subset was stimulated in proliferation in the presence of MSC, flow 
cytometric analysis of PBMC was carried out. MSC predominantly stimulated the proliferation 
of CD4+ T-cells and CD8+ T-cells, while co-culture with MSC had no effect on the proliferation 
of NK and B-cells. Co-culture of PBMC with MSC also significantly increased CD69 and CD25 
expression on the proliferating CD4+ and CD8+ T-cells (Figure 2B), while the expression of CD62L, 
FASL and CCR7 was unchanged in T-cells after culture with MSC. The increased CD25 expression 
of T-cells co-cultured with MSC was associated with a 2-fold increase in mRNA expression of 
IL-2 by the PBMC (data not shown). The expression of pro-inflammatory cytokines such as IL-6, 
IL-8, IFN-γ or TNF-a did not significantly change in PBMC co-cultured with MSC. Expression 
of the immunosuppressive factor IL-10 decreased by a factor 2 in PBMC co-cultured with MSC 
(p=0.0039).
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Figure 2. Proliferation and activation of PBMC cultured for seven days in the absence or presence of MSC (in 
direct culture systems). [A] Proliferation of PBMC co-cultured with autologous and allogeneic MSC measured 
by 3H-thymidine incorporation (n=13). Proliferation of MSC cultured without PBMC was low, 124 cpm for 
autologous and 133 cpm for allogeneic MSC. [B] Flow cytometric analysis of CD25 and CD69 expression on 
CD4+ and CD8+ T-cells that were cultured with or without MSC for seven days. One representative example of 
five experiments is shown. cpm=counts per minute. ** means p<0.01.
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The expression of pro-inflammatory, growth and anti-inflammatory factors by MSC is 
increased in the presence of PBMC
The observed stimulatory effect of MSC on PBMC proliferation was comparable in direct and 
transwell co-culture systems, which indicates that the effect is mediated by soluble factors. To 
identify which factors may be responsible, gene expression of pro-inflammatory, growth and 
immunosuppressive factors by MSC was investigated (Figure 3). MSC significantly increased the 
expression of IL-8 (527-fold), IL-6 (11-fold), TNF-a (3-fold), VEGFa (3-fold) and bFGF (4-fold) 
in the presence of PBMC. In addition, the anti-inflammatory factor IDO was 699-fold increased in 
MSC cultured with PBMC. IL-2, IFN-γ and IL-10 were not detectable.
T-cell proliferation dramatically increases after removal of MSC
To investigate whether the presence of MSC was needed for continuation of PBMC proliferation, 
MSC were removed from PBMC-MSC transwell co-culture systems and at the same time PBMC 
were continued in culture (Figure 1, week 2). PBMC proliferation was measured 1, 3, 5, 7 and 10 
days after removal of MSC. Continued culture of the PBMC led to an explosive 25-fold increase in 
proliferation with a maximum on day 7 after separation of PBMC from MSC (=experiment day 14) 
(Figure 4A). This extra increase in PBMC proliferation during the second week was not observed 
when PBMC were kept in the presence of MSC (Figure 4B).
As shown, on experimental day 17, PBMC proliferation declined compared to day 14. To rule out the 
possibility that this was due to exhaustion of the culture medium, fresh medium was added on day 
14 and PBMC proliferation measured on day 17. Refreshment of medium, however, did not improve 
the proliferation of the PBMC on day 17.
As the expression of IL-6 and especially IL-8 strongly increased in MSC during culture with 
PBMC, it was investigated whether IL-6 and IL-8 were involved in the stimulatory effect of MSC on 
resting PBMC. 
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Figure 3. Real-time RT-PCR analysis of MSC co-cultured with PBMC for seven days in transwell co-culture 
systems. Gene expression levels were normalized to the concentration of 18S RNA per 500ng RNA (n=9). ** 
means p<0.01; *** means p<0.001.
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Therefore, PBMC were co-cultured with MSC in the absence or presence of neutralizing antibodies 
against IL-6 or IL-8. Blocking IL-6 or IL-8 did not reverse the stimulatory effect of MSC on 
PBMC proliferation (Figure 4C). Protein levels of IL-6 and IL-8 in supernatants were measured by 
immunoassays. Anti-IL-8 antibodies strongly reduced the IL-8 concentration in PBMC-MSC co-
cultures (4x105-fold). The production of IL-6 in PBMC-MSC co-cultures was extremely high (3x108 
pg/ml).  While anti-IL-6 antibodies reduced the IL-6 levels 7-fold, they were unable to completely 
remove free IL-6 (Figure 4D). 
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Figure 4. Continued culture of PBMC previously transwell cultured with MSC and after removal of MSC at day 
7. [A] Proliferation of PBMC precultured with MSC and then continued in culture for 1, 3, 5, 7  or 10 days without 
MSC (experimental day 7-17). PBMC were cultured for 14 days without MSC (PBMC), or for seven days with 
MSC and continued in culture after removal of MSC at day 7 (PBMC+MSC). Proliferation was measured by 
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of four experiments. Proliferation was measured by 3H-thymidine incorporation at experimental day 14. [C] 
Proliferation of PBMC in the presence of MSC and neutralizing antibodies against IL-6 and IL-8. PBMC were 
cultured during experimental week 1 with MSC, anti-IL-6 or anti-IL-8 and 3H-thymidine incorporation measured 
at day 7. After seven days the PBMC cultured under the various conditions were washed and continued in culture 
for another week. Again, proliferation was measured by 3H-incorporation (at day 14) (n=2). 
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MSC induce activation and proliferation of Cd4+ T-cells
Flow cytometric analysis was performed to identify which PBMC subset(s) were responsible for 
the striking increase in proliferation observed seven days after removal of MSC. The proliferating 
fraction of PBMC expanded by MSC consisted predominantly of CD4+ T-cells (92%) (Figure 
4E). The percentages CD8+ T-cells, NK-cells and B-cells did not significantly change. The CD4+ 
T-cells previously cultured with MSC showed a strong increase in proliferation (as measured by 
PKH dilution) (Figure 4F). These cells highly expressed CD25 and CD69, while the expression of 
FAS-L, CD62L and CCR7 was unchanged. Furthermore, the percentage of CD4+CD25posFoxP3+ and 
CD127neg was significantly increased by a factor 1.7 compared to PBMC previously cultured without 
MSC. This indicates that there is expansion of CD4+CD25posFoxP3+CD127neg T-regs in PBMC 
previously cultured with MSC.
PBMC+MSC PBMC+MSC
+anti-IL-6
PBMC+MSC PBMC+MSC
+anti-IL-8
100
102
104
106
107
108
109
co
nc
en
tr
at
io
n 
(p
g/
m
l)
IL-6 IL-8
D
CD4+ T-cells CD8+ T-cells B-cells NK-cells
Subsets
%
 c
el
ls
0
10
20
30
40
50
60
70
80
90
100
E
101 102 103 104 105
PKH67
0
10
3
10
4
10
5
C
D
25
0 102 103 104 105
PKH67
0
10
3
10
4
10
5
C
D
25
CD4 (PBMC cultured without MSC)
3.8%
CD127
Fo
xP
3
CD127
Fo
xP
3
CD4 (PBMC cultured with MSC)
CD69
FA
S
-L
CD69
FA
S
-L
0 103 104 105
10
1
10
2
10
3
10
4
10
5
0 103 104 105
10
1
10
2
10
3
10
4
10
5
0-102 102 103 104 105
0
-1
03
10
3
10
4
10
5
0-102 102 103 104 105
0
-1
03
10
3
10
4
10
5
3.7%
6.1%
0.9%
0.8%
41.5%
2.9%
5.0%
28.7%
0.8%
7.8%
29.3%
0.8%
11.7%
59.1% 8.3%
F
MSC induce explosive T-cell proliferation
C
ha
pt
er
 6
107
Expression of pro- and anti-inflammatory genes in PBMC after removal of MSC
Next, PBMC were collected seven days after removal of MSC and RT-PCR analysis performed 
to characterize the PBMC expanded by MSC (Figure 4G). PBMC expanded by MSC showed 
significant, but minor, increases in the expression of pro-inflammatory factors IL-2 (3-fold), IL-6 
(2-fold), IL-8 (2-fold), TNF-a (2-fold) compared to PBMC not precultured with MSC. There was 
no significant change in the expression of IFN-γ or the anti-inflammatory factors TGF-b and IDO, 
while IL-10 expression increased by a factor 2.
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Figure 4 (continued). [D] Concentration of IL-6 and IL-8 in supernatants of PBMC-MSC co-cultures in the 
absence or presence of neutralizing antibodies for IL-6 or IL-8 (n=2). Supernatants were collected from co-
cultures at day 7. Data are expressed as mean+SEM. [E] Flow cytometric analysis of the proliferating fraction 
of PBMC expanded by MSC (day 14). Mean±SD is shown of eight experiments. [F] Flow cytometric analysis 
of cell proliferation (PKH dilution), CD25, CD69, CD127, FoxP3 and Fas-L expression on CD4+ T-cell subsets 
of PBMC previously cultured with and without MSC at experimental day 14. One representative example of six 
experiments is shown. [G] Real-time RT-PCR analysis (day 14) of PBMC previously co-cultured with MSC and 
then expanded for 7 days (n=4). Gene expression levels were normalized to the concentration of 18S per 500ng 
RNA. PBMC were cultured for 14 days without MSC (PBMC), or for seven days with MSC and continued in 
culture after removal of MSC at day 7 (PBMC+MSC). cpm=counts per minute.
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PBMC expanded by MSC maintain responsive to mitogen and alloantigen
After one week of culture with MSC, followed by one week of culture without MSC, PBMC were 
highly proliferative and showed an activated phenotype. To functionally examine the characteristics 
of these expanded cells, they were stimulated with mitogen (PHA) and alloantigen (γ-irradiated 
allogeneic PBMC) (Figure 1, week 3). PBMC precultured with MSC showed a good response upon 
stimulation with PHA (up to 42,000 cpm) (p=0.005) and was comparable with the proliferative 
response of PBMC cultured without MSC. Thus, despite two weeks of culture, the expanded cells 
still had good proliferative capacity.
PBMC expanded by MSC were then stimulated with γ-irradiated allogeneic PBMC (at a 1:1-ratio). 
These PBMC showed comparable proliferative responses compared to PBMC previously cultured 
without MSC. Thus, although the PBMC previously co-cultured with MSC were highly activated 
and proliferative, the cells were not hyper-reactive upon stimulation with alloantigen.
PBMC expanded by MSC have immunosuppressive capacity
We then investigated whether the expanded PBMC precultured with MSC had immunosuppressive 
capacity. Therefore, the PBMC were added at a 1:10-ratio to MLR (Figure 5A). PBMC that had been 
cultured with MSC inhibited the proliferation in MLR by 32% (p<0.0001), while PBMC previously 
cultured without MSC did not show this effect. 
The inhibitory capacity of the PBMC was independent of the origin of the cells used in the MLR, 
indicating that inhibition was not antigen specific. PBMC that were cultured for one week with MSC 
and added to MLR before their expansion had no immunosuppressive capacity, indicating that the 
expansion of these cells is crucial for obtaining their immunosuppressive capacity.
The immunosuppressive capacity of PBMC expanded by MSC resides in the Cd25pos T-cell 
fraction
Finally, the previous experiments showed that MSC induced both CD25 expression and 
immunosuppressive function in PBMC. To examine whether the CD25pos PBMC were responsible 
for the observed immunosuppressive capacity, PBMC expanded by MSC were sorted in CD25pos and 
CD25neg fractions and added to MLR at various ratios. Before sorting 51.9% of the PBMC previously 
cultured with MSC was positive for CD25. After sorting the purity of CD25pos cells was 93.6% 
(Figure 5B). While the CD25neg fraction had no inhibitory capacity at any ratio and even stimulated 
the proliferation of alloactivated PBMC, the CD25pos fraction significantly inhibited the proliferation 
of alloactivated responder cells in MLR by 62% (ratio 1:5), 40% (ratio 1:10) and 21%(ratio 1:20)
(Figure 5C).
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Figure 5. Functionality of PBMC previously transwell cultured with MSC and continued in culture for another 
seven days without MSC. [A] Immunosuppressive capacity of PBMC precultured with MSC and expanded after 
removal of MSC. Precultured PBMC were added to MLR at a 1:10 ratio (n=26). Proliferation was measured 
by 3H-thymidine incorporation at experimental day 21. [B] Purity and intensity of CD25 expression on CD3+ 
T-cells in PBMC previously cultured with MSC before and after sorting. One representative example is shown 
of six experiments. [C] Immunosuppressive capacity of CD25pos population of PBMC precultured with MSC 
and expanded after removal of MSC. Precultured PBMC were sorted in CD25pos and CD25neg fractions and 
added to MLR at a 1:5, 1:10 and 1:20 ratio (n=6). Proliferation was measured by 3H-thymidine incorporation at 
experimental day 21. cpm=counts per minute. * means p<0.05; *** means p<0.001.
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dISCuSSIOn
There is accumulating data on the immunosuppressive effect of MSC demonstrating that MSC 
inhibit mitogen and alloantigen activated immune cells. The effect of MSC on immune cells under 
low immunogenic conditions is, however, unknown. It is important to understand the full spectrum 
of immune regulation by MSC, when MSC are considered for clinical application. 
The present study demonstrates that the proliferation of non-activated, “resting”, PBMC increases 
by co-culture with MSC. Removal of MSC leads to accelerated proliferation of in particular CD4+ 
T-cells, whereas in the continuous presence of MSC PBMC proliferation is kept at a low level. This 
suggests that MSC activate resting CD4+ T-cells, but, when present, do prevent full activation and 
proliferation of these cells.
These results are in sharp contrast with previous studies reporting that MSC do not elicit 
proliferative responses from allogeneic lymphocytes 24-27. One of the reasons for this disparity is that 
most groups investigated the effect of MSC on activated PBMC, whereas the present study is the 
first to investigate the effect of MSC on non-activated PBMC in detail. Furthermore, this is the first 
study to examine the effect of removal of MSC from MSC-PBMC co-cultures. It can be speculated 
that the observed stimulatory effect of MSC on resting T-cells still is present in an activated setting, 
but that it is covered by the immunosuppressive effect of MSC on activated PBMC. 
It is generally considered that T-cell activation and proliferation is initiated by T-cell receptor 
triggering. In our study, however, we found that the activation was not antigen-dependent as the 
proliferation of T-cells was stimulated by both autologous and allogeneic MSC and that this effect 
was present in transwell systems, indicating that the T-cells can be activated by soluble factors 
only. Apart from the repeatedly reported production of anti-inflammatory factors 1-3, MSC can 
also produce growth and pro-inflammatory factors, such as basic fibroblast growth factor (bFGF), 
interleukin-6 (IL-6) and tumour necrosis factor-a (TNF-a), which can explain the stimulatory 
effect of MSC on PBMC 28. In the present study, gene expression analysis showed that MSC had 
particularly increased levels of IL-6 and IL-8 after co-culture with PBMC. Neutralizing IL-8 
dramatically reduced the IL-8 concentration in supernatants of PBMC-MSC co-cultures but had no 
effect on PBMC proliferation, suggesting that IL-8 is not a major player involved in the stimulatory 
effect of MSC on PBMC. 
In addition, reduction of levels of IL-6 by neutralizing antibody in PBMC-MSC cocultures did not 
prevent activation and proliferation of resting PBMC. However, remaining levels of IL-6 could still 
be responsible for the stimulatory effect of MSC on PBMC. We can therefore not rule out that the 
stimulatory effect of MSC on PBMC was independent of IL-6 and this needs further investigation. 
Concurrent with the increased expression of IL-6 and IL-8, MSC increased the expression of the 
anti-inflammatory factor IDO during co-culture with PBMC. This shows the dual effect of MSC 
on PBMC proliferation, which was further demonstrated by the persisted and even accelerated 
proliferation of PBMC after removal of MSC. This extra proliferative effect on PBMC was not 
observed when PBMC were kept in the presence of MSC, suggesting a blockade of PBMC activation 
and proliferation. Taken together, these results indicate that MSC have a regulatory function 
to maintain homeostasis in the (local) environment: under inflammatory conditions MSC are 
immunosuppressive, while MSC stimulate T-cell proliferation under low inflammatory conditions.
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The spectacular increase in proliferation of PBMC after removal of MSC was for an overwhelming 
part dependent on the proliferation of CD4+ T-cells. These cells highly expressed CD25 and CD69, 
reflecting their activation status. Furthermore, within the CD4+ T-cell population, the proportion 
of CD25posFoxP3+CD127neg T-regs was significantly increased. Our data therefore suggest that 
MSC favor the expansion of T-regs. Functional analysis showed that the T-cells that expanded after 
removal of MSC were not anergic and had immunosuppressive function. The CD25pos fraction of the 
generated cells was responsible for this effect, while the CD25neg fraction had no inhibitory effect 
on the proliferation of alloactivated cells. Expansion of these cells after removal of MSC was crucial 
for obtaining this immunosuppressive capacity.
There is currently a trend to apply MSC for an increasing number of applications, including organ 
transplantation. The relevance of the observed stimulatory effect of MSC on resting T-cells in 
clinical therapy is unknown. Although the expansion of T-cells by MSC harbors a potential danger, 
the net effect of MSC was an enhancement of the regulatory capacity of the T-cell compartment. It 
is important for successful clinical application of MSC that the interaction between MSC, T-regs 
and other immune cells is studied in further detail under various immunological conditions. 
In conclusion, the results of this study give new insights in the mechanisms of immune modulation 
by MSC under non-inflammatory conditions. Under these conditions, MSC have a stimulating 
effect on activation and proliferation of T-cells. At the same time, MSC show immune regulatory 
functions that can control full activation of T-cells. Removal of MSC will lead to further activation 
and explosive proliferation of T-cells. 
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ABSTrACT
There is growing interest in the use of mesenchymal stem cells (MSC) to improve the outcome of 
organ transplantation. The immunogenicity of MSC is, however, unclear and is important for the 
efficacy of MSC therapy and for potential sensitization against donor antigens. We investigated the 
susceptibility of autologous and allogeneic MSC for lysis by CD8+ T-lymphocytes and NK-cells in a 
kidney transplant setting.
MSC were derived from adipose tissue of human kidney donors and were CD90+, CD105+, CD166+ 
and HLA class I+. They showed differentiation ability and immunosuppressive capacity. Lysis of MSC 
by PBMC, FACS-sorted CD8+ T-cells and NK-cells was measured by europium release assay. 
Allogeneic MSC were susceptible for lysis by cytotoxic CD8+ T-cells and NK-cells, while autologous 
MSC were lysed by NK-cells only. NK cell-mediated lysis was inversely correlated with the expression 
of HLA class I on MSC. Lysis of autologous MSC was not dependent of culturing of MSC in FBS, 
and MSC in suspension as well as adherent to plastic were lysed by NK-cells. Pretransplant recipient 
PBMC did not lyse donor MSC, but PBMC isolated 3, 6 and 12 months after transplantation showed 
increasing lysing ability. After 12 months, CD8+ T-cell mediated lysis of donor MSC persisted, 
indicating there was no evidence for desensitization against donor MSC.  
In conclusion, lysis of MSC is important to take into account when MSC are considered for clinical 
application. Our results suggest that the HLA background of MSC and timing of MSC administration 
are important for the efficacy of MSC therapy.
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InTrOduCTIOn
Mesenchymal stem cells (MSC) have beneficial regenerative and immunomodulatory properties that 
make them promising for use in the treatment and prevention of a variety of disorders, including 
graft versus host disease and multiple sclerosis 1-3. Recently, interest has risen in the use of MSC to 
improve the outcome of organ transplantation 4. Animal models have demonstrated the ability of MSC 
to prolong the survival of skin 5, heart 6-7 and islets allografts 8 and to facilitate the recovery of kidney 
function after acute and chronic injury 9-10. It is therefore anticipated that MSC therapy in transplant 
patients may allow a reduction in the dosing of immunosuppressive drugs and thereby limit their side 
effects, and to aid the repair of ischemia-reperfusion injury of the transplant 11.
The immunomodulatory functions of MSC are largely mediated via soluble factors. Via these factors 
MSC inhibit T-cell proliferation 12-13, maturation of dendritic cells and differentiation of B lymphocytes 
14-16. Moreover, MSC inhibit the formation of cytotoxic CD8+ T-cells 17 and proliferation and cytotoxic 
activity of natural killer (NK) cells 18-20. Reversely, it is less clear how immune cells affect MSC. It is 
reported that MSC have a low immunophenotype as they express low levels of HLA class I, no HLA 
class II and co-stimulatory molecules like CD80 and CD86, and that they therefore do not provoke 
immune responses 21. This would make MSC transplantable across HLA barriers 22. In contrast, there 
is evidence that MSC are immunogenic and can induce memory T-cell responses 23-24. Furthermore, it 
has been reported that MSC are susceptible for lysis by NK-cells 17, 20, 25 as MSC express the activating 
NK cell-receptor ligands NKG2D and UL16 26. Interesting in this respect is the fact that intravenously 
administered MSC have repeatedly been demonstrated to disappear within days after infusion 
in immunocompetent mice 7. It is not unlikely that lysis by cytotoxic cells is responsible for the 
disappearance of MSC 24, 27. The observation of tumour formation after administration of autologous 
MSC in immunodeficient mice further strengthens this possibility 28.
It has been demonstrated that exposure of MSC to inflammatory conditions has an important impact 
on the immunomodulatory function of MSC 29-30. In concert with the increased immunosuppressive 
properties of MSC, these conditions also change the immunophenotype of MSC by up regulating the 
expression of HLA molecules, co-stimulatory molecules and adhesion molecules 31. This would make 
allogeneic MSC potentially more susceptible for recognition by CD8+ T-cells. The immunogenicity 
and survival of MSC after administration is important for the efficacy of MSC therapy. Furthermore, 
in an organ transplant setting potential priming by donor MSC is of great relevance as it may induce 
rejection of the donor graft or perhaps desensitize against donor antigens. Therefore in the present 
study we investigated the susceptibility of autologous and allogeneic adipose tissue-derived MSC 
for lysis by NK-cells and CD8+ T-cells. In addition, it was examined whether the susceptibility of 
donor-derived MSC for lysis by recipient cytotoxic cells changed in time after kidney transplantation. 
The results of this study are important for the choice of MSC and the timing of this therapy in organ 
transplantation. 
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MATErIALS And METhOdS
Isolation and culture of perirenal adipose tissue-derived MSC
During the kidney donation procedure, perirenal fat tissue was surgically removed after written 
informed consent as approved by the Medical Ethical Committee of the Erasmus Medical Center 
Rotterdam (protocol no. MEC-2006-190) and collected in a-MEM medium (Gibco BRL, Paisley, 
UK) with 100 IU/ml penicillin and 100 mg/ml streptomycin (p/s, Gibco BRL, Paisley, UK). Adipose 
tissue-derived mesenchymal stem cells (ASC) were subsequently isolated as described previously 
32-33. Cultures were kept at 37oC, 5% CO
2
 and 95% humidity and refreshed twice weekly with MSC 
culture medium, consisting of a-MEM (Gibco BRL) with p/s and 15% fetal bovine serum (FBS, 
Biowithaker, Verviers, Belgium). At 90% confluence, adherent cells were removed from culture 
flasks by incubation in 0.05% trypsin-EDTA at 37oC and cells were used for experiments described 
below or frozen at –150oC until further use. MSC were used for experiments between passages 2 to 
5. When indicated, MSC were cultured with 50 ng/ml IFN-γ (U-CyTech biosciences, Utrecht, The 
Netherlands) for seven days.
Silencing of hLA class I expression
HLA class I expression by MSC was modulated by small interfering RNA (siRNA). Seven ml of 
siRNA for HLA class I (Ambion, Austin, USA) was added to 50 ml Opti-MEM (Gibco BRL). Twelve 
ml of si-Port (Ambion) was added to 50 ml Opti-MEM. siRNA and si-Port were mixed and incubated 
for 10 min at room temperature and added to a 6-well plate. Cell suspension in a-MEM with 15% FBS 
(0.5 ml) was added and incubated for 3 days. Controls were treated with non-coding siRNA.
Flow cytometric characterization of MSC 
MSC were trypsinized, washed twice with FACSFlow (BD Biosciences, San Jose, CA, USA) and 
incubated with antibodies against CD90-APC, CD105-FITC (all R&D systems, Abingdon, UK), 
CD166-PE (BD Biosciences), HLA class I-ABC-PE, CD86-PE (Serotec) and HLA class II-DR-FITC 
(BD Biosciences) for 30 minutes. After incubation, cells were washed twice with FACSFlow and flow 
cytometric analysis performed using an 8-colour FACSCANTO-II with FACSDIVA Software (BD 
Biosciences).
differentiation of MSC
Osteogenic differentiation was induced by culturing confluent MSC cultures in a-MEM supplemented 
with 1% p/s, 15% heat-inactivated FBS, 5mM b-glycerophosphate (Sigma-Aldrich, Munich, 
Germany), 50µg/ml L-ascorbic acid-phosphate (Sigma-Aldrich), and 10nM dexamethasone (Sigma-
Aldrich) for 21 days. Cells were then washed with PBS and fixed in cold 4% paraformaldehyde for 
5 min at room temperature. After two washes with H
2
O, cells were incubated in 1% silver nitrate in 
H
2
O at room temperature on a light box until blackening occurred. The cells were then washed three 
times with H
2
O, incubated in 2.5% sodium thiosulfate in H
2
O for 5 min at room temperature, washed 
twice with H
2
O and photographed.
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Adipogenic differentiation was induced by culturing confluent ASC cultures in a-MEM supplemented 
with 1% p/s, 15% heat-inactivated FBS, 50µg/ml L-ascorbic acid-phosphate (Sigma-Aldrich), 500µM 
3-isobutyl-1-methylxanthine (IBMX, Fluka, Buchs, Switzerland), 60µM indomethacin (Fluka) and 
10nM dexamethasone (Sigma-Aldrich) for 21 days. Cells were then fixed in 60% isopropanol for 
1 min, and incubated in filtered 0.3% oil red O (Sigma-Aldrich) solution in 60% isopropanol for 10 
minutes to stain lipid droplets. After several washes with PBS the cells were photographed.
Inhibition of mixed lymphocyte reactions by MSC
The immunosuppressive capacity of MSC was tested in mixed lymphocyte reactions (MLR). 5x104 
responder PBMC were stimulated by 5x104 γ-irradiated (40Gy) allogeneic PBMC in RPMI+10% HI-
FBS in round-bottom 96-well plates (Nunc, Roskilde, Denmark). MSC were added at various ratios 
to responder cells. On day 7, proliferation was measured by incorporation of 3H-thymidine (0.5mCi/
well) during a 16-hour incubation using a b-plate reader. 
Isolation of peripheral blood mononuclear cells (PBMC)
Peripheral blood samples were collected from living kidney donors and the corresponding 
kidney transplant recipients. Heparinized blood of kidney transplant recipients was drawn before 
transplantation, and 3, 6 and 12 months after kidney transplantation. PBMC were isolated by density 
gradient centrifugation using Ficoll Isopaque (d=1.077, Amersham, Uppsala, Sweden) and frozen at 
–150oC until use.
Living kidney transplant recipient and donor pairs
To investigate the cytotoxicity-mediated lysis of MSC in a clinical kidney transplantation setting, 
non-HLA-identical living kidney donor-recipient pairs were included. Recipient PBMC isolated 
before transplantation and 3, 6, 12, 16, 18 and 24 months after transplantation were used as effector 
cells, while PBMC and MSC of the corresponding donor were used as targets in the cell-mediated 
lysis assays. Immunosuppressive therapy of kidney transplant recipients consisted of tacrolimus, 
mycophenolate mofetil and low-dose steroids.
Cytotoxicity-mediated lysis by europium release assay
Cytotoxicity-mediated lysis of target cells was determined by europium release assays as described 
previously 34-35. In brief, for effector cells PBMC derived from recipients and healthy kidney donors 
were stimulated with allogeneic γ-irradiated PBMC and 200 IU/mL IL-2 (proleukin; Chiron BV, 
Amsterdam, The Netherlands) in round-bottom 96-well plates for 7 days at 37°C. PHA blasts and MSC 
were used as target cells. To obtain PHA blasts, PBMC were stimulated with 200 IU/mL recombinant 
IL-2 and 2 mg/mL PHA in 24-wells plates (Greiner Bio-one, Alphen a/d Rijn, The Netherlands) for 
7 days at 37°C. At day 3 and 6, cell cultures were split in two and refreshed with culture medium 
containing 200 IU/mL recombinant IL-2. After seven days, target cells were washed and living 
cells counted using an automatic cell counter system Casy (Schärfe System, Reutlingen, Germany). 
In addition, 100,000 target cells were used for flow cytometric analysis of HLA class I-ABC. The 
remaining target cells were labeled with europium-diethylenetriaminepentaacetate (DTPA) (Sigma, 
St. Louis, MO, USA). Autologous PHA blasts were used as negative control; allogeneic PHA blasts 
were used as positive control. MSC were cultured under control conditions or with 50 ng/ml IFN-γ 
for seven days. 
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At day 7, cytotoxicity-mediated lysis-assays were performed by incubating 5x103 63Eu-labeled targets 
with various numbers of effector cells in 96-well plates for four hours. Effector:Target (ET) ratios 
ranged from 40:1 to 1.25:1. After incubation, the plates were centrifuged and 20 µL of the supernatant 
was transferred to 96-well plates with low background fluorescence (Fluoroimmunoplate, Nunc, 
Roskilde, Denmark). Subsequently, 100 µL enhancement solution (PerkinElmer, Groningen, The 
Netherlands) was added to each well. Released europium was measured in a time-resolved fluorometer 
(Victor 1420 Multilabel Counter, LKB-Wallac, Turku, Finland). Fluorescence was expressed in 
counts per second (cps). 
Maximum release of europium by target cells was measured by incubation of 5x103 labeled target cells 
with 1% triton (Sigma-Aldrich, Zwijndrecht, The Netherlands) for four hours. Spontaneous release 
of europium by target cells was measured by incubation of labeled target cells without effector cells. 
Percentage leakage was then calculated as (spontaneous release / maximum release)*100%. Mean 
percentage of leakage was 29±9% for PHA blasts, 25±6% for MSC and 26±7% for IFN-γ pretreated 
MSC. Finally, the percentage of cytotoxicity-mediated lysis was calculated as: % lysis = [(measured 
lysis-spontaneous release)/ (maximum release- spontaneous release)]*100%. 
Isolation of Cd8+ T-cells and Cd16+56+ nK-cells by FACS
PBMC cultured with allogeneic γ-irradiated PBMC and 200 IU/mL IL-2 for 7 days were washed 
twice with PBS with 1% heat-inactivated FBS and stained with antibodies against CD3-PE, CD4-
FITC, CD8-PE-Cy7, CD56-APC, CD19-Amcyan, 7AAD-viaprobe (all BD Biosciences) and CD16-
APC (Serotec) at room temperature and protected from light for 30 minutes. Subsequently, cells were 
sorted using a FACS ARIA-II with FACSDIVA Software (BD Biosciences). The lymphocytes were 
gated for CD3. The CD3+ cells were then gated for CD8 to obtain CD8+ T-cells. The CD3- cells were 
gated for CD16/56 to obtain NK-cells. Purity of sorted CD8+ T-cells and CD16+56+ NK-cells was 
³98%. PBMC of healthy kidney donors used as effector cells consisted of 23±10% (mean±SD) CD8+ 
T-cells and 22±11% NK-cells. Effector cells derived from PBMC of kidney recipients (12 months after 
transplantation) contained 22±9% CD8+ T-cells and 16±8% NK-cells.
Statistical analysis
Data was analyzed using two-way ANOVA for repeated measures with Bonferroni post-tests. 
Distribution of the data was tested with Kolmogorov-Smirnov test for normality. Parametric data 
are expressed as mean±SD, while non-parametric data are expressed as median (25th-75th percentile, 
interquartile range). Statistical significance was defined as p<0.05 (two-tailed).
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Characterization of MSC
The cells isolated from perirenal adipose tissue showed an immunophenotype typical for MSC with 
positive expression of CD90, CD105, CD166, HLA class I-ABC, and very low expression of CD86 
and HLA class II-DR (Figure 1A), as described earlier 33. They were adherent with a spindle-shaped 
morphology (Figure 1B) and showed the capacity to differentiate into the osteogenic lineage, as 
demonstrated by von Kossa staining for calcified nodules (Figure 1C) and the adipogenic lineage, as 
demonstrated by Oil red O staining for lipid vesicles (Figure 1D). Typically for MSC, they showed the 
capacity to dose-dependently inhibit the proliferation of alloactivated PBMC (Figure 1E). 
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Figure 1. Characterization of adipose tissue-derived MSC. 
[A] Immunophenotype of MSC determined by flow cytometry. 
Grey histograms depict unstained MSC, open histograms 
depict MSC stained for the indicated marker. [B] Bright-field 
image of cultured MSC (magnitude 100x). [C] Von Kossa 
staining of osteogenic differentiated MSC. Black staining 
indicates calcified nodules. [D] Oil red O staining of adipogenic 
differentiated MSC. Red staining indicates lipid-filled vesicles. 
[E] Effect of MSC on alloactivated PBMC proliferation. MSC 
show dose-dependent inhibitory effect on PBMC proliferation.
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Allogeneic MSC are susceptible for cytotoxicity-mediated lysis by Cd8+ T-cells and nK-cells
To investigate the susceptibility of MSC for lysis by cytotoxic immune cells, lysis of MSC was 
compared to lysis of PHA blasts. Over 95% of MSC and PHA blasts generated from PBMC of healthy 
kidney donors expressed HLA class I-ABC. Cytotoxic effector cells were generated from PBMC of 
healthy kidney donors by culture in the presence of γ-irradiated allogeneic PBMC and 200 IU/ml IL2 
for one week. Effector cells lysed allogeneic PHA blasts in a dose-dependent manner (Figure 2A). 
Allogeneic MSC were lysed in a comparable fashion. To investigate whether lysis of allogeneic PHA 
blasts and MSC was mediated by CD8+ T-cells or NK-cells, effector cells were sorted in CD3+/CD8+ 
T-cells and CD3-/CD16+56+ NK-cells. PHA blasts were lysed by CD8+ T-cells, but not by NK-cells 
(Figure 2B). MSC, in contrast, were lysed by both CD8+ T-cells and NK-cells (Figure 2B). Lysis of 
MSC by allogeneic NK-cells was most efficient (58% of MSC at an ET ratio of 1:40 vs 41% of MSC 
by allogeneic CD8+ T-cells at the same ET ratio).
IFn-g enhances Cd8+ T-cell-mediated lysis, but reduces nK cell-mediated lysis of allogeneic 
MSC
To investigate whether the susceptibility of MSC for cytotoxicity-mediated lysis was affected by 
inflammatory conditions, MSC were cultured for 7 days with IFN-γ. Culturing of MSC with IFN-γ 
increased the mean fluorescence intensity (MFI) of HLA-ABC 4.7-fold (Figure 3A). The susceptibility 
of allogeneic MSC for NK cell-mediated lysis was decreased by IFN-γ treatment (Figure 3B), while 
lysis of MSC by CD8+ T-cells was increased (Figure 3C).
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Figure 2. Cytotoxicity-mediated lysis of PHA 
blasts and MSC. [A] Cytotoxicity-mediated 
lysis of PHA blasts (▲) (n=15) and MSC (●)
(n=5) by allogeneic effector cells of healthy 
kidney donors. MSC are lysed by allogeneic 
PBMC with comparable or even greater 
efficacy than PHA blasts. [B] Cytotoxicity-
mediated lysis of MSC by purified allogeneic 
CD8+ T-cells (●) and NK-cells (■) of healthy 
kidney donors (n=4) and lysis of PHA blasts by 
purified allogeneic CD8+ T-cells (▼) and NK-
cells (▲) of healthy kidney donors (n=3). Purity 
of CD8+ T-cell and CD16+56+ NK cell fractions 
was ≥98%. ET-ratio = effector: target ratio.
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Figure 3. Effect of IFN-γ on cytotoxicity-mediated lysis of MSC. [A] Flow cytometric detection of HLA class 
I-ABC expression on MSC after seven days of culturing under control conditions or with IFN-γ (50 ng/ml). 
Representative example shown of n=16. [B] Cytotoxicity-mediated lysis of allogeneic MSC cultured under 
control conditions (□) or with IFN-γ (■) by purified NK-cells of healthy kidney donors (n=4). [C] Cytotoxicity-
mediated lysis of allogeneic MSC cultured under control conditions (○) or with IFN-γ (●) by purified CD8+ T-cells 
of healthy kidney donors (n=4). ET-ratio = effector: target ratio.
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Autologous MSC are susceptible for cytotoxicity-mediated lysis by nK-cells
After demonstrating that MSC were effectively lysed by allogeneic CD8+ T-cells and NK-cells, we 
questioned whether MSC were susceptible for lysis by autologous cytotoxic cells. Cytotoxic effector 
cells were not capable of lysing autologous PHA blasts at any ET-ratio, but lysed 27±20% of autologous 
MSC at an ET-ratio of 40:1 (Figure 4A). FACS purification of CD8+ T-cells and NK-cells showed that 
lysis of autologous MSC was the result of NK cell cytotoxic activity (Figure 4B). 
To exclude the possibility that the observed lysis of autologous MSC was the result of recognition of 
bovine proteins by NK-cells due to culture of MSC in foetal bovine serum (FBS), MSC were isolated 
from adipose tissue and cultures established and maintained in either medium containing 15% FBS or 
15% human serum (HuS). Autologous effector cells lysed MSC cultured in FBS as efficiently as MSC 
cultured in HuS (52±25 vs. 49±20 %lysis at an ET-ratio of 40:1) (Figure 4C). These results indicate 
that culturing of MSC in FBS is not the cause of their susceptibility to cytotoxicity-mediated lysis. 
To examine the role of HLA class I on NK cell lysis of autologous MSC, HLA expression was 
increased by treatment of MSC with IFN-γ for seven days or decreased by culturing MSC with siRNA 
for HLA class I for three days. Culturing MSC with siRNA for HLA class I strongly reduced HLA 
class I-ABC expression on MSC and only 13% of MSC showed positive expression, while the MFI 
reduced 2.8-fold (Figure 4D). 
In agreement with the findings with allogeneic MSC, the lysis of autologous MSC by NK-cells was 
decreased after IFN-γ treatment of MSC to 50±2% (ET ratio of 40:1) (Figure 4E). MSC cultured with 
siRNA for HLA class I showed significantly increased susceptibility of MSC for autologous NK cell-
mediated lysis (Figure 4F).
The fate of MSC after infusion is currently unclear. One possibility is that MSC home to sites of 
injury where they adhere to local stroma or epithelial cell layers. To determine whether adherent MSC 
would remain susceptible for lysis by autologous NK-cells, MSC were seeded in 6-well plates and 
purified NK-cells added. Autologous NK-cells showed potent capacity to lyse adherent MSC (92% 
lysis at an ET ration) (Figure 4G). IFN-γ treatment strongly reduced the susceptibility of adherent 
MSC for lysis by autologous NK-cells to 52% lysis. 
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Figure 4. Cytotoxicity-mediated lysis of autologous MSC. [A] Cytotoxicity-mediated lysis of autologous MSC (▲) 
(n=12), allogeneic MSC (∆) (n=5) and of autologous PHA blasts (●) (n=15) by effector cells of healthy kidney donors. 
[B] Cytotoxicity-mediated lysis of autologous MSC by purified CD8+ T-cells (■) or NK-cells (●) by effector cells 
of healthy kidney donors (n=3). [C] Cytotoxicity-mediated lysis of autologous MSC isolated and cultured in foetal 
bovine serum (FBS)(∆) or in human serum (HuS)(●) by effector cells of healthy kidney donors (n=4). [D] Flow 
cytometric detection of HLA class I-ABC expression on MSC cultured under control conditions, MSC cultured 
with siRNA for HLA class I-ABC for 3 days, or MSC cultured with IFN-γ (50 ng/ml) for seven days. Representative 
example shown of n=3. [E] Cytotoxicity-mediated lysis of IFN-γ–treated MSC by purified autologous NK-cells 
(∆) or CD8+ T-cells (∇) of healthy kidney donors and of control MSC by autologous purified NK-cells (○) or CD8+ 
T-cells (□) (n=3). [F] Cytotoxicity-mediated lysis of control MSC (○) and of MSC treated with siRNA for HLA class 
I (∇) by purified autologous NK-cells of healthy kidney donors (n=2). [G] Cytotoxicity-mediated lysis of adherent 
autologous MSC (○, n=4) or IFN-γ–pretreated MSC (□, n=3) by NK-cells of healthy kidney donors. ET-ratio = 
effector: target ratio.
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Kidney donor-derived MSC are lysed by recipient cytotoxic immune cells 
The immunogenicity and survival of MSC is an important issue for their application in organ 
transplantation. As we found that MSC are susceptible for CD8+ T-cell and NK cell-mediated lysis, 
we wanted to examine this in a kidney transplant setting using donor MSC and kidney recipient 
immune cells isolated at various time points after kidney transplantation. Cytotoxic effector cells of 
recipients isolated before transplantation showed poor capacity to lyse donor MSC (5±5% lysis at an 
ET ratio of 40:1). Recipient cytotoxic cells isolated 3, 6 and 12 months after transplantation showed 
increasing capacity to lyse MSC in time after transplantation (Figure 5A). Lysis of donor MSC 12 
month after transplantation was for 33 (9-57)% dependent on CD8+ T-cell-mediated lysis while the 
CD8+ T-cell depleted cell fraction was responsible for 55 (46-68)% of MSC lysis (Figure 5B). This 
indicates that the recovered lysis of donor MSC after transplantation is for a major part dependent on 
NK cell cytotoxicity.
Finally, we examined whether there was evidence for the development of hypo- or hyper-responsiveness 
(sensitization) of kidney transplant recipients against donor MSC after transplantation by looking at 
the capacity of recipient CD8+ T-cells to lyse donor MSC. As we found that non-CD8+ T-cell-mediated 
lysis of donor MSC was recovered 12 months after transplantation, we examined whether the balance 
between CD8+ T-cell-mediated and non-CD8+ T-cell-mediated lysis of donor MSC was shifted more 
than 12 months after transplantation compared to non-transplant healthy kidney donors. CD8+ T-cell-
mediated lysis of donor MSC remained well below the lysis of donor MSC by CD8+ T-cell depleted 
cells in 3 recipients that were 16, 18 and 24 months after transplantation (Figure 5C). These results 
suggest that there is no evidence for hypo- or hyper-responsiveness against donor MSC long after 
kidney transplantation.
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Figure 5. Cytotoxicity-mediated lysis of MSC in a kidney transplantation setting
[A] Cytotoxicity-mediated lysis of kidney donor-derived MSC by recipient immune cells collected before 
transplantation (●, n=5), and 3 months (■, n=5), 6 months (▲, n=8) and 12 months (♦, n=9) after transplantation. 
[B] Cytotoxicity-mediated lysis of kidney donor-derived MSC by purified CD8+ T-cells (○) and CD8+ T-cell-
depleted (□) recipient cells isolated 12 months after transplantation (n=6). [C] Cytotoxicity-mediated lysis of 
kidney donor-derived MSC by purified CD8+ T-cells (▲) and CD8+ T-cell-depleted (●) recipient cells isolated 16 
months (n=1), 18 months (n=1) and 24 months (n=1) after transplantation (n=6). ET-ratio = effector: target ratio. 
Tx = transplantation.
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dISCuSSIOn
In an increasing number of clinical trials the use of MSC for immune therapy is studied. Trials 
investigating the use of MSC in organ transplantation have recently initiated 11. Although the use of 
autologous MSC may be preferable to avoid recognition of MSC by the immune system, the use of 
“off-the-shelf” allogeneic MSC is more practical. The immunogenicity and survival of autologous and 
allogeneic MSC is, however, unknown and is important for the efficacy of clinical trials. In particular, 
it may have implications in an organ transplant setting where cross-reactivity between MSC and the 
organ transplant may induce allograft rejection. In the present study we investigated the susceptibility 
of autologous and allogeneic MSC cultured under control and inflammatory conditions for lysis by 
cytotoxic CD8+ T-cell and NK-cells. Subsequently, the susceptibility of donor-derived MSC for lysis 
by kidney transplant recipient cytotoxic cells isolated before and after kidney transplantation was 
examined.
Several studies reported that MSC can inhibit the formation of cytotoxic cells 17-18, 36. Data on the 
susceptibility of MSC for lysis by cytotoxic cells is, however, contradictory. It has been suggested 
that MSC are immune privileged and that they are not susceptible for lysis by cytotoxic immune cells 
18, 21. Others reported that MSC are susceptible for cytotoxicity-mediated lysis, especially by NK-cells 
37-38. In our hands, allogeneic adipose tissue-derived MSC were highly susceptible for cytotoxicity-
mediated lysis, at a rate comparable to allogeneic PHA blasts. Whereas allogeneic PHA blasts were 
lysed by CD8+ T-cells only, allogeneic MSC were lysed by CD8+ T-cells and NK-cells. This difference 
may lie in expression of activating NK cell receptor ligands on MSC and PHA blasts of which several 
are found on MSC 26, 37. Autologous MSC were not lysed by CD8+ T-cells, but were susceptible for 
lysis by NK-cells. Expression levels of HLA class I molecules modulated the susceptibility of MSC 
for NK cell lysis, as down-regulation of HLA class I increased lysis of MSC by NK-cells, whereas 
up-regulation of HLA class I by IFN-γ was associated with protection of MSC. We ruled out the 
possibility that lysis of MSC was the result of recognition of bovine antigens due to culture of MSC 
in FBS by establishing and maintaining MSC cultures in medium with human serum. Culturing in 
human serum had no effect on lysis of MSC.
The fate of MSC after intravenous infusion is not yet clear. One possibility is that MSC home to 
specific tissue sites or to sites of injury, and adhere to the stroma or epithelial cell layers at these sites. 
To find out whether homing would protect MSC from lysis by NK-cells, we added autologous NK-
cells to adherent MSC monolayers. Under these conditions, MSC remained susceptible for lysis by 
NK-cells, suggesting that homed MSC can still be cleared by NK-cells.
Our finding that both autologous and allogeneic MSC are susceptible for lysis by cytotoxic cells may 
explain why MSC seem to disappear shortly after infusion 4, 27, 39. Nevertheless, lysis of autologous 
MSC remains remarkable. We previously demonstrated that MSC of donor origin can be isolated from 
heart biopsies up to six years after heart transplantation in human 40. These heart transplant patients 
were obviously under immunosuppression, suggesting that the lysis of MSC may be preventable with 
immunosuppressive drugs.
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It has been reported previously that exposure of MSC to inflammatory conditions affects 
immunophenotype and enhances the immunosuppressive function of MSC 30, 41-42. This is particularly 
relevant when MSC are used as clinical immune therapy. Pro-inflammatory cytokines, such as IFN-γ, 
increase the expression of HLA class I and II subtypes on MSC. Pre-treatment of autologous and 
allogeneic MSC with IFN-γ made them less susceptible for NK mediated lysis, whereas it increased 
CD8+ T-cell-mediated lysis of allogeneic MSC as a result of elevated HLA class I expression. In line 
with the results obtained from healthy individuals, we found that kidney transplant recipient-derived 
cytotoxic CD8+ T-cells and NK-cells were capable of lysing donor-derived MSC. Recipient cytotoxic 
cells isolated with increasing time after transplantation were increasingly efficient in lysing MSC 
compared to recipient cells isolated before transplantation. The lack of lysis of MSC by recipient 
immune cells isolated prior to transplantation could reflect the poor renal function and general health 
of the patients, while the increasingly efficient lysis of MSC after transplantation may be the result 
of recovery of the renal function or improvement of the recipient’s immune system and tapering of 
immunosuppressive drugs after transplantation. We also found that CD8+ T-cell-mediated lysis of 
donor MSC more than a year after transplantation remained well below the lysing efficiency of NK-
cells, similar as found in healthy kidney donors, indicating that hyper-responsiveness against donor 
MSC may not occur.
In conclusion, our results suggest that controlling MSC lysis by cytotoxic immune cells may be 
important for successful MSC therapy in organ transplantation. Recent data shows that blocking of 
CD16 on NK-cells inhibits lysis of MSC 43. Other approaches to improve MSC survival may include 
in vitro modulation of MSC to reduce their immunogenicity. Pre-clinical models should be used to 
find out whether such approaches affect the balance between the efficacy and safety of MSC therapy.
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SuMMArY
End-stage renal disease (ESDR) is gradually but inevitably leading to dialysis. Kidney transplantation 
is the only effective treatment for patients with ESRD, but requires life-long use of immunosuppressive 
medication to prevent graft rejection. Although immunosuppressive drugs are effective in preventing 
graft loss, they can have severe side effects, such as allowing the occurrence of cardiovascular diseases, 
opportunistic infections, development of malignancies and nephrotoxicity 1-2. There is therefore 
an ongoing search for new approaches for immunosuppression. These include the development of 
cellular therapies. One of the candidate cell types are mesenchymal stem cells (MSC) (Chapter 1). 
This thesis investigates the immunomodulatory properties of mesenchymal stem cells for application 
in organ transplantation and in particular in kidney transplantation.
MSC and are virtually present in all adult tissues 3. They can be relatively easily isolated and expanded 
in vitro for clinical use and appear as spindle-shaped, adherent cells in culture (Figure 1). 
The classical source of MSC is bone marrow. Because the collection of bone marrow is invasive, 
painful and yields variable numbers of MSC, currently alternative sources of MSC are investigated. 
In Chapter 2 we demonstrated the isolation of MSC from human spleen, heart and perirenal adipose 
tissue and compared their phenotype and function with bone marrow-derived MSC. We found 
that MSC derived from the different tissues had comparable characteristics to bone marrow MSC. 
Especially adipose tissue may be a good alternative source for MSC, as it can be obtained under local 
anesthesia through a simple, little invasive surgical procedure and provides more consistent numbers 
of MSC than bone marrow.
MSC have two interesting properties that can be beneficial in solid organ transplantation. Firstly, MSC 
have the potential to differentiate into more specialized cell types, such as adipocytes or osteoblasts, 
but probably many others such as renal cells 4-6. Furthermore, MSC secrete a diversity of trophic 
factors that stimulate proliferation and differentiation of tissue resident progenitor cells 7. In solid 
organ transplantation MSC therapy may therefore repair ischemia-reperfusion injury of the graft and 
enhance graft function. 
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Figure 1. Mesenchymal stem cells in culture
Secondly, MSC have immunomodulatory properties. MSC demonstrate potent immunosuppressive 
capacity by inhibiting the proliferation and antibody production of mitogen and alloactivated T and 
B lymphocytes and by preventing the differentiation of antigen-presenting cells in vitro 8-10. These 
immunomodulatory effects are partly mediated via soluble mechanisms, such as via the depletion 
of tryptophan by indolamine-2,3-dioxygenase (IDO), and via the secretion of anti-inflammatory 
factors such as prostaglandin E2, TGF-β, IL-10, HLA-G, hepatocyte growth factor, and nitric oxide 
11-15. In addition, MSC establish cell contact interactions with immune cells that may enhance the 
immunomodulatory effects of MSC 16-17. In a kidney transplantation setting, we found that MSC 
significantly suppressed donor-stimulated proliferation of transplant recipient peripheral blood 
mononuclear cells (PBMC), especially of T-cells (chapter 3). Autologous, donor and third-party MSC 
had comparable efficacy to inhibit alloreactivity, suggesting that the inhibition of PBMC proliferation 
by MSC is HLA independent. MSC were furthermore able to effectively suppress donor-directed 
mixed lymphocyte reactions after kidney transplantation, which shows that MSC are capable of 
inhibiting memory responses. 
If MSC are used as cellular therapy in solid organ transplantation, it is likely that they will be given in 
conjunction with immunosuppressive medication. In chapter 4, the effect of the immunosuppressants 
tacrolimus, rapamycin and mycophenolic acid (MPA) on MSC immunophenotype and functionality 
was examined. Clinical concentrations of these immunosuppressive drugs did not induce toxicity 
or apoptosis in MSC. The differentiation capacity of MSC was, however, differentially affected by 
the different drugs. Unexpectedly, MSC hampered the immunosuppressive efficacy of tacrolimus 
and rapamycine. There was no adverse effect of MSC on the function of MPA. These data therefore 
suggest that MPA is the best immunosuppressant to combine with MSC therapy in transplant patients.
In contrast to most studies that investigate the immunomodulatory effects of MSC on activated 
immune cells, we examined in chapter 5 the effect of inflammatory conditions on MSC. MSC 
were exposed to two inflammatory conditions; alloactivated PBMC (MLR) separated from MSC in 
transwell culture systems or pro-inflammatory cytokines (IFN-γ, TNF-α and IL-6), and examined the 
immunophenotype and function of MSC. We found that the inflammatory conditions differentially 
affected the immunophenotype and proliferation capacity of MSC. While the regenerative properties 
of MSC were not affected, the immunosuppressive effects of MSC were strikingly boosted after 
exposure to inflammatory conditions. In particular the expression of IDO was stimulated by pre-
treatment of MSC with pro-inflammatory cytokines. Increased expression of IDO was correlated to 
enhanced immunosuppressive effects of MSC, while blocking of IDO reduced the immunosuppressive 
effect of MSC. Furthermore, gene expression analysis also showed that both inflammatory conditions 
increased the expression of genes for HLA class I and II and for a variety of chemokines in a 
differential manner. This suggests in the first place that MSC adapt a potentially more immunogenic 
phenotype under inflammatory conditions and secondly that the phenotype and function of MSC is 
differentially affected by different inflammatory conditions. Consecutively, these results indicate that 
in vitro modulation of MSC can be used to modulate MSC function before clinical application.
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Whereas the immunosuppressive effects of MSC on activated immune cells are intensively investigated, 
we demonstrated in chapter 6 that MSC stimulate the activation and proliferation of resting, non-
activated T-cells. MSC of autologous origin had the same effect as allogeneic MSC, indicating the 
activating effect of MSC is independent of HLA. Further experiments demonstrated that removal 
of MSC from co-cultures with resting PBMC resulted in a striking increase in the proliferation of 
T-cells. An increased proportion of these T-cells demonstrated a regulatory T-cell phenotype, i.e. 
CD4+CD25+FoxP3+CD127low, and had immunosuppressive capacity. These results indicate that by 
stimulation of the proliferation of resting T-cells MSC can generate functional regulatory T-cells.
Despite the promising properties of MSC demonstrated in in vitro studies, there are a number of 
issues concerning the survival of MSC after in vivo administration that need to be clarified before 
clinical application of MSC. Firstly, it is unclear whether MSC are recognized by cytotoxic CD8+ 
T-cells and risk the development of memory responses. Furthermore, it is unclear how the innate 
immune system tolerates infused culture expanded MSC. 
In chapter 7 the susceptibility of MSC for lysis by CD8+ T-cells and natural killer (NK) cells was 
examined. In contrast to several studies demonstrating that MSC are not immunogenic, we found that 
allogeneic MSC were efficiently lysed by both cytotoxic CD8+ T-cells and NK-cells. Surprisingly, 
autologous MSC were also susceptible for lysis by NK-cells. Pre-treatment of MSC with IFN-γ 
increased the expression of HLA class I on MSC and led to increased CD8+ T-cell-mediated lysis, 
but reduced NK-cell-mediated lysis. In a kidney transplantation setting, recipient’s cytotoxic immune 
cells were able to lyse donor-derived MSC with increased efficacy in time after transplantation, 
probably by recovering of the immune system after transplantation. These results are important 
should be taken into account for timing of MSC therapy.
In conclusion, the immunosuppressive and regenerative capacities of MSC make them attractive 
candidates for numerous clinical applications, including end-stage renal disease and kidney 
transplantation. MSC therapy has the potential to target various aspects of organ transplantation, 
from stretching the life-span of progressively deteriorating organs and delay transplantation, 
preservation of procured organs, reduction and repair of ischemia-reperfusion injury, to treatment of 
acute rejection and reduction of chronic allograft injury by sparing long-term anti-rejection drugs and 
eventually promoting tolerance. 
It is clear that more basic research is needed to understand how MSC can most effectively be applied 
in organ transplantation. Well-controlled clinical trials can greatly accelerate the process. Early 
safety trials should take the opportunity to look at mechanistic effects of MSC in clinical organ 
transplantation accompanied by proper biomarker evaluation. Several phase I trials testing the 
safety of MSC infusion before and after liver and kidney transplantation are currently in preparation 
and a small number have recently started. Very preliminary results indicate that MSC therapy in 
transplantation patients is feasible and safe. Hopefully, new data from the first trials will confirm this, 
while ongoing pre-clinical studies can further address the impact of MSC cell source, timing and in 
vitro modulation to identify the optimal efficacy of MSC therapy. The coming years will be critical 
for the implementation of the lessons learned from basic and clinical studies in MSC therapy in solid 
organ transplantation.
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dISCuSSIOn
In the present thesis the potential of MSC for application in solid organ transplantation as an alternative 
for current drug-based immunosuppressive regimens was investigated. The immunosuppressive 
properties of MSC may reduce immune reactivity, while at the same time their regenerative properties 
may improve graft function by repairing damage of the transplanted organ. For these perspectives 
several topics relevant for the use of MSC in kidney transplantation were investigated. We studied 
the tissue source for MSC, the immunosuppressive capacity of autologous and allogeneic MSC before 
and after kidney transplantation, the effect of concurrent immunosuppressive drugs or inflammatory 
conditions on the phenotype and function of these cells. Finally, we examined whether in vitro-
expanded MSC are susceptible for lysis by cytotoxic immune cells. The results of these studies 
are important to understand the biology and function of MSC, which may contribute to the clinical 
application of MSC in solid organ transplantation.
1. Mesenchymal stem cells
A recurrent topic in MSC research is the poor definition of MSC due to lack of a specific MSC marker. 
MSC consist of a heterogeneous pool of cells with comparable characteristics and their distinction 
from fibroblasts is difficult 1-2. Better characterization of MSC is recommended, which would facilitate 
the comparison of results between studies. Heterogeneity of MSC in culture, however, does not 
hamper the promising results obtained from in vitro, animal and human studies and is not necessarily 
disadvantageous for application of MSC in organ transplantation as cellular (immune) therapy. There 
is, however, a possibility that various subsets within the MSC pool possess different functions, which 
may be more or less suitable for use of MSC as immune modulators.
It has been reported that MSC can be isolated from virtually all adult tissues 3. The question remains 
what the physiological role of MSC in these tissues is. It can be speculated that tissue-resident 
MSC contribute to tissue regeneration and (immunological) homeostasis via secretion of various 
immunomodulatory and trophic factors. These functions may in fact be shared by all stromal cells, 
including fibroblasts 1, 4.
2. Tissue source of MSC 
Traditionally, MSC are isolated from bone marrow. Currently, this source is used for most clinical 
applications. Although bone marrow is a reliable source of MSC, bone marrow procurement 
procedures are painful and invasive, and may yield relatively low and variable numbers of MSC upon 
processing 5. Several other sources for MSC are investigated, such as umbilical cord blood, placenta 
or adipose tissue 6-7. Subcutaneous adipose tissue is a suitable source of MSC that can be obtained 
under local anaesthesia through a simple, less invasive surgical procedure that provides repeatable 
access to large quantities of tissue. As we demonstrated in Chapter 2, adipose tissue-derived MSC 
have comparable phenotype, multilineage differentiation capacity and immunosuppressive properties 
compared to MSC derived from bone marrow 8-9. Therefore, several clinical studies using adipose 
tissue as source for MSC are currently in the planning phase. In our opinion, adipose tissue seems to 
be an ideal substitute for bone marrow for the isolation of MSC. Although the functional properties 
of the MSC derived from these different sources appear to be similar, it is important to consider that 
MSC derived from various tissues are not identical and may differ in (tissue-specific) gene expression 
that may have subtle effects on their function 5, 10.
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3. Immunosuppressive effects of MSC; potential in kidney transplantation?
One of the main properties of MSC is their immunosuppressive capacity. Several studies reported that 
MSC inhibit the proliferation and function of activated immune cells. In Chapter 3 we demonstrated 
that MSC can also potently inhibit anti-donor reactivity in a kidney transplantation setting in vitro. In 
addition, MSC were able to inhibit anti-donor responses after transplantation, suggesting that donor-
directed memory responses can be inhibited. The immunosuppressive effects were independent of 
the HLA background of the MSC, as autologous and allogeneic MSC showed comparable efficacy to 
inhibit alloreactivity. The immunosuppressive effects were mediated via soluble immunosuppressive 
factors, such as transforming growth factor-b1 (TGF-β1), hepatocyte growth factor (HGF), 
prostaglandin E2 (PGE2), IL-10, HLA-G and nitric oxide 11-12. Blocking each of these factors alone 
does not completely restore the proliferation of activated immune cells, indicating that multiple 
factors are involved. Also the expression of IDO is an important mechanism of MSC to inhibit T-cell 
proliferation. Thus, based on the immunosuppressive effect of MSC in vitro, there is no preference 
in the use of recipient (autologous), donor or third-party MSC for immune modulation. Nevertheless, 
HLA-background of MSC may be important for other issues, for example for the immunogenicity of 
MSC and for induction of memory responses as we demonstrated (Chapter 7). 
4. Effect of immunosuppressive drugs on MSC
When immune therapy with MSC is used in solid organ transplantation, the immunosuppressive drugs 
used by the recipients may affect the function of MSC. In Chapter 4 we therefore investigated the 
effect of tacrolimus, mycophenolic acid (MPA) and rapamycin on MSC 13. While the molecular targets 
of these drugs are expressed in MSC, their effect on MSC and in particular their immunosuppressive 
capacity is largely unknown. We found that clinical doses of these drugs induced no toxicity in MSC, 
but that the proliferation of MSC was inhibited by MPA and rapamycin. Strikingly, MSC in combination 
with MPA showed enhanced immunosuppressive capacity. The synergistic effect between MSC and 
low doses of MPA found in vitro was confirmed by others and it has been shown in a rat model that the 
combination of MSC and MPA could induce long term acceptance of heart allografts 14-15. In contrast, 
we found that tacrolimus and rapamycin antagonized the immunosuppressive effects of MSC, because 
these drugs inhibit the activation of immune cells and thereby remove the pro-inflammatory trigger 
for MSC activation needed to exert their immunosuppressive function.  These findings were later 
confirmed by another group 14. In addition, Buron et al. found that the glucocorticoid dexamethasone 
did not modify the inhibitory effects of MSC. The interaction between MSC and cyclosporine A is 
less clear. Some in vitro and animal studies showed that a combination of MSC and cyclosporine 
A was more immunosuppressive 16-17, while others found no, or even adverse, effects of combining 
cyclosporine A and MSC 18-19. Based on these data, it can be hypothesized that addition of MSC 
to the immunosuppressive drug regimen consisting of MPA and steroids, allows dose reduction 
without affecting the efficacy of the therapy and seems preferential for application in clinical organ 
transplantation.
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5. In vitro pre-treatment of MSC to modulate MSC functions
MSC are responsive to their environment and adapt their function to local circumstances 20. Therefore, 
pre-treatment of MSC in vitro, i.e. modification of culture medium by specific factors, offers the 
possibility to modulate the properties of MSC. Evidence from experimental studies convincingly 
demonstrated that pre-treatment of MSC with IFN-γ strongly enhances their immunosuppressive 
effect, which allows more efficient immune therapy with MSC 20-22. Furthermore, IFN-γ pre-treatment 
of MSC reduces their susceptibility for lysis by NK-cells, as we showed in chapter 5. Pre-treatment 
may therefore prolong the presence of administered MSC, which may result in increased efficacy of 
MSC treatment.
Besides modulation of their immunosuppressive effects, the differentiation capacity of MSC can 
be modulated in vitro 23-24. This may be beneficial for applications that require that MSC are (pre)
differentiated in more specific cell types. Interestingly, MSC in vitro differentiated into adipogenic, 
osteogenic or chondrogenic lineages might preserve their immunosuppressive capacity 25-26. This 
suggests that MSC contribute to tissue regeneration and at the same time control immune reactivity. 
Modulation of the properties of MSC offers the opportunity to adapt the function of MSC for 
use in specific clinical applications. In organ transplantation both enhanced regenerative and 
immunosuppressive function may be beneficial, as fewer cells may be required and potential side 
effects may be reduced by guiding the function of the MSC. Pre-activation or pre-differentiation of 
MSC therefore adds a new aspect to MSC therapy.
Another advantage of ex vivo expansion of MSC is that MSC-derived culture medium can be obtained, 
because MSC-conditioned medium could have therapeutic value 27-28. However, it is unlikely that 
conditioned medium can fully replace the effects of MSC, because MSC establish cell-membrane 
interactions with for example activated immune cells resulting in more effective inhibition of the 
proliferation or function of these cells 29. The potential of MSC-derived products is still under 
investigation.
6. MSC exert dual immunomodulatory functions
We and others clearly showed that MSC have potent immunosuppressive effects on activated immune 
cells. Alternatively, we demonstrated in Chapter 6 that MSC can also stimulate and control the 
activation and proliferation of resting T-cells, thereby generating cells with immunosuppressive 
capacity. Thus besides the direct immunosuppressive effects of MSC on activated T-cells themselves, 
they also indirectly affect activated T-cells via regulatory T-cells (T-regs). Furthermore, it has been 
reported that MSC have a supportive function and can prevent lymphocytes from apoptosis 30. Based 
on the current data, it can therefore be hypothesized that the balance between the regenerative 
and immunosuppressive functions of MSC in vivo strongly depends on the local conditions 20, 31-32. 
Under inflammatory conditions, MSC employ immunosuppressive mechanisms in addition to the 
production of trophic factors that may be important for tissue repair 33. On the other hand, under 
non-inflammatory conditions MSC are supportive to immune cells and support their differentiation. 
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7. Immunogenicity of MSC
7.1 Susceptibility of MSC for lysis by cytotoxic immune cells
Some studies claim that MSC are immune privileged due to their low immunophenotype, i.e. low 
or absent expression of HLA molecules and co-stimulatory molecules. MSC would therefore not 
provoke proliferation of allogeneic lymphocytes 25, 34, and escape lysis by cytotoxic immune cells 35-36. 
Theoretically, the low immunogenicity of MSC would reduce the clearance of allogeneic MSC by the 
immune system after infusion, suggesting that transplantation of MSC across MHC HLA barriers 
may be possible. In contrast to many studies, we demonstrated in chapter 7 that allogeneic MSC 
are susceptible for lysis by CD8+ T-cells. Lysis of allogeneic MSC by CD8+ T-cells was even further 
increased after up-regulation of HLA class I expression by IFN-γ pre-treatment of MSC. Moreover, 
allogeneic MSC were susceptible for CD16+56+ NK cell-mediated lysis. As expected, autologous 
MSC were  not susceptible for lysis by CD8+ T-cells, but, to our surprise, they were susceptible for 
lysis by NK-cells. We furthermore demonstrated that IFN-γ enhanced HLA class I expression on 
MSC resulted in reduced lysis of MSC by NK-cells, whereas the NK cell-mediated lysis increased 
after reducing the expression of HLA class I on MSC by small interfering RNA (siRNA). Therefore, 
lysis of MSC is at least partly dependent on the expression of HLA class I on MSC. In particular the 
non-classical molecules HLA-E and HLA-G have been suggested to be involved 37-39. Our finding that 
autologous MSC are lysed by cytotoxic immune cells is difficult to interpret in view of MSC biology 
in vivo. A possibility might be that NK-cell mediated lysis prevent uncontrolled proliferation of MSC, 
for example leading to the formation of sarcomas 40. Alternatively, it can be speculated that MSC 
cultured ex vivo have a different phenotype compared to tissue resident MSC, which make them more 
susceptible for lysis by NK-cells. 
Furthermore, MSC in suspension as used in the clinic for intravenous administration could have 
changed characteristics compared to MSC present in tissue and those MSC could be recognized 
as foreign and subsequently killed. Lysis of autologous MSC suggests that HLA matching is not 
sufficient to avoid clearance of administered MSC and that control of NK cell lysis may be important 
for optimisation of MSC therapy.
The susceptibility of MSC for CD8+ T-cell and NK cell-mediated lysis were confirmed in a kidney 
transplantation setting. Recipient CD8+ cytotoxic T-cells and NK-cells efficiently lysed donor-derived 
MSC. The capacity to lyse donor-derived MSC increased in time after transplantation: pretransplant 
immune cells did not lyse donor MSC, while immune cells isolated 3, 6 and 12 months after 
transplantation showed increasing ability to lyse MSC. After 12 months, the lysing ability of recipient 
cytotoxic cells was fully recovered. While this could be explained by recovery of the recipients’ 
immune system and tapering of the immunosuppressive drugs during the first year, it may also result 
from sensitization against donor-antigens. However, both the NK cell and CD8+ T cell-mediated 
lysis of donor MSC increased after transplantation, maintaining the balance between NK cell and 
CD8+ T cell-mediated lysis of MSC. This suggests that  there was no CD8+ T-cell sensitization or 
desensitisation against donor MSC. 
Our cytotoxicity data indicate that infused MSC, both of autologous and allogeneic origin, are 
recognized and subsequently cleared by the recipient’s immune system, and thereby reject the claim 
that MSC are immune privileged. Moreover, clearance of MSC by cytotoxic cells may explain the 
observations in animal models, in which infused cells can not be traced within a few days after 
infusion 15, 41. 
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The question is whether clearance of MSC is beneficial or disadvantageous for MSC therapy. 
Clearance of MSC may be beneficial when only a temporary therapeutic effect is desired and it would 
omit the risk for tumour formation on the long-term, while rapid clearance of MSC shortens the time 
of MSC effects, leading to reduced efficacy.
7.2 Choice between autologous or allogeneic MSC
One of the major questions concerning the clinical application of MSC is whether MSC of autologous 
or allogeneic origin should be used. This is especially important for their application in organ 
transplantation. In an organ-transplantation setting, there is theoretically a choice of MSC from three 
origins; MSC can be derived from the recipient, from the donor, or from a third-party. In planned 
living-organ transplantation, there is an opportunity to isolate and expand MSC of recipient or donor 
origin; in contrast, the transplantation of organs from deceased donors would limit the options to 
recipient and “of-the-shelf” third-party MSC.
Although it has been suggested that allogeneic MSC are better immunosuppressors 16, we, like 
others, found that autologous and allogeneic MSC have a comparable immunosuppressive capacity 
in vitro 42-44. Furthermore, in clinical studies in which patients with GVHD are treated with MSC, 
no differences in the effects of autologous, haploidentical and third-party MSC have been observed. 
This indicates that, based on the immunosuppressive effect of MSC, there is no preference in the 
use of recipient (autologous), donor or third-party MSC for treatment of transplant patients. The 
HLA background of MSC may, however, be important for the immunogenicity of MSC and for the 
induction of memory responses. It has, indeed, been demonstrated in murine models that pretransplant 
infusion of allogeneic MSC can induce memory T-cell responses 45. Priming with donor MSC may 
thus potentially sensitize the recipient to donor antigens, and thereby accelerate graft rejection 45-46. 
To avoid cross-reactivity between administered MSC and the graft, MSC derived from the recipient 
or MSC that are mismatched with donor HLA could be used in clinical studies.
Nevertheless, recognition of donor MSC by the host immune system does not necessarily lead to 
sensitization. It is also possible that recognition of donor MSC prior to transplantation desensitizes 
the recipient to donor antigens. Such a mechanism would resemble the effect seen in the past with 
the use of pretransplant donor blood transfusions, which in some cases led to donor-specific hypo-
responsiveness 47. If MSC have the capability of inducing donor hypo-responsiveness, this is likely 
to rely on a balanced dosing and timing of MSC administration. The clinical consequence of the 
application of MSC with a different HLA background needs further investigation.
In summary, MSC have regenerative and immunosuppressive properties that could be beneficial for 
improving the outcome of solid organ transplantation, in particular kidney transplantation. Several 
aspects of these cells, however, need further investigation in order to develop effective MSC therapy 
for improvement of current standard therapy.
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InTrOduCTIOn
The present thesis investigated the immunomodulatory properties of MSC to explore their potential 
as immune therapy in solid organ transplantation as an alternative for the current drug-based 
immunosuppressive regimens. The immunosuppressive properties of MSC may reduce immune 
reactivity, but at the same time their regenerative properties may improve graft function by repairing 
damage of the transplanted organ. Although the effects of MSC obtained from in vitro and animal 
studies seem promising, their applicability in clinical organ transplantation is still unknown. 
Furthermore, several issues need to be addressed if MSC therapy in solid organ transplantation is 
considered, such as dosing, timing and route of administration. It is crucial to investigate the role of 
the HLA-background of the MSC source to find out whether autologous (recipient), donor-derived or 
third-party MSC should be preferred as cellular therapy for immunomodulatory purposes in solid 
organ transplantation. Based on the results of the present thesis and current literature, these and other 
issues relevant for the application of MSC as therapy in clinical organ transplantation are discussed 
below.
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POTEnTIAL PITFALLS And FuTurE dIrECTIOnS
1. dosing of MSC
An important issue in the clinical application of MSC involves establishing the dosing that will 
achieve the best results, but does not induce toxicity. In vitro studies show immunosuppressive effects 
at (MSC:PBMC)-ratios of (1:10) or higher in vitro 1, while these high concentrations of MSC can not 
be achieved in vivo. Furthermore, animal studies demonstrated that the majority of MSC disappear 
within days after infusion. This could be the result of distribution to other organs, of increased 
clearance of MSC by immune cells or due to cell loss caused by mechanical stress after infusion 
of MSC. In a human setting, there is some experience with dosing of MSC in the treatment of bone 
marrow transplant patients with severe GVHD. A multicenter trial showed that doses of 0.5x106 to 
9x106 cells per kg body weight did not lead to adverse side effects 2-3. In this study, doses from 0.8x106 
were found to be effective to reduce GVHD, but no clear dose-dependent effect was obtained. In 
breast cancer patients that underwent myeloablation, infusion of 1x106 and 2.2x106 MSC per kg body 
weight showed no toxic effects 4. Trials in Crohn’s disease patients are currently testing doses of 
2x106 and 8x106 bone marrow MSC per kg body weight, or amounts of 600x106 and 1200x106 MSC 
per patient (clinicaltrials.gov). In solid organ transplantation the safety and optimal dose of MSC is 
unknown. 
If local administration of MSC is considered in organ transplantation, it is unclear whether the 
number of MSC should be calculated per kg body weight or whether the number of MSC per target 
organ should be calculated. As MSC migrate poorly in tissue, repeated multi-focal injections with 
MSC may be required to obtain an effective dose of MSC in the graft. 
In view of dosing it is also crucial to consider the susceptibility of MSC for lysis by cytotoxic immune 
cells, especially NK-cells as demonstrated in Chapter 7. While most studies do not investigate this 
effect or neglect it, cytotoxicity-mediated lysis of administrated MSC can dramatically reduce the 
number of MSC and thus the efficiency of the therapy. We found that even autologous MSC were 
killed by NK-cells, therefore in an autologous transplant setting this phenomenon should be taken 
into account. In addition, it was demonstrated that pre-treatment of MSC with IFN-γ resulted in 
reduced susceptibility for lysis by NK-cells, which (party) depended on the expression of HLA class 
I molecules. It can therefore be speculated that in vitro pre-treatment of MSC may therefore reduce, 
yet not avoid, the clearance of the cells after administration. Currently animal studies are being 
performed to investigate the effect of  IFN-γ treatment of MSC and immunogenicity in vivo.
2. Timing of MSC administration
Another important issue that needs to be considered in planning a clinical study in solid organ 
transplantation is the moment of infusion. Choices in time (before or after transplantation) or disease 
phase (acute versus chronic rejection) should be made. Timing of administration of cells depends on 
the aim of the cellular therapy. If the aim of MSC therapy is tolerance induction, donor-MSC should 
be administered before transplantation. By this, donor-derived MSC may induce long-term allograft 
acceptance, as shown previously in murine heart transplantation models and a rat hind-limb allograft 
model after bone marrow transplantation 5-7. Most experimental and clinical studies, however, do not 
study tolerance induction by MSC, but investigate the direct immunosuppressive effects of MSC on 
activated immune cells in various in vitro studies and animal models. 
MSC in organ transplantation;  potential pitfalls and future directions
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As a result, there is currently little evidence whether and how tolerance induction by MSC works, 
and whether this is a special MSC characteristic or just dependent of the pretransplant presentation 
of donor-antigen.
Besides tolerance induction, MSC may be used for anti-rejection therapy, as MSC possess 
immunosuppressive properties. Their immunosuppressive effects are even further enhanced under 
inflammatory conditions as shown by our group and others 8-10. 
Furthermore, it can be speculated that addition of MSC to the conventional treatment may reduce the 
need for immunosuppressive drugs and could allow tapering of immunosuppressive medication. As 
shown in Chapter 4, the commonly used immunosuppressive drugs (MPA, tacrolimus and rapamycin) 
in kidney transplantation did not induce apoptosis or toxicity in MSC. We also found that MPA, in 
contrast to tacrolimus and rapamycin, did not hamper the immunosuppressive effects of MSC. A 
treatment with MPA may therefore be preferred above tacrolimus or rapamycin. 
Application of MSC therapy for acute versus chronic rejection?
If MSC are applied as anti-rejection therapy, the question is whether MSC are most effective in 
treatment of acute or chronic graft rejection. Most experimental studies focus on the effect of MSC on 
activated immune cells in vitro or acute inflammatory processes, such as (autoimmune) inflammatory 
disease models, for example colitis or rheumatoid arthritis 11-12. Little is known about the efficacy of 
MSC in acute versus chronic graft rejection in solid organ transplant. In acute rejection very active 
immune responses are ongoing, which activate the immunosuppressive mechanism in MSC, leading 
to strong immunosuppressive effects by MSC. This suggests that the application of MSC in acute 
rejection may be effective.
In vitro studies have shown that MSC successfully suppress lymphocyte activity in the afferent phase 
and not in the cytotoxic phase of an allo-response 13-15. In addition, data from animal models have 
shown that MSC were effective immune suppressors when infused before the onset of inflammatory 
processes 6, and that they could prevent the development of autoimmune encephalitis in a murine 
model 16. Moreover, in the same model, MSC were also effective when administered at the peak 
phase of the disease, suggesting that they can also ameliorate active inflammatory processes. This 
was further demonstrated in patients with severe drug-resistant GVHD whose clinical condition 
was improved by treatment with MSC 3, 17. Consequently, MSC based-therapy may be effective in 
preventing anti-donor reactivity and in reducing active rejection in organ transplantation. 
In addition to application in acute inflammatory processes, MSC therapy could be used in chronic 
inflammatory processes, such as in chronic allograft rejection or biopsy-proven sub-clinical rejection. 
In organ transplantation, immune modulation by MSC in an early phase after transplantation may 
result in reduced damage of the graft which may improve graft function in the long-term. Only a 
few studies investigated the effect of MSC in chronic inflammatory diseases such as chronic 
experimental autoimmune encephalomyelitis 18-19. Many studies, however, investigate the potential 
of MSC in acute inflammatory diseases, and to much lesser extent to the effects of MSC on chronic 
immune processes. In view of long term immunomodulatory effects of MSC, the reported induction 
of regulatory T-cells by MSC is relevant. Via the induction of T-regs, the immunosuppressive effect 
of MSC may remain present long after the disappearance of MSC and in this way contribute to long 
term immunosuppression that could serve to dampen chronic inflammatory processes.
These data suggest that timing of MSC administration may be crucial for the efficacy of the therapy.
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3. route of administration and migration of MSC
MSC used for immune therapy in solid organ transplantation can be administered via two routes: 
systemic or local. It is, however, unknown where MSC exert their potential immunoregulatory effects. 
This could be in the target organ or perhaps in the lymph nodes. As a result it is unknown whether it is 
more effective to administer MSC locally (into the target organ, i.e. the graft) or systemic. The choice 
of administration depends on the clinical effect that is aimed for, for example the regenerative effects 
of MSC may be more effective if MSC are infused locally in the damaged target organ, as a result of 
the local production of trophic factors by MSC 20.
Until now intravenous infusion has been the route of administration of choice for all clinical studies 
with MSC for immunomodulatory purposes. The few clinical studies performed so far suggest that 
intravenous administration of MSC is feasible and safe. To date, no severe adverse reactions have 
been recorded in humans after MSC administration, both in terms of immediate, infusion-related 
toxicity and of late effects 2-3, 21. For, tissue repair purposes, however, MSC have injected in various 
local tissues such as in muscle (e.g. in myocardial infracted hearts) or in skin (e.g. in burn/irradiation 
wounds or treatment-resistant diabetic wounds) 22-24.
Although MSC express homing receptors 25, it is unclear whether such receptors would lead 
systemically administered MSC to the target organ. Data from a number of studies suggests that 
intravenously injected MSC home to sites of inflammation 26-30, while other studies demonstrated 
systemic intravenous route of administration was not appropriate for MSC to reach their target site 31-32.
An important point to consider is that in vitro expansion of MSC changes the expression of cell 
surface markers on MSC and thereby may affect the homing behaviour of MSC. Sackstein et al. 
demonstrated that modification of the cell surface molecule CD44 on ex vivo expanded MSC can 
influence the migration of MSC after infusion 33. This is of great interest for the specific delivery 
of MSC for clinical applications. However, other studies reported that selective homing of MSC to 
lymphoid tissues 34 or sites of inflammation 29, 35 is limited, and that MSC get trapped in lungs and liver 
by space constrictions 36. 
To increase the number of MSC in the target organ, intra-arterial infusion can be considered 37-39. In a 
rat kidney transplantation model intra-arterial infusion of MSC prevented acute cellular rejection 40. 
In our own group we studied the effect of renal arterial infusion of labelled MSC in pigs (unpublished 
data). We, however, did not find traces of  labelled MSC in the kidney one hour after infusion. We then 
hypothesized that MSC may prefer a inflammatory environment by the up-regulation of adhesion 
molecules and production of pro-inflammatory cytokines. We, therefore, induced 45 minutes of 
hypoxia in the kidney and subsequently infused labelled MSC via the renal artery. Again, no labelled 
MSC were found in the kidney. Although this was only a pilot study, these results do not support 
the hypothesis that arterial infusion increases the number of MSC. Interestingly, infusion of MSC 
via the renal artery in a small animal model demonstrated that MSC remain in the kidney, but mal-
differentiate into adipocytes in within weeks after administration 41. Furthermore, it has been reported 
that infusion of MSC via coronary artery can lead to micro-infarcts in the pigs heart 41-42.
Therefore, as most experience with MSC as immune therapy has been gained with intravenous 
administration of MSC, it seems most safe to perform the initial trials in organ transplantation with 
intravenous administered MSC.
MSC in organ transplantation;  potential pitfalls and future directions
C
ha
pt
er
 9
151
Chapter 9
4. Potential risks of MSC
Besides the promising results of MSC in experimental and clinical studies, there are also several 
issues concerning potential risks and safety of MSC therapy that need to be discussed. For example 
effects of ex vivo expansion, systemic immune suppression, ectopic tissue formation and malignant 
transformation of MSC. Furthermore, while MSC are relatively modestly present within tissues 
under physiological conditions and are particularly rare in the circulation, MSC used for clinical 
applications are infused intravenously in high numbers. Currently, more than 1,000 patients have 
received MSC and there have not been reported acute or intermediate-term side effects of MSC 3, 43. 
Long-term follow-up studies, however, are certainly required to fully address safety issues associated 
with MSC therapy. 
4.1 Infusion-related and acute allergic reactions
As the lungs are the major filters for intravenous administered cells, MSC are expected to accumulate 
predominantly in the lungs. This could potentially lead to effects on breathing. These or allergic side 
effects, however, have not been observed in humans. 
4.2 In vitro expansion of MSC
It is important to consider the potential functional differences between tissue-resident MSC and 
in vitro-expanded MSC and to consider the non-physiological aspects of MSC therapy. In vitro 
expansion of MSC may affect the properties of MSC, for example proliferation rate and exposure to 
culture media, including bovine serum. Below examples of these concerns are discussed.
4.2.1 chromosomal abnormalities
There is some evidence that chromosomal abnormalities develop in MSC after long-term expansion in 
vitro, e.g. culturing MSC for more than 25 passages. In particular, continued culturing of MSC after 
senescence increases the risk for genetic changes 44-49. Other studies, however, found no or neglectable 
aberrations occurring in culture 50-51. Furthermore, it has been reported that murine MSC frequently 
have chromosomal abnormalities and lead to tumour formation, while human MSC have a stable 
karyotype 52-53. The tendency for MSC to undergo malignant transformation could vary according to 
the source (e.g. bone marrow, adipose tissue), species (e.g. human vs. mice) and culture conditions. 
Thus, for safety reasons, the use of high-passage “senescent” MSC for clinical applications should be, 
and can easily be, avoided. Moreover, karyotyping of ex vivo-expanded MSC is recommended before 
clinical administration. 
4.2.2. In vitro expansion of MSC; need for bovine serum free conditions?
Until now most clinical trials using ex vivo-expanded MSC, cultured their MSC in medium with 
foetal bovine serum. Although most experience has been gained using these culture conditions and no 
allergic reactions against bovine antigens have occurred, there is a potential risk of priming recipients 
with bovine antigens 54 or transferring bovine-related disease. This problem is easily to overcome as 
bovine-free MSC medium is now commercially available.
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4.3 Systemic immunosuppressive effect: increased risk for infections due to suppression of the 
host’s immune system?
Other safety issues that involve systemic administration of MSC are the potential modulation of the 
overall immune system as the immunosuppression by MSC is not antigen-specific. Consecutively, 
systemic suppression may potentially reduce patients’ resistance to infections or support the 
development of pre-existing tumours 46. The occurrence of opportunistic infections and tumours 
have already been reported for immunosuppressive drugs, but are still unclear for MSC. In baboons 
treated with multiple administrations of high dose allogeneic MSC, alloreactive immune responses 
were affected, but there was no compromising of the overall immune system 55. In contrast, in a 
considerable number of patients that has been treated with MSC for several diseases, the incidence 
of infections seemed high 3. Unfortunately, until now almost all the clinical studies reported are non-
placebo controlled studies. Thus, it is too early to conclude that MSC therapy leads to an increased 
risk for infections.
4.4 Ectopic tissue formation
4.4.1 Calcifications, adipogenesis and fibrosis
Another concern is the multilineage differentiation potential of MSC, which may not always be 
beneficial, as it may lead to the formation of the “wrong” cell types. It has been reported that treatment 
of mice with myocardial infarcts with MSC induced increased calcification of the heart 56 or formation 
of adipose tissue in the kidney 41. Alternatively, differentiation of MSC in the wrong cell type may 
lead to tumour formation. Until now, this has not been observed in a human setting. 
Perhaps more likely is the induction of fibrosis by MSC, as MSC are progenitors of fibroblast-like cells 
and therefore may be associated with tissue fibrosis. Although some evidence for this is provided by 
a recent clinical study in which local administration of progenitor-enriched adipose tissue in breasts 
induced fibrosis 57, it is unclear whether ex vivo-expanded MSC will act in the same way. Studies in 
animal models showed that MSC infusion did not worsen, yet ameliorated fibrosis 28, 58.
4.4.2 Tumour formation  
Because there is evidence that tumours are sites of inflammatory cytokine and chemokine production, 
MSC may home to, and immunomodulate, the tumour environment 59. There is evidence that MSC 
actively migrate to, and proliferate in, tumours 60-61. MSC were found to contribute to the tumour-
associated stroma within sites of inflammation and were in close proximity with tumour cells as part 
of the remodelling process. Furthermore, there are also theories that stromal tumours, e.g. sarcomas 
62, originate from developmental abnormalities in progenitor cells, possibly MSC. Other animal and 
clinical studies, however, did not find an increased incidence of these tumours 3, 53, 63. Although these 
preliminary results suggest that the use of MSC is safe in respect to tumour formation, again, it is too 
early to conclude and longer follow-up is needed.
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4.5 Dual functions of MSC  
We and others have shown that the immunomodulatory function of MSC strongly depends on 
the local environment. This can be referred to as the “dual” immunomodulatory effect of MSC: 
immunosuppression versus immune stimulation 64-66. In an inflammatory condition MSC employ their 
immunosuppressive mechanisms, such as activation of IDO and secretion of pre-dominantly anti-
inflammatory factors, while in a non-inflammatory setting MSC can stimulate immune activation. 
Immune activation in a transplantation setting is a potential risk as induction of immune reactivity 
may stimulate graft rejection. Since this is an important issue, we demonstrated in this thesis that 
indeed MSC modestly stimulated the proliferation of lymphocytes, but kept the proliferation of 
activated lymphocytes under control. We subsequently found that MSC could also generate regulatory 
T-cells from resting T-cells. Under non-inflammatory conditions MSC may rather employ functions 
to support other (more specialized) cells than to bring about their immunosuppressive functions. It 
can therefore be speculated that administration of MSC in patients with low of no immune reactivity, 
such as in the absence of rejection, does not lead to accelerated rejection due to the activation of 
immune cells by MSC. 
COnCLuSIOn
There is accumulating evidence from in vitro, animal and some clinical studies that MSC have tissue 
repair and immunosuppressive properties which are promising for treatment of various diseases. It 
is, however, currently unknown whether these capacities are functional or beneficial in a human 
organ transplantation setting. We believe that MSC have unique properties that allow them to prevent 
damage of the transplant, improve graft acceptance and its function. We therefore subscribe to the 
current high hopes regarding their use in cell therapy, but future research and clinical trials in organ 
transplantation will show whether this is justified. In addition, it is important not to overestimate the 
potential therapeutic effects of MSC, since almost all the clinical studies reported so far are non-
placebo-controlled studies. The complexity of the MSC suggests the introduction of successful MSC 
therapy in organ transplantation is going to be a long-term process of trial and error. 
Although multiple clinical trials are ongoing for various applications, the safety and feasibility of 
MSC infusion also needs to be confirmed in kidney transplantation. To avoid interference of MSC 
therapy with the transplantation, phase I clinical study can be performed in kidney patients with 
end-stage renal disease (ESRD). If the infusion is safe, the application of MSC in a clinical kidney 
transplantation setting can be investigated. 
This thesis presents some of the first steps in exploring the possibilities for the use of MSC for clinical 
immune therapy in solid organ transplantation.
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Door een aangeboren afwijking of verworven ziekte kunnen mensen steeds slechter functionerende 
nieren krijgen, waardoor ze in veel gevallen moeten gaan dialyseren om de filter functie van de nier 
over te nemen en de schadelijke stoffen uit het lichaam te verwijderen. De nier heeft echter veel meer 
functies die niet door dialyse vervangen kunnen worden. Daarnaast is dialyse een lichamelijk en 
psychologisch zware belasting voor de nierpatiënt. De enige definitieve behandeloptie voor patiënten 
met eindstadium nierfalen is dan ook niertransplantatie. Tijdens de transplantatie wordt het zieke 
orgaan van de ontvanger vervangen door een gezond orgaan van een donor. Het immuunsysteem van 
de ontvanger ziet het nieuwe orgaan echter als lichaamsvreemd en zal pogen het transplantaat af te 
stoten. Om een dergelijke afstotingsreactie te voorkomen moet een ontvanger van een transplantaat 
levenslang behandeld worden met medicijnen die het immuunsysteem onderdrukken, zogenaamde 
immunosuppressieve medicijnen. Deze medicatie kan het immuunsysteem onder controle houden 
en daarmee het risico op afstoting van het orgaan verminderen. Helaas heeft deze medicatie allerlei 
(ernstige) bijwerkingen, zoals een verhoogd risico op hart- en vaatziekten, infecties, kanker en, 
paradoxaal genoeg, tast ze ook de nierfunctie aan 1-2. Daarom wordt er uitgebreid onderzoek gedaan 
naar nieuwe behandelmethoden die effectiever de afstotingsreactie kunnen remmen. Hierdoor zou 
de hoeveelheid immunosuppressieve medicijnen verlaagd of zelfs gestopt kunnen worden, zodat het 
risico op bijwerkingen verlaagd wordt. 
Eén van de veelbelovende nieuwe behandelingen is zogenaamde cellulaire (immuun)therapie, waarbij 
cellen met speciale eigenschappen aan de patiënt worden toegediend om immuunreacties te remmen. 
Eén van de cellen die geschikt lijken is de zogenaamde mesenchymale stamcel (MSC) (hoofdstuk 
1). Hierover gaat dit promotieonderzoek.
MSC zijn grillig gevormde cellen met lange uitlopers in kweek (Figuur 1). Ze kunnen worden 
geïsoleerd uit vrijwel alle weefsels van zowel embryo’s als volwassenen 3. De klassieke weefselbron 
voor MSC is beenmerg. Omdat beenmergpuncties pijnlijk en belastend zijn en het beenmerg zeer 
gevarieerde hoeveelheden cellen oplevert, wordt tegenwoordig ook de bruikbaarheid van andere 
weefselbronnen onderzocht. In hoofdstuk 2 werden mesenchymale stamcellen geïsoleerd uit milt-
, hart- en vetweefsel en de eigenschappen van deze MSC zijn vergeleken met MSC geïsoleerd uit 
beenmerg. Hoewel er subtiele, weefselspecifieke verschillen kunnen zijn, vonden wij dat de algemene 
kenmerken en eigenschappen van MSC uit de verschillende weefsels vergelijkbaar zijn. In ons 
onderzoek werden ook stamcellen uit zogenaamd perirenaal vetweefsel van nierdonoren geïsoleerd. 
Perirenaal vetweefsel is gelokaliseerd rondom de nier en komt bij nierdonatie vrij als afvalproduct. In 
ons onderzoek bleek echter dat perirenaal vet een zeer rijke bron is voor mesenchymale stamcellen. 
Tevens kunnen stamcellen uit buikvet geïsoleerd worden; voor klinische studies kan dit een 
toegankelijke en betrouwbare stamcelbron zijn.
Mesenchymale stamcellen kunnen relatief makkelijk uit weefsels worden geïsoleerd en in kweek 
gebracht worden (zie figuur Hoofdstuk 2). Het kweken van MSC in het laboratorium heeft het grote 
voordeel dat de celaantallen vergroot kunnen worden en dat de kweekcondities beïnvloed kunnen 
worden. Op deze manier kunnen voldoende cellen worden verkregen voor toediening bij klinische 
toepassingen.
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Mesenchymale stamcellen hebben eigenschappen die mogelijk gunstig zijn bij de behandeling van 
nierfalen of transplantatie patiënten. Allereerst hebben ze de interessante eigenschap dat ze kunnen 
veranderen van min of meer naïeve, ongedifferentieerde, “pluripotente” cellen in gespecialiseerde 
weefselcellen, zoals botcellen, vetcellen, spiercellen en mogelijk ook niercellen (Figuur 2) 4-6. Dit 
veranderingsproces wordt differentiatie genoemd. Hoewel het verloop van dit proces in het lichaam 
nog onduidelijk is, zouden MSC met deze eigenschap mogelijk beschadigde weefsels in het lichaam 
kunnen herstellen. Bovendien maken MSC allerlei groeifactoren die de groei van weefselcellen kan 
verbeteren, bijvoorbeeld de weefselcellen in het transplantaat 7. 
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Figuur 2: Differentiatie capaciteit van mesenchymale stamcellen. Mesenchymale stamcellen hebben de 
interessante eigenschap, dat ze in het laboratorium onder speciale kweekcondities in enkele weken van min of meer 
naïeve, ongedifferentieerde, ‘pluripotente’ cellen [A] kunnen differentiëren naar gespecialiseerde weefselcellen, 
zoals bot-, vet-, spier-. [B] Differentiatie naar bot wordt zichtbaar gemaakt met een Von Kossa kleuring wat 
kalkafzettingen zwart maakt. [C] Differentiatie van MSC naar vetcellen kan worden zichtbaar gemaakt door 
de vetblaasjes die door de vetcellen gemaakt zijn, rood te kleuren. [D] Differentiatie naar spiercellen kan 
morphologisch gevolgd worden en tevens kan de hoeveelheid gevormde spiereiwitten  gekwantificeerd worden. 
Figuur 1. Mesenchymale stamcellen in kweek
A
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Hoewel de “reparatie” eigenschap van MSC zeer interessant is, heeft dit promotieonderzoek zich gericht 
op een andere interessante eigenschap van MSC, namelijk hun zogenoemde immunosuppressieve 
functies. Immunosuppressie betekent letterlijk onderdrukking van de (natuurlijke) afweerreactie. 
Hoewel immuuncellen, ofwel witte bloedcellen, ons lichaam beschermen tegen indringers van 
buitenaf, zoals tegen bacteriën en virussen, zullen in geval van transplantatie de immuuncellen zich 
tegen de cellen in het lichaamsvreemde niertransplantaat richten. De afstotingsreactie die volgt is, 
zoals eerder gezegd, ongewenst en resulteert in afstoting van het getransplanteerde orgaan. Er is 
toenemend bewijs dat mesenchymale stamcellen de mogelijkheid hebben om de proliferatie en functie 
van geactiveerde immuun cellen te remmen. Vooral een bepaald type witte bloedcellen, namelijk 
zogenaamde T-lymfocyten, kunnen in hun celdeling en functie beïnvloed worden door MSC. 
Momenteel wordt veel onderzoek gedaan naar de verschillende mechanismen die betrokken zijn bij 
de onderdrukking van immuun cellen door MSC. Hoewel er nog veel onderzoek nodig is, is het 
inmiddels wel duidelijk dat de immunosuppressieve effecten van MSC grotendeels berusten op de 
productie van oplosbare immunosuppressieve factoren 8-10. De productie van deze factoren door MSC 
kan worden opgeschroefd indien de mesenchymale stamcellen in aanraking komen met geactiveerde 
immuun cellen (Figuur 3) 11-12. 
Verder is gevonden dat ook enzymen belangrijk zijn voor de immunosuppressieve functie van MSC, 
in het bijzonder het enzym indolamine-2,3-dioxygenase (IDO) wordt hierbij genoemd 13-14. IDO 
zorgt ervoor dat tryptofaan, een voedingsstof voor T-lymfocyten, onttrokken wordt uit de omgeving, 
zodat de groei van deze cellen geremd wordt. Een ander mechanisme waarmee MSC (indirect) 
immuun reacties zouden kunnen beïnvloeden is dat ze de ontwikkeling van zogenaamde regulatoire 
T-lymfocyten (T-regs) stimuleren. T-regs zijn T-lymfocyten die andere geactiveerde witte bloedcellen 
kunnen remmen. Samengevat, kunnen we zeggen dat MSC zowel directe en indirecte manieren 
hebben om immuun cellen te beïnvloeden.
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Figuur 3. Geactiveerde immuuncellen worden gebonden door mesenchymale stamcellen, zodat, naar men denk, 
de MSC nog effectiever de geactiveerde cellen kunnen inactiveren.
In hoofdstuk 3 worden experimenten beschreven die uitgevoerd zijn waarbij  een niertransplantatie 
werd nagebootst in het laboratorium (zgn. in vitro experimenten). Hiertoe reageerden witte bloedcellen 
van de ontvanger met witte bloedcellen van de donor, waarbij de proliferatie van de ontvanger cellen 
als surrogaat uitleespunt werden gebruikt voor de afstotingsreactie in het lichaam van de ontvanger. 
Het bleek dat MSC zeer goed de proliferatie van geactiveerde T-lymfocyten, en daarmee dus de 
afstotingsreactie, konden remmen. Bovendien kon de afstotingsreactie van de ontvanger gericht tegen 
de donor cellen, zowel vóór als na transplantatie, significant geremd worden. Aangetoond werd dat 
het voor deze immunosuppressieve effecten niet uitmaakte of de mesenchymale stamcellen afkomstig 
waren van de ontvanger zelf, van de nier donor of van een vreemde stamcel donor.
Indien MSC gebruikt gaan worden in de kliniek is het waarschijnlijk dat ze aanvankelijk worden gebruikt 
in combinatie met de immunosuppressieve medicijnen die niertransplantatie patiënten momenteel 
krijgen. Daarom werd onderzocht wat de effecten zijn van de immunosuppressieve medicijnen 
tacrolimus, rapamycine en mycofenolaat mofetil (MMF) op de functies van MSC (hoofdstuk 4). 
Bovendien zitten in MSC namelijk de aangrijpingspunten van deze immunosuppressieve medicijnen, 
zodat mogelijk de functie van MSC beïnvloed kan worden. Bij klinische doseringen bleek de 
medicatie niet giftig voor MSC. Blootstelling aan de verschillende medicijnen beïnvloedden echter 
wel de differentiatie capaciteit van MSC. Verder toonden we aan dat de immunosuppressieve effecten 
van MSC verminderd werden indien MSC blootgesteld werden aan rapamycine of tacrolimus. 
Verrassend genoeg bleek dat de combinatie van MSC en MMF de immunosuppressieve effecten juist 
vergrootte. Op basis hiervan lijkt MMF het beste immunosuppressieve medicijn om MSC therapie 
mee te combineren in niertransplantatie patiënten.
Hoewel vrijwel alle onderzoeksgroepen die onderzoek doen naar de immunosuppressieve 
eigenschappen van stamcellen zich concentreren op de effecten van MSC op geactiveerde immuun 
cellen, onderzochten we in hoofdstuk 5 het omgekeerde, namelijk wat het effect van geactiveerde 
immuun cellen –oftewel de inflammatoire omstandigheden- op MSC eigenschappen en functies 
is. We vonden dat blootstelling van MSC aan inflammatoire reacties, eigenschappen van de MSC 
beïnvloedden. Het meest opvallend was dat - terwijl de differentiatie eigenschappen niet beïnvloed 
werden - de immunosuppressieve eigenschappen enorm versterkt werden door voorbehandeling van 
MSC onder inflammatoire condities. Door deze interessante bevinding kunnen we speculeren dat 
de vermeerdering en voorbehandeling van MSC met inflammatoire factoren in het laboratorium 
het mogelijk maakt om de immunosuppressieve eigenschappen van MSC al te activeren voordat de 
MSC ingespoten worden voor klinische behandeling. Op deze manier zouden een grote hoeveelheid 
stamcellen met nog sterkere immunosuppressieve eigenschappen gemaakt kunnen worden.
In tegenstelling tot het immunosuppressieve effect van MSC op geactiveerde immuun cellen, bleek 
ook dat MSC niet-geactiveerde immuun cellen kunnen activeren (hoofdstuk 6). Het grootste 
gedeelte van deze cellen die geactiveerd worden gaan zich echter ontwikkelen tot immuun cellen die 
immunosuppressieve eigenschappen hebben, de eerdergenoemde T-regs.
Een zeer belangrijke vraag bij de klinische toepassing van cel therapie is of MSC ook immuun reacties 
kunnen opwekken, met andere woorden of ze immunogeen zijn. Het al dan niet herkend worden door 
het immuun systeem van de ontvanger is van belang voor de duur van de aanwezigheid van MSC na 
toediening. Daarnaast zou het herkennen van lichaamsvreemde donor MSC door het immuunsysteem 
van de ontvanger kunnen leiden tot het opwekken van een “geheugenreactie” bij de immuun cellen, 
een proces wat sensitisatie wordt genoemd. Het gevolg van sensitisatie zou kunnen zijn dat de immuun 
cellen de donor nier herkennen als lichaamsvreemd en deze aanvallen. Indien dit het geval is, zou het 
nederlandse samenvatting
C
ha
pt
er
 1
0
163
Chapter 10
geven van stamcellen van de nierdonor aan de ontvanger ervoor zorgen dat het nier transplantaat van 
de donor versneld afgestoten kan worden. Allereerst vonden we, in tegenstelling tot veel studies, dat 
MSC immunogeen zijn en dus herkend worden door immuun cellen, namelijk door de zogenaamde 
cytotoxische T-cellen (CD8+ T-cellen) en natural killer (NK) cellen (hoofdstuk 7). Als gevolg van 
deze herkenning werden de MSC gedood, zogenoemd gelyseerd. Verder bleek dat lichaamsvreemde 
MSC door zowel CD8+ T-cellen als door NK cellen gelyseerd werden. Lichaamseigen stamcellen 
werden echter niet gedood door CD8+ T-cellen. Tot onze verrassing werden ook MSC van de 
ontvanger zelf, dus lichaamseigen cellen, herkend en gelyseerd door NK cellen, maar niet door CD8+ 
T-cellen. Hoe dit komt weten we niet, maar het zou kunnen komen doordat het kweken van MSC in 
het laboratorium de vorm van de cellen verandert, zodat ze vervolgens als vreemd worden herkend. 
Deze resultaten zijn belangrijk om mee te nemen in de klinische toepassing van MSC in de kliniek.
Concluderend kunnen we zeggen dat, op basis van de resultaten van onze experimenten en de huidige 
literatuur, mesenchymale stamcellen beschadigde nieren zouden kunnen herstellen en tegelijkertijd 
de afstotingsreactie zouden kunnen onderdrukken. Hoewel de resultaten uit de laboratorium- en 
dierstudies veelbelovend zijn, moet de effectiviteit van mesenchymale stamcellen in klinische orgaan 
transplantatie nog bewezen worden. Daarnaast is er nog veel onbekend over de basale werking van 
MSC en hun functie in het lichaam. Dit vraagt om verder onderzoek. hoofdstuk 9 beschrijft daarom 
op basis van de huidige literatuur en de resultaten van dit promotieonderzoek de mogelijkheden 
voor toepassing van mesenchymale stamcellen bij orgaan transplantatie, en dan met name bij 
niertransplantatie. Er worden enkele overwegingen en valkuilen genoemd die daarbij relevant 
kunnen zijn. Voorbeelden hiervan zijn veiligheid, tijdsplanning en effectiviteit van MSC behandeling. 
Voor succesvolle ontwikkeling van een nieuwe therapie, zoals mesenchymale stamcel therapie, is 
de interactie tussen laboratorium experimenten en goed opgezette klinische studies cruciaal. In de 
komende jaren zal duidelijk worden of de op dit moment veelbelovende mesenchymale stamcellen een 
succesvolle nieuwe behandeling zullen worden voor patiënten met nierziekten of niertransplantatie.
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dAnKwOOrd
Na deze drieënhalf jaar van promotie onderzoek ben ik vele ervaringen rijker. Heel bewust heb 
ik na mijn studie geneeskunde gekozen om promotie onderzoek te gaan doen. De interesse voor 
onderzoek was al sinds mijn doctoraalscriptie gewekt en het leek me een mooie kans om op een 
andere manier naar de geneeskunde te kijken. Enkele maanden voor mijn afstuderen als arts heb ik 
een open sollicitatie gestuurd naar de afdeling Interne geneeskunde met de vraag of er een interessant 
onderzoek was om in te stappen. Binnen de afdeling niertransplantatie was toen heel recent een 
project gestart om te kijken of mesenchymale stamcellen nuttig konden zijn bij niertransplantatie. Bij 
mijn sollicitatie werd duidelijk dat het gehele onderzoek nog opgezet moest worden en dat de richting 
waarin het onderzoek zich zou ontwikkelen nog niet duidelijk was. Dit deed mij echter geenszins 
afschrikken. Integendeel, het motiveerde mijn juist om de (immunosuppressieve) eigenschappen van 
mesenchymale stamcellen en de  mogelijkheden bij orgaantransplantatie uit te zoeken. Ik denk dat 
we inmiddels een zeer mooie en vernieuwde (onderzoeks)weg ingeslagen zijn, die niet alleen tot een 
heel aantal mooie publicaties heeft geleid, maar ook een wetenschappelijke basis heeft gelegd voor 
potentiële toepassing van mesenchymale stamcellen in de kliniek.
Hoewel onderzoek doen iets volledig anders is dan het klinische werk als arts ben ik nog steeds van 
mening dat het voor een professionele arts essentieel is om affiniteit met en begrip van wetenschappelijk 
onderzoek te hebben. Het toepassen van resultaten behaald door onderzoek in de dagelijkse praktijk 
maakt het mogelijk de patiëntenzorg steeds weer te verbeteren, de zogenaamde “evidence-based” 
geneeskunde. Naast basale biologie en laboratoriumtechnieken heb ik veel geleerd over praktisch, 
gestructureerd experimenten bedenken, uitvoeren en analyseren. Ik heb hierbij veel geleerd van de 
collega’s met wie ik samen heb gewerkt. Hieronder staan enkele mensen genoemd die ik graag in het 
bijzonder wil bedanken. Ook diegenen die niet expliciet genoemd worden, maar waarmee ik leerzame 
en leuke momenten heb beleefd: bedankt!
Allereerst wil ik mijn promoter Prof. dr. W. Weimar bedanken. Beste Willem, bedankt dat je mijn 
promotor wilde zijn. Door mijn open sollicitatie kwam ik bij jou terecht, omdat er op jouw afdeling 
net een nieuwe onderzoekslijn opgestart werd onder leiding van Martin Hoogduijn. Hoewel de titel 
veelbelovend “mesenchymale stamcellen en transplantatie” luidde, was de inhoud daarvan nog 
grotendeels blanco. Bovendien was het onbekend of het onderzoek een succes zou worden. 
Eén van je eerste vragen waarmee ik tijdens mijn werkbespreking geconfronteerd werd, was of 
“mesenchymale stamcellen niet gewoon fibroblasten zijn”, en of “fibroblasten dezelfde resultaten 
geven in een MLR? heb je dat getest?”. Ik denk dat we er na vier jaar onderzoek nog steeds niet 
met zekerheid kunnen zeggen of de ene cel heel anders is dan de andere cel. Toch hebben we mooie 
resultaten behaald met deze fibroblast-achtige MSC (of zijn het dan toch MSC-achtige fibroblasten?!). 
Van onze besprekingen heb ik onder andere geleerd dat de titel en het abstract de belangrijkste zijn 
van een manuscript. Dit heeft zich bevestigd door het feit dat ik nog nooit zoveel e-mails heb ik 
ontvangen met het verzoek om een PDF op te sturen als van het manuscript met in de titel “Explosive 
T-cell proliferation”; een titel waar we hard over hebben gelachen, en catchy is de titel dus zeker! Ook 
heb ik geleerd dat de rest van een manuscript zo duidelijk moet zijn dat reviewers mijn manuscript 
begrijpen zonder dat ze mijn (soms erg uitgebreide) toelichting erbij hebben, die ik wel bij onze 
besprekingen kon geven. 
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Ook weet ik dat het inzicht van de ene week, niet hetzelfde inzicht van de week erna hoeft te zijn (“…
moet die titel niet veranderen in …”?, “o, je bedoelt dat wat er vorige week stond”). “Voortschrijdend 
inzicht” is een mooie term hiervoor. Bedankt ook dat ik mijn resultaten op zoveel congressen mocht 
presenteren, een leerzame en leuke ervaring. De “één-boodschap” presentaties zal ik zeker onthouden, 
hoewel het me soms door mijn enthousiasme toch niet lukt minder te vertellen. 
Dank ook voor het mogelijk maken van de labweekenden, ook namens mijn vrouw Eefje. Het 
waren elke keer leuke en gezellige momenten met elkaar. Ik heb veel geleerd op het Transplantatie 
laboratorium en ik denk dat dit een mooi begin is geweest voor mijn toekomst waarin hoop ik 
onderzoek en onderwijs een belangrijke rol mogen spelen naast het klinische werk.
Mijn promotie zou zeker niet zo leuk, humoristisch, inspirerend en voorspoedig zijn gelopen zonder 
mijn co-promotor Dr. M.J. Hoogduijn. Beste Martin, inspirerende baas, trouwe labonderzoeker en 
goede vriend. Ik wil je heel hartelijk bedanken voor je begeleiding. Onze inzichten kwamen vrijwel 
altijd goed overeen. Je hebt me veel geleerd over het opzetten van experimenten, het pipetteren en 
het schrijven van mijn manuscripten. Hoewel de eerste kennismaking nogal een verrassing voor je 
was (Meindert: “ik ben je nieuwe AIO!”; Martin: “oh, krijg ik een nieuwe AIO dan”?!), is onze 
samenwerking in de afgelopen jaren zeer succesvol gebleken en heeft dit ook nog eens geleid tot een 
goede vriendschap. Dat ik je bij het squashen af en toe met het balletje raakte, kwam meer door mijn 
geringe squash ervaring dan uit frustraties opgedaan in de werksituatie. Ook op congressen hebben 
we veel leuke momenten beleefd. Ik hoop nog veel contact met je te houden, zowel wetenschappelijk 
als vriendschappelijk.
Carla, alweer een kleine vier jaar geleden leerde ik je kennen tijdens het sollicitatie gesprek. Hoewel 
het voor mij als dokter zeker even wennen was om basaal wetenschappelijk onderzoek te gaan 
doen (“pipetteren”), heb ik het heel leerzaam gevonden om op je “lab” bezig te zijn. Gelukkig is 
het praktische werk prima gelukt. Onze samenwerking kan ik als direct, vriendelijk en kritisch 
beschrijven. Bedankt voor je begeleiding, je goede aanvullende ideeën en opbouwende kritiek. Ik 
denk dat de uitbreiding van het transplantatie lab met onderzoek naar MSC veel mogelijkheden biedt 
naast de andere interessante onderzoekslijnen.
Mijn paranimfen: Jasper Brugts en Ramin Vafadari. Twee mannen die mij zullen bijstaan op een 
belangrijke dag: een dag waar ik vier jaar naar toe hebt gewerkt. Super bedankt Jasper, of moet ik 
Dr. Brugts zeggen! We kennen elkaar sinds de opleiding geneeskunde, en werden samen met Sietse 
ook wel de drie musketiers genoemd. Altijd samen hard studeren, maar ook veel plezier maken, zoals 
wintersport. Wij tweeën hebben na het artsdiploma besloten wetenschappelijk onderzoek te gaan, iets 
wat ons allebei goed ligt denk ik. Samen zijn we nu ook in het Albert Schweitzer ziekenhuis met de 
patiëntenzorg bezig. Leuk om onze levenslijnen zo dicht bij elkaar te zien. Als collega en als vriend 
hoop ik nog samen veel te beleven.
Ramin, mijn achterbuurman in het AIO hok: we hebben de afgelopen jaren een goede band opgebouwd 
die zich kenmerkt door werkinhoudelijk opbouwende kritiek, maar bovenal door droge humor en 
vriendschap. Voor jouw onderzoek heb ik bij heel wat mensen bloed afgetapt. Nu ik weg ben, ben ik 
blij dat je eindelijk zelf geleerd hebt om bloed te prikken. Ik vind het bijzonder dat mijn paranimf wil 
zijn.
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Collega AIO’s. Allen met een andere achtergrond, variërend van biologie, geneeskunde, 
gezondheidswetenschappen en farmacologie. Ik denk dat we een hele leuke groep vormden waarin we 
ook laagdrempelig met elkaar konden overleggen, plezier maakten en zeker ook kritisch konden zijn. 
Beste Varsha, Dr. Sewgobind inmiddels, jij was mijn “bling-bling” buurvrouw met een uitgesproken 
voorkeur voor roze en goud. Ik heb het erg gezellig samen met je gevonden, hoewel we af en toe 
ook pittige discussies over statistiek hadden. Dat we het afgelopen jaar beiden als “oudste” AIO’s 
in het AIO hok zaten om “het boekje” af te ronden, gaf zeker een gevoel van saamhorigheid. Ook 
op congressen (o.a. Boston) was je een trouwe supporter bij mijn presentaties. Ik vond het bijzonder 
om jouw “supporter” (para-nimf) bij jouw promotie te zijn. Nu heb je dan toch het basale onderzoek 
verlaten en komen er geen regulatoire T-cellen meer voor in jouw presentaties: je bent (zoals wel 
enigszins verwacht) in de farmaceutische industrie terecht gekomen. Heel veel succes daar!
Anja, als hardwerkende AIO kom je er wel; je begon vaak nog vroeger dan ik, wat op zich al een hele 
prestatie was, omdat je helemaal uit Breda moet komen! Het is erg leuk dat je met jouw onderzoek 
“de interactie tussen Tregs en MSC” onderzoekt, aangezien het onderzoek naar deze twee cel typen 
belangrijke onderzoekslijnen in het transplantatie laboratorium zijn. De grote vraag blijft, ben je een 
“Tregs-believer” of een “MSC-believer”? Ik ben benieuwd welke cel de race gaat winnen!
Martijn, samen zijn we een begonnen met iets nieuws op ons lab: renale tubulus epitheel cellen (TEC’s). 
Hoewel de groei van TEC’s in het begin moeilijker was dan de groei van schimmels, hoop ik dat je 
mooie resultaten vindt. Erg gezellig dat je meedeed met vrijwel alle activiteiten die georganiseerd 
werden, van borrels tot bowling! We hebben heel wat plezier gehad. 
Anne, collega dokter. Je kwam als meest recente AIO ons AIO hok binnen en werd mijn 
achterbuurvrouw. Hoewel je aanvankelijk wat moeilijk je draai kon vinden, hoop ik dat je onderzoek 
leuke resultaten gaat opleveren. En je weet het, je mag altijd nog aansluiten bij het “stamcel groepje”, 
zoals je dat noemde. Tot snel weer in de kliniek; het Albert Schweitzer ziekenhuis in Dordrecht 
misschien? Dat zou gezellig zijn.
De laatste AIO die ik expliciet wil noemen is Marieke. Beste Marieke, je solliciteerde naar het 
onderzoekproject dat mijn werk zou gaan vervolgen, nog voordat je afgestudeerd was. Waar ik alleen 
maar basaal wetenschappelijk experimenten deed, zal jij waarschijnlijk de meer klinische toepassing 
gaan mee maken. Hoewel ik daar ook graag direct bij betrokken had willen zijn, ben ik heel blij dat jij 
het “stamcel-stokje” over hebt genomen. Het is spannend hoe het (klinische) stamcel onderzoek gaat 
lopen. Ik weet echter zeker dat je met jouw enthousiasme er alles aan zal doen om mooie resultaten 
te verkrijgen. Het is noemenswaardig dat door jouw contacten bij de chirurgie, de hoeveelheid 
vetweefsel die verwerkt werd tot stamcellen significant gestegen is. Van perirenaal of subcutaan vet 
van de ontvanger, tot subcutaan vetweefsel van de donor; jij weet aardig wat potjes vet op de OK te 
regelen. Heel veel succes, ik blijf graag op de hoogte van de stamcelletjes!
Dan zijn er verder nog enkele oud-collega’s die ik wil bedanken: Thijs, Jeroen en Esmé. Bedankt voor 
het inwerken aan het begin van mijn promotie. In de AIO kamer en op congressen waren we er voor 
elkaar. Bedankt voor jullie vrolijke noot, kopje filter koffie en ook voor de opbouwende kritiek. Ook 
Monique Quaedackers wil ik graag bedanken voor onze leuke momenten samen, niet alleen in de 
kantine (zgn. “lunchen met Mo en Ho”) – trek er dan maar 10 minuten extra voor uit”), cappuccino na 
de lunch, maar ook op congres. Je hebt een hele overstap gemaakt door als “hardcore basic scientist” 
docent te worden, maar ik ben blij dat je het zo naar je zin hebt.
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Collega’s op het transplantatie lab. Ik wil jullie allen graag bedanken voor de leuke tijd die ik heb 
gehad. Van borrels, bowlinguitjes en paaslunches tot labweekenden, het was erg gezellig met elkaar. 
Als kersverse dokter zonder enige pipetteer ervaring kwam ik op het lab. Mede dankzij jullie 
inwerken en hulp, heb ik erg mooie experimenten kunnen doen. Hoewel ik hier niet alle ervaringen 
kan opschrijven, heb ik het erg naar mijn zin gehad op het lab: van ‘s morgens 7.30 tot soms laat in 
de avond!”.
In het bijzonder wil ik Sander bedanken. Door jouw nauwgezetheid en gedrevenheid vond ik onze 
samenwerking erg aangenaam. Ik ben heel blij dat jij als echte “Kill Bill” de Europium-“kill”-assays 
weer aan de praat gekregen hebt. We hebben erg mooie resultaten behaald en jouw naam staat met 
trots bij de artikelen. Bedankt voor je inzet, ook al werd het soms wat later op vrijdagmiddag. Ook het 
samen monteren van de film ter ere van de promotie van Esmé was erg gezellig, alhoewel “nog een 
paar kleine dingetjes, en dan is het klaar” toch wel enkele uurtjes extra tijd kostten.
De resultaten in dit promotieboekje zijn mede mogelijk gemaakt door de transplantatie chirurgen van 
het Erasmus MC onder leiding van Prof. Jan IJzermans. Heel hartelijk dank voor het verzamelen van 
het “potje met vet”….en ja, alle mogelijke woordspelingen en liedjes zijn daar al over gemaakt. Ook 
arts-onderzoeker Nienke Dols die soms op de OK aanwezig was en mijn “redding” dat het vet niet per 
ongeluk weggegooid werd, wil ik hartelijk bedanken. Bovendien kwamen we elkaar geregeld tegen 
bij congressen, zoals in Boston en Vancouver.
Luc van der Laan en Abdulla Pan, beiden ook ervaren onderzoekers in het stamcel veld, waarbij jullie 
focus niet lag op de toepasbaarheid van MSC in de niertransplantatie, maar in de levertransplantatie. 
Spannend hoe de MSC zich in de orgaantransplantatie verder gaan ontwikkelen. Met mijn “wilde” 
idee tijdens de koffie pauze, is inmiddels een mooi onderzoek opgestart. Deze “uitvinding” is nu een 
Europees geaccepteerd patent. Hopelijk volgt binnenkort een mooie paper met alle resultaten. We 
houden contact. Ik ben benieuwd hoe het zich verder ontwikkelt.
Graag wil ik op deze manier ook Prof. Zietse bedanken. Beste Bob, jij hebt me door je rustige, 
opbouwende en soms zelfs komische kritiek door mijn eerste wetenschappelijke tekst gesleept. De 
eerste zinnen waren soms lastig en soms zelfs komisch. Het wordt “slepen” kunnen we wel heel 
letterlijk nemen bij ons artikel over de “dysmorfjes”. Dat artikel was een zeer lange tijd een blok aan 
mijn/ons been. Ik denk echter dat we er uiteindelijk toch nog een erg leuk stuk van hebben gemaakt. 
Bedankt voor je inspiratie en geduld. Ook met Ewout Hoorn heb ik in de context van “hypokaliëmie” 
fijn samengewerkt. Ewout, samen met Bob sta je aan het begin van mijn onderzoekscarrière. Het was 
geweldig om met jullie te mogen samenwerken. Nu moeten we misschien nog echt eens een keer 
afspreken om samen te gaan tennissen!
Verder wil ik de mensen op de D-vleugel hartelijk bedanken voor hun hulp bij mijn onderzoek; o.a. 
de internisten / nefrologen, de onderzoekers, de (research)verpleegkundigen en de secretaresses. 
Speciaal wil ik ook jou, Saïda, secretaresse van professor Weimar, bedanken voor je hulp, maar ook 
voor je geduld. Geduld voor als ik weer eens om een “nog even tussendoor afspraak” kwam vragen; 
of omdat mijn bespreking met de professor weer uitliep, omdat we alleen nog maar de “laatste paar 
dingetjes” van de paper hoefden door te spreken voordat het manuscript klaar was. Uiteraard duurde 
dit altijd langer dan gepland!
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Anderen van het Erasmus MC die ik graag wil bedanken zijn de assistenten van de nierpoli. Dankzij 
jullie heb ik een mooie database opgebouwd. Bedankt voor het prikken van alle patienten onder 
vermelding van “5 hep bb Tx lab meindert”).
Dit proefschrift zou niet mogelijk zijn geweest als nierontvangers en nierdonoren geen toestemming 
zouden hebben gegeven om hun vetweefsel te gebruiken voor het onderzoek. Ik wil hen daar heel 
hartelijk voor danken. Sommigen waren niet geheel tevreden met de hoeveelheid vetweefsel die 
we gebruikten: i.p.v. enkele grammen wilden ze graag kilo’s afstaan! Misschien een idee voor een 
vervolgproject, in navolging van de afdeling experimentele cardiologie: eerst een volledige liposuctie 
doen om vervolgens stamcellen uit het vetweefsel te halen?
Lieve vrienden en familie. Lieve pap en mam. In de afgelopen jaren ben ik met dingen bezig geweest 
die soms nauwelijks voor jullie te begrijpen waren en waarbij Engelse termen, zoals “multilineage 
differentiation capacity”, “immunomodulatory effects”, and “mixed lymphocyte reactions”, de revue 
passeerden. Mijn promotieonderzoek was wat dat betreft soms een “ver-van-je-bed” show, en zo 
anders dan het “echte” dokter zijn. Toch ben ik blij met de interesse en steun die ik van jullie heb 
gekregen, want soms was het best pittig. Nu ligt het resultaat voor jullie. Hoewel ik natuurlijk de 
patiëntenzorg erg gemist heb, is mijn promotietraject een leerzame en interessante tijd geweest en 
heeft mij zeker verrijkt. 
De afgelopen periode was erg hectisch door de combinatie tussen het klinische werk in het ziekenhuis 
en het afronden van mijn proefschrift. Daarom hoop ik dat ik de komende periode weer meer tijd voor 
jullie te hebben.
Lieve Sietse, mijn tweelingbroer. Hoewel onze levens heel parallel gelopen zijn tot en met het 
artsexamen, hebben we daarna ieder onze eigen weg gekozen. Jij bent gaan werken op de Spoedeisende 
hulp in Zeeland en ik startte met mijn promotieonderzoek. Twee totaal verschillende werelden: van 
acute patiëntenzorg tot stamcellen kweken in het laboratorium. Ondanks dat we ons afzonderlijk 
verder ontwikkeld hebben, blijf  jij mijn trouwe broer en grootste vriend. Ik ben blij dat je samen met 
Lieke gelukkig bent.
 
Bovenal wil ik mijn lieve vrouw Eefje bedanken. Jij hebt mij altijd gesteund en gaf me rust en zekerheid 
als ik weer laat thuis was of lang door moest werken. Vooral de laatste periode was erg intensief. Jouw 
nuchterheid en praktische insteek zorgden ervoor dat ik ook afstand kon nemen van het onderzoek. 
Hierdoor bleef ik met beide benen op de grond en kon ik mijn onderzoek ook hopelijk enigszins 
begrijpelijk overbrengen naar mijn omgeving. Door het afronden van mijn promotieonderzoek en het 
starten van mijn werk in de kliniek zijn onze werk-gerelateerde gesprekken een stuk beter op elkaar 
af gestemd. Bovendien ben ik door jou als diëtist gespitst om bij patiënten ook op de voedingsstatus te 
letten. Naast een zorgzame en lieve vrouw, kan je erg lekker koken. Elke avond, na een lange werkdag, 
is het weer genieten en het spreekwoord “liefde van de man gaat door de maag” had zomaar één van 
mijn stellingen kunnen zijn! Je muzikaliteit vind ik geweldig. Ik geniet ervan om naar je piano spel 
en zang te luisteren. Je bent een fantastische, veelzijdige, en zelfstandige vrouw; ik houd veel van jou!
Meindert
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Phd POrTFOLIO
Name PhD student: Meindert Johannes Crop
Erasmus MC Department: Internal Medicine – Transplantation
Research School: Molecular Medicine (MolMed) Graduate school
PhD period: October 2006 – May 2010
Promotor: Prof. Dr. Willem Weimar
Supervisor (co-promotor): Dr. Martin J. Hoogduijn
1. Phd training
Courses
2010 Feedback geven – Albert Schweitzer Ziekenhuis, Dordrecht
2010 Basic Life Support / Advanced Life Support – Albert Schweitzer Ziekenhuis, Dordrecht
2010 Brain training (speed reading, mind mapping) – MT company BV
2010 Geavanceerde beeldvormende technieken voor dokters, MolMed, Erasmus MC, Rotterdam
2009 Communicatie rond donatie, Nederlandse Transplantatie Stichting
2009 Partek Training Course micro-arrays, MolMed, Erasmus University, Rotterdam
2009 Mini-course Patient-related Research, Erasmus Medical Center, Rotterdam
2008 Overview course molecular techniques, MolMed, Erasmus University, Rotterdam
2008 Classical Methods in Biostatistics, NIHES, Erasmus University Rotterdam
2008 Literature Search, Central Library Erasmus Medical Center, Rotterdam
2008 European Transplant Fellow (EFTW) – Workshop presentation skills
2006 Biomedical English writing and communication, MolMed, Erasmus University, Rotterdam
2006 Irradiation Hygiene Expertise 5A/B, Erasmus University, Rotterdam
(Inter)national conferences and presentations presentation
2010 International Transplantation Society (ITS) congress, Vancouver, Canada  2xmini-orals
2010 Annual Meeting Bootcongres NTV, Rotterdam, The Netherlands 2x oral
2010 Wetenschapsdagen Interne Geneeskunde Erasmus MC, Antwerpen, Belgium oral
2009  Annual Meeting ATC, Boston, USA oral
2009 Annual Meeting Bootcongres NTV, Zeewolde, The Netherlands oral
2009 Annual Meeting NND (NfN), Veldhoven, The Netherlands oral
2009 MolMed Day, Erasmus MC, Rotterdam, The Netherlands oral
2009 Wetenschapsdagen Interne Geneeskunde Erasmus MC, Antwerpen, Belgium oral
2009 Annual Meeting ESOT, Paris, France 2x oral*
2009 ISSCR meeting, Barcelona, Spain  poster
2009 Basic Science meeting ESOT, Bruxelles, Belgium poster
2008 MolMed Day, Erasmus MC, Rotterdam, The Netherlands poster
2008 Meeting European Society of Hematology (ESH), Cannes, France poster
2008 International Transplantation Society (ITS) congress, Sydney, Australia mini-oral&poster*
2008 Annual Autumn NfN, Utrecht, The Netherlands
2008 Annual Meeting NTV   oral
2008 Annual Meeting NND Dutch Society of Nephrology, Veldhoven, The Netherlands   oral
2008 PLAN Research day, Rotterdam, The Netherlands oral
2007 Annual Autumn NfN, Utrecht, The Netherlands poster
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2007 Annual Meeting ESOT, Prague, Czech Republic oral
2007 Annual Meeting NVVI, Noordwijkerhout, The Netherlands poster
2007 Annual Meeting Bootcongres NTV, Zeewolde, The Netherlands oral
2007 Wetenschapsdagen Interne Geneeskunde Erasmus MC, Goes, The Netherlands poster
* Presentations given by Dr. Martin Hoogduijn
Abbreviations:
NTV = Nederlandse Transplantatie Vereniging (Dutch Transplantation Society)
ATC = American Transplant Congress (American Transplantation Society)
ESOT = European Society of Transplantation
ISSCR = International Society of Stem Cell Research
ITS / TTS = International Transplantation Society / The Transplantation Society
MolMed = Molecular Medicine Graduate school
NND = Nederlandse Nefrologie Dagen (Dutch Society of Nephrology)
NfN = Nederlandse Federatie voor Nefrologie (Dutch Federation of Nephrology)
NVVI = Nederlandse Vereniging voor Immunology
PLAN = Platform Aio’s/post-docs Nefrologie (PLAN) 
Scientific Awards 
2010 Annual Meeting Bootcongres NTV congress grant
2009 Genzyme award for best oral presentation best oral presentation
2009 American Transplant Congress  young investigator award
2009 Novartis Pharma Transplantation Advisory Board travel grant ATC
2007 Genzyme award for best oral presentation best oral presentation
2007 European Transplant Congress  young investigator award
2010 Novartis Pharma Transplantation Advisory Board travel grant ISOT
Memberships
2010 -   Jonge Nederlandse Internisten Vereniging (JNIV)
2006 - 2010 Nederlandse Transplantatie Vereniging (NTV)
2006 - 2010 European Society of Transplantation (ESOT)
2006 - 2010 Nederlandse Federatie voor Nefrologie (NfN)
2006 - 2010 International Society of Stem Cell Research (ISSCR)
2006 - 2010 The Transplantation Society (TTS)
Scientific boards / committees
2009 Nephrological Issues in Experimental Research (NIER) (www.nier.eu); editor
2007-2009 Nederlandse Federatie voor Nefrologie – sectie Wetenschap
2007 Organizer of the PhD information market Erasmus MC, Rotterdam
2006-2009 Platform Landelijke AIO’s/post-docs Nefrologie (PLAN); chairman (2007-2009)
2. Teaching activities
2010 Lecture for medical students 2010
2010 Supervising medical student Master’s thesis 2009
2007 Lecture for medical students 2007
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PATEnTEd SCIEnTIFIC InvEnTIOn
Patent (WO2010053350): “Inhibition of viral infection and replication by mesenchymal stem cells 
(MSC) and MSC-derived products”.
Available at http://ep.espacenet.com/ or https://register.epoline.org/espacenet/application;jsessionid=9
2E6F963091BC8A77515CF5E6B5DBEAF.RegisterPlus_prod_0?number=EP08876226&tab=main
Inventors: Luc J. W. van der Laan, Qiuwei (Abdulla) Pan, Meindert J. Crop
Content: This invention is related to the field of viral control, more specifically to the control of viral 
replication, especially of chronic viruses and particularly hepatitis C virus (HCV) and hepatitis B 
(HBV).
Summary:
The invention now concerns a method for inhibition of a viral infection comprising exposing said 
virus to mesenchymal stem cells (MSC), preferably said virus is a hepatitis virus, more preferably 
HCV or HBV. In a preferred embodiment, the inhibition is the inhibition of viral replication in a host 
cell. In a further preferred embodiment the cells harbouring the virus are co-cultured with MSC. 
Alternatively, the cells harbouring the virus are contacted with exudate of MSC. In the latter case, it is 
preferred that the exudate is concentrated by removing small molecules, preferably smaller than 3 kD, 
more preferably smaller than 10 kD, even more preferably smaller than 50 kD, preferably by filtration. 
Also, it is preferred that the exudate is heat-treated, preferably by subjecting it to a temperature of at 
least 60ºC for at least 20 minutes, more preferably for at least 100ºC for at least 30 minutes. 
In a further preferred embodiment, the antiviral active component produced by the MSC is a protein 
with an amino acid sequence of more than approximately 400 amino acids.
The invention also comprises the use of mesenchymal stem cells (MSC) for the inhibition of a viral 
infection, preferably a hepatitis virus, more preferably HCV or HBV. For said use, the MSC are co-
cultured with cells harbouring said virus.
The invention also comprises the use of exudate of MSC for the inhibition of a viral infection, 
preferably a hepatitis virus, more preferably HCV or HBV. Preferably, said exudate is concentrated by 
removing small molecules, preferably smaller than 3 kD, more preferably smaller than 10 kD and even 
more preferably smaller than 50 kD, by filtration. In another embodiment, a preferred use is wherein 
said exudate is heat-treated, preferably by subjecting it to a temperature of at least 60ºC for at least 
20 minutes, more preferably for at least 100ºC for at least 30 minutes. Further, preferably the exudate 
comprises a protein with an amino acid sequence of more than 80 amino acids.
Also part of the invention is a pharmaceutical composition for use in the treatment of viral infection, 
wherein said composition comprises MSC or exudate from MSC.
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LIST OF PuBLICATIOnS:
2010 Crop MJ, Korevaar SS, Kuiper, de, R, et al. Human mesenchymal stem cells are susceptible to 
lysis by CD8+ T-cells and NK cells. (submitted)
2010 Hoogduijn MJ, Popp FC, Grohnert A, et al. Advancement of mesenchymal stem cell therapy 
in solid organ transplantation (MISOT). Transplantation 2010; 90 (2): 124-6.
2010 Crop MJ, de Rijke YB, Verhagen PC, Cransberg K, Zietse R. Diagnostic value of urinary 
dysmorphic erythrocytes in clinical practice. Nephron Clin Pract 2010; 115 (3): c203-12.
2010 Crop MJ, Baan CC, Korevaar SS, et al. Inflammatory conditions affect gene expression and 
function of human adipose tissue-derived mesenchymal stem cells. Clin Exp Immunol 2010 
Sept 15 (in press).
2010 Crop M, Baan CC, Korevaar SS, Ijzermans JN, Weimar W, Hoogduijn MJ. Human adipose 
tissue-derived mesenchymal stem cells induce explosive T-cell proliferation. Stem Cells Dev 
2010 Apr 5 (in press).
2009 Hoogduijn MJ, Crop MJ, Peeters AM, et al. Donor-derived mesenchymal stem cells remain 
present and functional in the transplanted human heart. Am J Transplant 2009; 9 (1): 222-30.
2009 Crop MJ, Baan CC, Korevaar SS, et al. Donor-derived mesenchymal stem cells suppress 
alloreactivity of kidney transplant patients. Transplantation 2009; 87 (6): 896-906.
2009 Crop M, Baan C, Weimar W, Hoogduijn M. Potential of mesenchymal stem cells as immune 
therapy in solid-organ transplantation. Transpl Int 2009; 22 (4): 365-76.
2008 Hoogduijn MJ, Crop MJ, Korevaar SS, et al. Susceptibility of human mesenchymal stem cells 
to tacrolimus, mycophenolic acid, and rapamycin. Transplantation 2008; 86 (9): 1283-91.
2007 Hoogduijn MJ, Crop MJ, Peeters AM, et al. Human heart, spleen, and perirenal fat-derived 
mesenchymal stem cells have immunomodulatory capacities. Stem Cells Dev 2007; 16 (4): 
597-604.
2007 Crop MJ, Hoorn EJ, Lindemans J, Zietse R. Hypokalaemia and subsequent hyperkalaemia in 
hospitalized patients. Nephrol Dial Transplant 2007; 22 (12): 3471-7.
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Mesenchymal Stem Cells
in Organ  Transplantation
Immunomodulatory properties of 
mesenchymal stem cells
for application in organ transplantation
Meindert J. Crop
 CURRICULUM VITAE AUCTORIS
 Meindert Johannes Crop werd samen met 
zijn eeneiige tweelingbroer op 31 maart 1982 
geboren te Delft. Van 1994 tot 2000 zat hij 
op het Christelijk Gymnasium Beyers Naudé 
te Leeuwarden. Al sinds zijn jeugd was hij 
geïnteresseerd in de geneeskunde. Hoewel het 
genezen van dieren lange tijd zijn voorkeur 
had, heeft hij uiteindelijk de voorkeur 
gegeven aan de humane geneeskunde. Na 
initieel uitgeloot te zijn, kon hij in 2000 door 
naplaatsing toch met de studie geneeskunde beginnen aan de 
Erasmus Universiteit te Rotterdam. 
 
 Na het afronden van het doctoraal en co-schappen, deed hij 
een aanvullend keuze co-schap interne geneeskunde in het 
Diakonessenhuis te Paramaribo Suriname. Zijn artsexamen 
legde hij af in 2006. Tot zover liepen de levenspaden van hem en 
zijn tweelingbroer parallel, maar Meindert koos toen zijn eigen 
weg door met promotie onderzoek te beginnen op de afdeling 
niertransplantatie van het Erasmus Universitair Medisch Centrum 
te Rotterdam onder leiding van Dr. Carla Baan. Onder begeleiding 
van prof. Willem Weimar en Dr. Martin Hoogduijn deed hij 
onderzoek naar de mogelijkheden van mesenchymale stamcellen 
als immunosuppressieve behandeling in niertransplantatie. 
 
 Per 1 mei 2010 startte hij als arts-assistent in opleiding tot specialist 
(AIOS) interne geneeskunde in het Albert Schweitzer ziekenhuis 
te Dordrecht. Meindert is getrouwd met Eefje Huizer.
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